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 In the first part of Chapter I, the focus is on Cushing’s syndrome, followed by a 
second section explaining the link between Cushing’s syndrome and the kidney, and ending 
with an overview of renal function evaluation and a conclusion. 
 First, physiology of the hypothalamus-pituitary-adrenal gland axis in the dog is briefly 
explained, to provide the reader with adequate background information to understand the 
pathophysiology of Cushing’s syndrome. Secondly, the clinical presentation, diagnosis and 
treatment of canine Cushing’s syndrome is briefly discussed. Next, the interaction between 
glucocorticoids and renal function is described, with emphasis on vascular and hemodynamic 
effects, glomerular filtration rate (GFR), proteinuria and tubular function.In the last section, 
evaluation of kidney function with routine renal markers as well as GFR and urinary 
biomarkers are discussed.  
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1.1 The hypothalamus-pituitary-adrenal gland axis (HPA-axis) 
 The canine pituitary gland (hypophysis cerebri) is connected to the brain in the ventral 
midline of the diencephalon. As illustrated in Figure 1, it consists of two parts, the 
adenohypophysis (AH) and neurohypophysis (NH). The major part of the NH is the pars 
distalis NH (also called posterior lobe) of the pituitary gland, which is in close contact with 
the inner part of the AH, also called pars intermedia. The major part of the AH, the pars 
distalis AH or anterior lobe (AL) is separated from the pars intermedia by the hypophyseal 
cleft and wraps around the NH like a cuff (pars tuberalis).
1
  
 
Figure 1. Sagittal section of the canine brain with detail of the pituitary gland.  
A: pars distalis adenophypophysis (AH), B: pars tuberalis AH, C: pars distalis neurohypophysis (NH), 
D: pars intermedia AH, E: hypophyseal cleft. 
 
A
B
C
D
E
  
CHAPTER I:  General introduction 
5 
 
 Connected by a portal circulation, neurosecretory pathways and direct neural control, 
the pituitary gland acts as a functional unit together with the hypothalamus. Release hormones 
are secreted from hypothalamic axon terminals into portal blood veins, providing access to the 
five main endocrine cell types of the AL: somatotropic, gonadotropic, lactotropic, thyrotropic 
and corticotropic cells. This will lead to secretion of their respective hormones: growth 
hormone, follicle-stimulating hormone and luteinizing hormone, prolactin, thyroid stimulating 
hormone and adrenocorticotropic hormone (ACTH), although recently multi-responsive cells 
with receptors for different release hormones have also been found.
2
 These hormones target 
endocrine glands such as gonads, thyroid and adrenal glands.  
 
The adrenal glands are paired organs located craniomedially near the kidneys and 
consist of two functionally distinct areas: the inner part or medulla, producing catecholamines 
such as epinephrine and norepinephrine and the outer part or cortex, secreting steroid 
hormones such as cortisol, aldosterone and androgens. Histologically, three zones can be 
distinguished in the cortex: the zona reticularis and zona fasciculata which produce cortisol 
and androgens and the zona glomerulosa, in which aldosterone is synthesized. Only cells of 
the zona fasciculata and reticularis contain 17-α-hydroxylase, the enzyme necessary for 
synthesis of cortisol- and androgen-precusors 17-α-hydroxypregnenolone and 17-α-
hydroxyprogesterone.
3
 Steroid hormones are synthesized by enzymatic action on cholesterol 
as shown in Figure 2. Conversion of cholesterol to pregnenolone in the mitochondria is the 
rate-limiting step and this is regulated primarily by ACTH through activation of adenylyl 
cyclase, increase of cyclic adenosine monophosphatase and activation of phosphoprotein 
kinases.
4
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Figure 2. Pathways of adrenocortical steroid biosynthesis.  
SCC: cholesterol side chain cleavage, 3β: 3β-hydroxysteroid dehydrogenase, 11: 11β-hydroxylase, 17: 
17α-hydroxylase, 21: 21-hydroxylase. Adapted from Rijnberk A. and Kooistra H.S., 2010. Clinical 
Endocrinology of Dogs and Cats, p. 95. 
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Cortisol secretion is mainly controlled by the HPA axis as depicted in Figure 3. 
Several physical, emotional and chemical stress stimuli stimulate secretion of corticotropin 
release hormone (CRH) by the hypothalamus, leading to secretion of ACTH by corticotropic 
cells of the pituitary AL into the systemic circulation. This is followed by synthesis and 
secretion of cortisol by the adrenal gland. Cortisol will in its turn cause a long-loop negative 
feedback signal to the AL and the hypothalamus, thus decreasing its own secretion. 
Adrenocorticotropic hormone also limits its own production via a short-loop feedback 
mechanism to the hypothalamus.
4
  
 
 
Figure 3. Hypothalamus-pituitary-adrenal gland axis.  
+, stimulation signal; -, negative feedback signal; CRH, corticotropin-releasing hormone; ACTH, 
adrenocorticotropic hormone. 
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Cortisol and synthetic glucocorticoids exert their effects in many tissues by interaction with 
the glucocorticoid receptor, but also through mineralocorticoid receptors and their tissue-
specific activity is mediated by the microsomal enzyme 11-β-hydroxysteroid dehydrogenase 
(11β-HSD).5 There are two distinct isotypes of 11β-HSD: 11β-HSD type 1 (11β-HSD1) 
predominantly has reductase activity converting cortisone to biologically active cortisol, 
whereas 11β-HSD type 2 (11β-HSD2) oxidises cortisol to inactive cortisone. Although 11β-
HSD1 is found in most tissues, 11β-HSD2 is preferentially located in mineralocorticoid target 
organs, such as the kidney.
6,7
 
 
 After lipophilic glucocorticoids permeate the cell membrane, they bind to a cytosolic 
receptor protein and the glucocorticoid-receptor complex then enters the nucleus to interact 
with specific sites of the deoxyribonucleic acid (DNA). This leads to changes in messenger 
ribonucleic acid (mRNA) transcription and subsequent synthesis of specific proteins, eliciting 
the glucocorticoid response.
3,8
 Gene expression inhibition is a key glucocorticoid action, 
responsible for anti-inflammatory effects and catabolic effects on muscle, bone and 
connective tissue. In the liver, however, glucocorticoids activate mRNA transcription and 
synthesis of important enzymes for gluconeogenesis.
3,8
 Through metabolic effects and other 
mechanisms, glucocorticoids affect almost all tissues. Therefore, cortisol excess, either 
endogenous or by administration of exogenous glucocorticoids, leads to multiple clinical 
signs and laboratory abnormalities that are referred to as “Cushing’s syndrome”, which will 
be discussed in the following section. 
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1.2 Canine Cushing’s syndrome  
1.2.1 Etiology and clinical presentation  
 The clinical and biochemical abnormalities resulting from chronic overexposure to 
glucocorticoids are referred to as hypercortisolism or Cushing’s syndrome, after Dr. Harvey 
Cushing, who first described this disease in people in the 1930s.
9
 In 80 to 85% of canine 
cases, chronic glucocorticoid excess is caused by increased ACTH secretion by a pituitary 
tumor, this is also referred to as Cushing’s disease or pituitary-dependent hypercortisolism 
(PDH). Secondly, adrenocortical tumors or ACTH-independent hypercortisolism account for 
about 15 to 20% of cases of spontaneous hypercortisolism in dogs.
3
 Most adrenocortical 
tumors are unilateral solitary lesions and can be carcinoma’s or adenoma’s, with bilateral 
tumors occurring in about 10% of cases.
10-12
 In a minority of human patients, a third form of 
Cushing’s syndrome results from ectopic ACTH secretion caused by carcinoid tumors or 
small-cell lung carcinomas.
13
 In dogs, only two case reports describe Cushing’s syndrome as 
a result of ectopic ACTH secretion caused by carcinoid tumors.
14,15
 Rarely, aberrant 
expression of ectopic or overactive eutopic receptors in adrenal glands cause adrenal 
hypercortisolism in people and there is one case-report describing this fourth variety of 
Cushing’s syndrome in a dog.16,17 
 
 Cushing’s syndrome is one of the most common endocrine disorders in middle aged to 
older dogs, with an estimated incidence of 1 to 2 cases/1000 dogs/year.
18
 Cushing’s disease 
has been diagnosed in virtually all dog breeds, with a possible predilection for small breed 
dogs such as miniature poodles and dachshunds. Poodles, German shepherd dogs, labrador 
retrievers and terriers appear among the most frequently affected breeds with adrenal tumor 
hypercortisolism (ATH).
19
 Typical clinical signs of both PDH and ATH are polyuria and 
polydipsia, polyphagia, central obesity or “pot-belly”, muscle wasting and skin changes, 
including atrophy, alopecia and comedones. A dog with typical “Cushingoid” features is 
presented in Figure 4. As previously stated, glucocorticoids act on many tissues and the 
clinical manifestations resulting from glucocorticoid excess are shown in Table 1.  
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Table 1. Clinial manifestations of glucocorticoid excess in dogs.  
Pp, polyphagia; pu/pd, polyuria and polydipsia; AP, alkaline phosphatase; ALT, alanine 
aminotransferase; T4, thyroxine. Adapted from Rijnberk A. and Kooistra H.S., 2010. Clinical 
Endocrinology of Dogs and Cats, p. 114. 
 
System Common Less common 
Urinary pu/pd, proteinuria urinary tract infection, 
glucosuria 
Skin and hair thin coat, alopecia, skin 
atrophy, comedones 
hyperpigmentation, 
calcinosis cutis 
Respiratory/   
Cardiovascular 
panting at rest, hypertension congestive heart failure, 
pulmonary thrombo-
embolism 
Metabolic pp, weight gain 
hepatomegaly, pot-belly 
weight loss (muscle 
wasting), intolerance to 
hot environment 
Neuromuscular lethargy, muscle weakness, 
muscular atrophy 
myotonia 
Reproductive absence of estrus testicular atrophy 
Hematology and 
biochemistry 
neutrophilia, eosinopenia, 
lymphopenia, increased AP 
and ALT, low T4, 
hypercholesterolemia, 
hyperlipidemia 
increased hematocrit 
value, hyperglycemia, 
hypernatremia, 
hypokalemia 
 
 
Figure 4. Cushingoid features in a Boxer dog. Note the "pot-belly", skin atrophy and alopecia on the 
abdomen and limbs, lordosis and severe atrophy of the masticatory muscles. Pictures courtesy prof. S. 
Daminet. 
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1.2.2 Diagnosis  
Diagnosis of Cushing's syndrome is based on history and clinical signs, physical 
examination, endocrine function tests and medical imaging. 
 Frequent hematology and biochemical abnormalities include a stress leukogram 
(neutrophilia, monocytosis, lymphopenia, eosinopenia), thrombocytosis, increased alkaline 
phosphatase, increased cholesterol and triglycerides. Urinalysis often indicates dilute urine 
(urinary specific gravity, USG < 1.020) and sometimes signs of a urinary tract infection.
8 
 
 When a patient is suspected of Cushing's syndrome, the diagnosis must be confirmed 
using endocrine screening tests. An easy and minimal invasive test is measurement of urinary 
corticoid-to-creatinine ratios (UCCR) in two consecutive morning urine samples. To avoid 
influence of stress, urine samples must be collected by the owner in the dog's home 
environment.
20
 Other "stress-factors" like concomitant disease can also cause falsely elevated 
UCCRs, which decreases the specificity of the test.
21,22
 With a negative predictive value of 
0.98, the UCCR is a very sensitive test, and therefore a good screening method.
23
 A second 
screening test is the low-dose dexamethasone suppression test (LDDST). The test principle is 
that administration of an exogenous glucocorticoid will suppress cortisol production by a 
negative feedback signal to the pituitary gland in normal dogs, but not in dogs with Cushing's 
syndrome.
23
 A third screening test is the ACTH-stimulation test, but due to its low sensitivity, 
this test is being increasingly abandoned in veterinary endocrinology.
8 
 Once Cushing’s syndrome is confirmed based on a screening test, differentiation is 
needed to distinguish between PDH and ATH since this has consequences for the choice of 
therapy. In some cases the LDDST allows differentiation between PDH and ATH. However, 
some pituitary tumors are "dexamethasone"-resistant and will yield LDDST results 
comparable to ATH.
8
 The UCCR can also be coupled to an oral high dose dexamethasone 
suppression test. This test has the same limitations as the LDDST for differentiating ATH 
from PDH. Furthermore, plasma ACTH can be measured to distinguish between PDH (high 
concentration) and ATH (low concentration).
3 
 
When endocrine testing confirms PDH, the pituitary gland can be visualized using 
computed tomography or magnetic resonance imaging. This is necessary when 
hypophysectomy or pituitary irradiation are considered for therapy.
3
 An adrenal tumor can be 
detected with abdominal ultrasonography, indicating enlargement of the affected adrenal 
gland and atrophy of the contralateral gland in ATH. In dogs with PDH, both adrenal glands 
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usually have a normal size or are bilaterally enlarged, but in some cases ultrasonography 
indicates unequivocal asymmetry. However, in a recent study a measurement cut-off was 
determined that may overcome this problem, allowing ultrasonographic distinction between 
ATH and PDH with improved sensitivity and specificity.
24
   
 
1.2.3 Treatment 
In dogs with PDH, treatment of choice is transsphenoidal hypophysectomy because it 
eliminates the source of hypercortisolism, i.e. the pituitary tumor causing excessive ACTH 
secretion (Figure 5). However, it must be kept in mind that this complex procedure has a steep 
learning curve for the surgeon. When performed by an experienced surgeon, efficacy is high, 
although survival and disease free period is higher in dogs with non-enlarged than with 
enlarged pituitary glands.
25,26
 Post-operatively, lifelong supplementation with thyroxine and 
cortisone-acetate, and transient administration of desmopressin is needed.
27
 Post-operative 
follow-up includes measurement of  UCCR and total thyroxine.
25
  
 
When hypophysectomy is not possible, medical treatment directed at inhibition of 
cortisol synthesis by the adrenals is an option. In the past, the adrenal cortex was selectively 
or non-selectively destroyed with o,p’-DDD (mitotane), but since the registration of 
trilostane, its main use is limited to treatment of adrenal tumors.
28
 Trilostane is a reversible 
inhibitor of the 3-β-hydroxysteroid-dehydrogenase/isomerase system, which is necessary for 
cortisol synthesis. Starting dose is 2 mg/kg once daily, or 1 mg/kg twice daily in patients 
where short duration of action is suspected.
29,30
 Trilostane effectively controls clinical signs of 
hypercortisolism, with a median survival time of 662 days (once daily) and 900 days (twice 
daily), with a negative correlation between survival time and age and bodyweight at 
diagnosis.
28,31-33
 Optimal dosage and treatment efficacy are assessed based on clinical signs, 
ACTH-stimulation tests, measurement of sodium and potassium and ideally also endogenous 
ACTH.
27
 Mild to moderate transient hyperkalemia can be observed during trilostane 
treatment. Increased ACTH and severe electrolyte abnormalities can indicate trilostane 
overdose, which may potentially cause life threatening hypocortisolism and mineralocorticoid 
deficiency.
27,31,34
  
 
In dogs with a resectable adrenal gland tumor and without metastasis, surgical 
removal of the tumor is recommended. Most veterinary surgeons prefer a celiotomy, because 
it allows better exposure of the tumor and of possible tumor thrombi in the caudal vena cava, 
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but as in human medicine, laparoscopic adrenalectomy may become the treatment of 
choice.
35,36
 Complication rate and mortality in the perioperative period are high, but patients 
that survive the 1- to 4-week post-operative period have a good life expectancy.
8,37
  
 
In poor surgical candidates or patients with metastasis or a nonresectable tumor, 
adrenal gland tumors can be treated medically with the adrenocorticolytic drug o,p’-DDD 
(mitotane). Aim of treatment is to completely destroy the adrenocortical tissue and provide 
substitution therapy with cortisone acetate, fludrocortisone acetate and sodium chloride. The 
treatment protocol is described elsewhere.
3
 Measurements of plasma sodium and potassium 
and ACTH-stimulation testing or UCCRs can be used to monitor response to therapy or 
possible recurrence.
3
 Mitotane is potentially toxic to humans and should not be used in 
households with pregnant women or little children. 
Trilostane can also be used as an adrenocorticostatic drug in cases where mitotane is 
not an option. However, information on treatment of adrenal tumors with trilostane is limited 
to one case series and some case-reports.
38-40
 
 
Figure 5. Female neutered, 8.5 years old Boxer with PDH (A) before and (B) six months after 
transsphenoidal hypophysectomy. Note the difference in posture and improved haircoat. Pictures 
courtesy of  Joop Fama, Utrecht University. 
 
 
 
 
 
 In the next section, focus will be on effects of glucocorticoids on renal function and, 
most importantly, the lack of information about renal consequences of Cushing’s syndrome in 
human and canine patients.  
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1.3 Cushing’s syndrome, glucocorticoids and the kidney  
Adapted from: Smets P.M.Y., Meyer E., Maddens, B.E.J. and Daminet S. (2010). Cushing’s 
syndrome, glucocorticoids and the kidney. General and Comparative Endocrinology 169: 1–
10. 
 The functional unit of the kidney is the nephron, which consists of the renal 
corpuscule or glomerulus and the tubuli (Figure 6). The glomerulus contains a capillary 
network with a fenestrated endothelium, surrounded by the glomerular basement membrane 
and visceral epithelial cells (podocytes). These three components form the glomerular barrier 
through which blood is filtered to form the ultrafiltrate (Figure 7).
41
 The glomerular barrier is 
charge and size selective and under physiological circumstances it retains cellular components 
and intermediate to high molecular weight (IMW, HMW) proteins.
41
 Primary ultrafiltrate 
arrives in Bowman’s capsule and flows to the tubular lumen. In the tubuli, some of the filtered 
substances are reabsorbed, while other plasma components are secreted into the tubular 
lumen. Passing through different segments of the tubuli, the tubular fluid is altered and 
concentrated, which eventually leads to production of urine. Normal urine is practically 
devoid of proteins. 
 
Figure 6. The nephron. From Dorit RL,Walker WF and Barnes RD, 1991. Zoology, p. 356. 
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Figure 7: The renal corpuscule. Adapted from Dorit RL, Walker WF, Barnes RD, 1991. Zoology, p. 
356. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Because of its similarity with the syndrome in humans and its high estimated 
incidence compared to the low incidence in people, canine Cushing’s syndrome is an 
interesting animal model for its human counterpart.
42
 Surprisingly, very little information 
exists on renal consequences of Cushing’s syndrome in people as well as in dogs, while this 
could have important consequences for long-term outcome of this disease and patient well-
being. 
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1.3.1 Vascular and hemodynamic changes  
Hypertension is a common complication of Cushing’s syndrome in humans, with a 
prevalence of approximately 55 to 80% in adult patients and 50% in children and 
adolescents.
43-45
 Likewise, systemic hypertension occurs in 59 to 86% of canine Cushing’s 
patients.
46-49
 Glucocorticoid (GC)-induced hypertension results from many interacting 
pathophysiological pathways, which may ultimately lead to an increased cardiac output (CO), 
total peripheral resistance (TPR) and renal vascular resistance (RVR).
50
 Dexamethasone 
treatment raised blood pressure and TPR, without increase of CO in humans, and CO was 
actually decreased in dogs.
51,52
  
 
Glucocorticoids affect vascular tone. Patients with Cushing’s syndrome show 
increased sensitivity to angiotensin II and elevated plasma levels of the potent vasoconstrictor 
endothelin-1.
53,54
 Increased diastolic and mean arterial pressure responses to noradrenaline 
have been demonstrated in eight human patients with Cushing’s syndrome and in eight dogs 
with experimentally induced Cushing’s syndrome.55,56 Glucocorticoids seem to downregulate 
the expression of the Na
+
/Ca
2+
-exchanger in vascular smooth muscle cells, which causes an 
increased intracellular Ca
2+
 concentration and vasoconstriction.
57
 In cortisol-induced 
hypertension in humans, the serum erythropoietin concentration was increased and changes in 
blood pressure were correlated with changes in erythropoietin concentration. Erythropoietin is 
a direct vasoconstrictor, but its primary or bystander role in GC hypertension remains 
unclear.
58
  
Additionally, GCs may also impair vasodilator activity. There is substantial evidence 
for interactions between GCs and the nitric oxide system in humans as well as rats.
59-61
 In 
addition, GCs inhibited production of other vasodilating agents, such as prostacyclin, 
prostaglandin E2 and kallikrein.
62
  
 
Glucocorticoids are also associated with occlusive vascular disease in humans, which 
occurs through a myriad of effects on vascular smooth muscle, endothelial cells, myocardium 
and macrophages, as well as their link with obesity, hypertension, dyslipidemia and insulin 
resistance.
63
 Patients with Cushing’s syndrome may have abnormal carotid intima thickness 
that persists after removal of the tumor causing GC excess.
64,65
 Occlusive vascular disease is 
rare in canine patients, and dogs with atherosclerosis were not more likely to have concurrent 
hypercortisolism than dogs that did not have atherosclerosis.
66
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1.3.2  Glomerular filtration rate 
 The rate of ultrafiltrate formation through the glomerular barrier is the glomerular 
filtration rate (GFR). It depends on four determinants: glomerular blood flow, hydrostatic 
pressure gradient, plasma oncotic pressure and the glomerular ultrafiltration coefficient.
67
 The 
ultrafiltration coefficient is the product of the glomerular barrier permeability and its surface 
area.
41
 Increases in the first three determinants and a decrease in plasma oncotic pressure will 
lead to a rise in GFR.  
 
The above mentioned GC-induced vascular and hemodynamic changes also influence 
renal vasculature, renal blood flow (RBF) and GFR as summarized in Figure 8. Short term 
administration of ACTH or GCs increases GFR in humans, rats, sheep and dogs.
68-71
 Several 
hypotheses have been postulated to explain the increase in GFR. 
One factor that might contribute to the increased GFR is an increased RBF. In dogs, 
rats and sheep, GCs increase RBF, but this outcome is not always present in humans.
71-75
 In 
ACTH-induced hypertensive rats and rats treated with methylprednisolone, GFR and RBF 
were increased, which may have been due to nitric oxide-mediated vasodilation of the pre- 
and post-glomerular arterioli.
72,76
 In dogs treated with dexamethasone, RBF increased 
significantly. This alteration was accompanied by a decrease in RVR, which suggested that 
dexamethasone may have opposite effects on systemic and renal vasculature.
75
 In the only 
study on RVR in dogs with spontaneous Cushing’s syndrome, renal resistive index and 
pulsatility index were calculated as indices of RVR using Doppler ultrasound. Only 2 out of 
12 dogs had higher indices, suggesting RVR may not be increased in dogs with Cushing’s 
syndrome.
49
  
The catabolic effects of GCs increase plasma amino acid levels, which may be another 
mechanism leading to an increased GFR. Indeed, the ingestion of a protein-rich meal not only 
increases circulating amino acids, but also RBF and GFR in humans and dogs.
77,78
 
Intravenous infusion of plasma to dogs caused hyperproteinemia, which led to a rise in GFR 
due to renal vasodilation, a higher RBF, either no change or a moderate increase in glomerular 
hydrostatic pressure and probably an increase in the glomerular ultrafiltration coefficient.
79
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Figure 8. Glucocorticoid-induced vascular and hemodynamic changes influencing renal  
vasculature, RBF and GFR.  
CO, cardiac output; RVR, renal vascular resistance; RBF, renal blood flow, TPR, total peripheral 
resistance; GFR, glomerular filtration rate; VC, vasoconstriction; ↑, increased; ↓, decreased; +, 
positive influence; -, negative influence. 
 
 
 
Although acute effects of synthetic or endogenous GCs increase the GFR in laboratory 
animals, dogs and humans, long-term effects of Cushing’s syndrome in humans may decrease 
GFR as shown by Haentjens and coworkers.
80
 Most of the patients included in the latter study 
had been cured of Cushing’s syndrome, and had a decreased GFR compared to matched 
controls. Permanent alterations of vessel remodeling due to the chronic endogenous state of 
excess cortisol may have contributed to a lower GFR in these patients.
80
  
 
Serum creatinine (screat) is often used as an indirect measurement of GFR, although it 
has several limitations. Because muscle mass is the main source of serum creatinine and 
urinary creatinine elimination is constant over time, diseases affecting muscle mass influence 
the screat level.
81,82
 Both muscular atrophy and truncal obesity are features of Cushing’s 
syndrome in humans and dogs, and they have been shown to result in a decreased creatinine 
production rate.
83
  
In people with Cushing’s syndrome, both increased and reference range screat levels 
have been reported.
80,83,84
 Patients receiving prednisone showed a rise in plasma creatinine 
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and urinary creatinine excretion, which was probably due to a catabolic effect.
85
 Screat in 
dogs with Cushing’s syndrome was usually within or lower than the reference range.8,86  
 
1.3.3 Proteinuria 
In normal urine, only small amounts of protein are present. Proteinuria occurs in 44 to 
75% of dogs with Cushing’s syndrome and is a sign of kidney dysfunction.46,47 It can be 
caused by glomerular dysfunction, allowing leakage of excess proteins into the ultrafiltrate, 
and/or by tubular dysfunction, leading to impaired reabsorption of filtered proteins.
87
 There is 
evidence that protein overload in the ultrafiltrate may be toxic to the tubular cells and trigger 
pathways that cause tubulo-interstitial injury.
88
 Urinary albumin (ALB) is increased in 
humans, dogs and rats treated with glucocorticoids as well as canine Cushing patients.
89-93
 In 
dogs treated with hydrocortisone, hypertension was suggested as a possible mechanism 
contributing to proteinuria, along with the known hemodynamic alterations leading to 
increased renal blood flow and GFR.
75,91
 In one study in people, increased urinary albumin 
excretion in patients with active Cushing’s syndrome was suggested to be associated with 
disturbances in lipid metabolism.
94
 Even with a normal permselectivity of the glomerular 
barrier, excessive binding of serum albumin to free fatty acids may lead to increased urinary 
albumin excretion.
95
 Activation of the protein kinase C pathway by excessive plasma free 
fatty acids in renal endothelial cells may also contribute to renal injury and proteinuria.
96-98
  
 
1.3.4  Tubular changes 
Electrolyte handling 
In states of excess cortisol, 11β-HSD2 enzyme activity (see paragraph 1.1, p.7) is saturated 
and cortisol is allowed to bind to mineralocorticoid receptors in renal distal tubular and 
collecting duct cells.
99
 Mineralocorticoid receptors regulate expression of the epithelial 
sodium channel and the sodium-potassium ATP-ase pump. Thus, receptor ligand binding 
causes increased sodium reabsorption.
100-102
 This finding was demonstrated in dogs treated 
with methylprednisolone which had very high filtered sodium loads but only mild increases in 
urinary sodium-excretion.
74
 Mean urinary sodium levels in human patients with active 
Cushing’s syndrome were lower compared to cured patients and healthy controls.84 The 
mineralocorticoid effect of cortisol does not seem to influence renal potassium handling, 
except in human and canine patients with ectopic secretion of ACTH who often have 
hypokalemia.
14,15,103
 In the syndrome of ectopic ACTH secretion, ACTH may inhibit 11β-
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HSD2 enzyme activity either directly or by stimulating an inhibitory adrenal product, in 
addition to enzyme saturation by excess cortisol.
103
 In most people and dogs with Cushing’s 
syndrome, plasma sodium and potassium concentrations were within reference ranges.
48,104,105
  
 
Glucocorticoids decrease renal calcium (Ca
2+
) absorption. Mineralocorticoid receptor-
mediated activation of the epithelial sodium channel causes depolarization of the cell 
membrane, which inhibits Ca
2+
-entry and Ca
2+
-efflux via the sodium/Ca
2+
-exchanger and 
Ca
2+
-ATPase in distal tubular cells, leading to an increased fractional Ca
2+
 excretion.
106
 
Hypercalciuria is present in 86% of people with Cushing’s disease, and dogs with Cushing’s 
syndrome are 10 times more likely to have calcium-containing uroliths than control dogs.
84,107
 
Despite hypercalciuria, plasma ionized Ca
2+ 
was normal in people and dogs with 
hypercortisolism compared with control subjects.
86,108
  
 
Human patients with Cushing’s syndrome have decreased renal phosphate 
reabsorption and hypophosphatemia whereas canine patients have elevated serum phosphorus. 
Dogs with Cushing’s syndrome have a marked increase in basal parathyroid hormone. In 
comparison, humans only show a mild elevation in parathyroid hormone, if any. It has been 
suggested that increased parathyroid hormone levels in dogs with Cushing’s syndrome may 
be a compensatory response to increased Ca
2+ 
loss and/or increased phosphate concentration. 
After treatment, serum ionized Ca
2+
 and phosphorus rise in humans, but they decrease in 
dogs. These findings illustrate marked differences in calcium and phosphorus metabolism 
between humans and dogs.
86,108,109
  
 
Urine concentrating ability 
In addition to electrolyte handling, GCs are also involved in renal water excretion. 
Studies from the 1950s have demonstrated impaired water load excretion in adrenocortical 
insufficiency and increased diuresis with cortisone administration in people and dogs.
110-112
 
Although both humans and dogs with endogenous Cushing’s syndrome can present with 
polyuria as a clinical sign, this feature is most pronounced in dogs and is one of the principal 
symptoms.
8,113,114
 Dilute urine with a USG < 1.020 occurs in 85% of dogs with Cushing’s 
syndrome.
8
 Glucocorticoid effects on diuresis are mediated by their dual interaction with 
arginine vasopressin (AVP). Excess cortisol disturbs osmoregulation of AVP release at the 
level of the hypothalamus and/or neurohypophysis, and causes resistance to AVP action in the 
kidneys.
113-116
 Stimuli that increase AVP, such as water deprivation or administration of 
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desmopressin, only caused marginal increases in urine osmolality in humans and dogs with 
hypercortisolism.
113,114
 Polyuria in canine hypercortisolism and hyperaldosteronism has been 
suggested to be caused by AVP resistance and increased osmotic threshold of AVP 
release.
113,117,118
  
 
Urinary dilution and concentration is regulated by water channels or aquaporins 
(AQP), urea and ion transporters, some of which are under AVP control.
119
 In dexamethasone 
treated rats, AQP1 and AQP3 expression was upregulated, whereas AQP2 expression was not 
significantly different compared with control rats. If alterations in these water channels 
contributed to the urinary concentration defect, their expression should have been 
downregulated.
120
 However, expression of urea transporters was consistently decreased in 
dexamethasone treated rats or adrenalectomized rats with GC replacement.
120,121
 Therefore, 
the authors concluded that decreased urea accumulation caused lower interstitial osmolality in 
the inner renal medulla through downregulation of urea transporters, which contributed to the 
impaired urine concentrating ability in the excess GC state.
120
 Effects of ACTH, endogenous 
or exogenous GCs on renal glomerular and tubular function are summarized in Table 2. 
 
Table 2. Effects of ACTH, endogenous (CS) or exogenous GCs (DEX, MP) on renal glomerular 
and tubular function. ACTH, adrenocorticotrophic hormone; CS, endogenous Cushing’s syndrome; 
DEX, dexamethasone; MP, methylprednisolone; ↑, increased; ↓ decreased. 
 
 
↑ or ↓ Species ACTH, CS, DEX, MP 
Glomerular function: 
GFR 
 
Proteinuria 
 
acute ↑ 
chronic ↓ 
↑ 
 
humans, rats, sheep, dogs 
humans 
humans, rats, dogs 
 
ACTH, DEX, MP 
CS 
DEX, CS, MP 
Tubular function: 
Na
+ 
reabsorption 
Ca
2+ 
reabsorption 
Phosphate reabsorption 
Urine concentrating 
ability 
 
↑ 
↓ 
↓ 
↓ 
 
humans, rats, dogs 
humans, dogs 
humans 
humans, rats, dogs 
 
ACTH, CS, DEX, MP 
CS 
CS 
ACTH, DEX, CS 
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The vast majority of information on the interaction between GCs and the kidney was 
generated after administration of ACTH or exogenous GCs. Only one study has described 
GFR in human Cushing patients and there are no studies evaluating both glomerular and 
tubular function.
122
 Two studies in the nineties described hypertension and proteinuria in dogs 
with Cushing’s syndrome.46,47 However, the cut-off for proteinuria was higher than currently 
defined, GFR measurement and long-term follow-up post-treatment was not available and 
dogs were treated with mitotane, while nowadays trilostane is used for medical treatment. 
Therefore, evaluation of renal consequences of this endocrine disorder is needed in human 
and canine patients, because they may have implications for the general well-being of the 
patient. 
 
In the last section of this chapter we will discuss different methods for evaluation of 
renal function in dogs. 
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1.4 Evaluation of renal function  
1.4.1 Routine renal markers 
Kidney function is routinely assessed by measurement of serum or plasma creat and 
urea. The classification system for canine and feline chronic kidney disease (CKD), 
developed by the International Renal Interest Society (IRIS) is based on measurement of 
screat (Table 3). Dogs or cats with stable renal disease are assigned to stage I to IV according 
to their screat concentration, with substages based on systolic blood pressure (SBP) and 
proteinuria. Patients are sub-staged by SBP according to the degree of risk of end-organ 
damage or presence of end-organ damage or complications. In dogs, a SBP < 150 mmHg is 
suggested to cause minimal risk, a SBP between 150-159 mmHg low risk, between 160-179 
mmHg moderate risk, and ≥ 180 mmHg high risk. Canine patients are considered non-
proteinuric when their urinary-protein-to-creatinine ratio (UPC) is < 0.2, borderline 
proteinuric when their UPC is > 0.2 but < 0.5, and proteinuric when their UPC is > 0.5. Based 
on this staging proces, guidelines for treatment and follow-up are recommended.
123
 
 
Table 3. International Renal Interest Society (IRIS) staging of CKD in dogs, based on screat 
concentration.
123
  
 
CKD stage screat (µmol/l) Comments 
I < 125 
Non-azotemic 
Some other renal abnormality present e.g.: 
- inadequate concentrating ability without 
identifiable non-renal cause 
- abnormal renal palpation and/or abnormal 
renal imaging findings  
- proteinuria of renal origin 
- abnormal renal biopsy results 
II 125-179 
Mild renal azotemia  
Clinical signs usually mild or absent 
III 180-439 
Moderate renal azotemia 
Many systemic clinical signs may be present 
IV > 440 
Severe renal azotemia 
Many extra-renal clinical signs present 
Note: screat levels apply to average sized dogs – extreme sizes may cause variation 
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However, screat and urea allow detection of kidney dysfunction only when at least 
75% of renal functional mass is lost.
124
 Hence there is a need for markers that allow early 
detection of renal dysfunction. Glomerular filtration rate is considered the best overall index 
of renal function. In human medicine, certain urinary markers allow early and site-specific 
indication of renal dysfunction. 
 
1.4.2 Measurement of glomerular filtration rate 
Measurement of GFR is considered a more sensitive index of renal function, because it 
allows detection of a decreased glomerular function before development of azotemia.
125,126
 
Determination of GFR is based on the concept of clearance, or the rate with which plasma is 
cleared of a substance by the kidney. Clearance can be determined using both urinary and 
plasma data of a certain marker (urinary clearance) or using only plasma concentration versus 
time data (plasma clearance).
127
 Urinary clearance of a marker is calculated with the 
following formula: Clurinary = (U x Cu)/Cp, where U = urine flow in mL/min, Cu = marker 
concentration in urine in mg/mL, and Cp = marker concentration in plasma in mg/mL. Plasma 
clearance is calculated by the formula: Clplasma = D/AUC where D = dose of the marker and 
AUC = area under the plasma concentration versus time curve. The AUC is calculated based 
on an appropriate pharmacokinetic model.
125,127 
 
An ideal filtration marker is not protein bound, does not enter the red blood cells, is 
homogenously distributed in bodywater, and is solely excreted through the kidney by 
glomerular filtration, without tubular reabsorption or secretion. Additionally, it must not be 
toxic or in itself alter GFR.
125,127
 The fructose polymer inulin approaches these prerequisites 
and urinary inulin clearance is considered the gold standard for determination of GFR.
128,129
  
However, urinary clearance tests are impractical in veterinary practice because they 
require accurate collection of timed urine samples. There is also a risk of urinary tract 
infection. Plasma clearance methods using a single bolus injection of a marker followed by 
timed blood sampling are therefore more attractive.
125,127
  
 
Several markers have been evaluated for measurement of plasma clearance in dogs, 
such as radiolabeled filtration markers, exogenous creatinine and iodinated contrast media.
127
 
125
I- or 
131
I-iothalamate, 
51
Cr-ethylenediaminetetraacetic acid (
51
Cr-EDTA) and 
99m
Tc-
diethylenetriaminepentaacetic acid (
99m
Tc-DTPA) have all been widely used as GFR markers 
in the dog.
130-132
 Important disadvantages are the need for a specialised nuclear medicine 
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laboratory and the safety hazard related to working with radionuclides. Plasma clearance of 
exogenous creatinine was described to be an accurate indicator of GFR in healthy and renal 
impaired dogs, correlating well with urinary inulin clearance.
125
 Weak tubular secretion of 
creatinine exists in the dog, but is of negligible significance for GFR determination.
125,133
 
Advantages are that plasma creatinine can be measured with inexpensive, rapid and widely 
available assays which require only a small volume of blood. Potential drawbacks for use in 
practice is that there is currently no commercially available injectable creatinine 
preparation.
125
 Iohexol is a iodinated compound of a contrast medium that can also be used to 
measure GFR in dogs.
134
 Plasma iohexol clearance is often considered as a reference method 
in humans and correlates well with urinary clearance of inulin and creatinine in dogs.
135-138
 
Iohexol is stable in frozen samples, safe, even in patients with decreased renal function, and 
commercially available. However, a disadvantage is that iohexol analysis with high- 
performance liquid chromatography requires a specialised laboratory.
127
 
Plasma exogenous creatinine clearance has been used to determined GFR in dogs with 
spontaneous and experimentally induced hypothyroidism, dogs with leishmaniasis and dogs 
with CKD.
139-142
 Plasma iohexol clearance was measured in dogs with heart failure, 
experimentally induced renal failure and pyometra.
135,143,144
 To date, there are no studies 
investigating GFR in dogs with Cushing’s syndrome.  
 
1.4.3 Urinary biomarkers 
Adapted from: Maddens B.E.J., Daminet S., Smets P.M.Y. and Meyer E. (2011). Urinary 
biomarkers for kidney dysfunction in dogs. Journal of Veterinary Internal Medicine, in 
preparation. 
 
Biomarkers are defined as biological parameters that can be objectively measured, and 
act as indicators of normal or pathological processes, or of the response to intervention. The 
ideal biomarker for kidney injury or dysfunction should be able to (1) detect kidney 
dysfunction in an early stage, (2) localize the site of kidney dysfunction (e.g. glomerular 
versus tubular), (3) differentiate renal injury from pre-, post-, and non-renal injury, (4) predict 
the severity of kidney injury and (5) allow monitoring of effects of  intervention.
145
 To be 
clinically applicable, the biomarker should be accurate, easy to measure and non-invasive. 
Increased concentrations of serum markers are only useful in diagnosis of the primary renal 
insult if they are known to originate specifically from the kidney.
146
 In contrast, urine may be 
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a more promising biological fluid to identify the earliest biomarkers of kidney dysfunction 
because of its proximity to the kidney, and its easy accessibility.
147
 
 
1.4.3.1 Glomerular markers 
Albumin and other intermediate molecular weight proteins 
  Albumin (ALB, 69 kDa) is one of the first candidate urinary markers that has been 
studied in dogs. Microalbuminuria is defined as a urinary albumin concentration of 1-30 
mg/dl and persistent microalbuminuria is considered the mildest form of renal proteinuria.
148
 
Several studies suggest that microalbuminuria may be an early indicator of glomerular disease 
in dogs.
149,150 
However, increased urinary (u) concentrations of ALB were also observed in 
dogs with non-renal diseases, raising questions concerning specificity for diagnosis of renal 
disease.
151,152
 Furthermore, its potential for early detection of kidney dysfunction in 
nonazotemic dogs has recently been questioned.
153
 Presence of uALB can be related to both 
glomerular and tubular dysfunction, although large uALB amounts generally reflect altered 
glomerular permselectivity.
148
 
 
Other intermediate molecular weight proteins (IMW) such as vitamin D-binding 
protein (56 kDa) and transthyretin (55 kDa) have been reported to reflect proximal tubular 
dysfunction. Urinary transferrin (76 kDa) was demonstrated to be indicative of glomerular 
proteinuria.
154
 Increased urinary amounts of these proteins were observed by western blot 
analysis of samples from dogs with chronic renal failure and X-linked hereditary nephropathy 
(XLHN).
155,156
 However, these proteins remain to be quantitatively analyzed and their 
potential as urinary biomarker for kidney dysfunction in dogs is unknown. 
  
Immunoglobulin G and other urinary high molecular weight proteins 
Immunoglobulin G (IgG, 150 kDa) is produced by activated B-lymphocytes (plasma 
cells) and circulates in plasma as part of the humoral immunity. Presence of this high 
molecular weight (HMW) protein in urine has been linked to altered glomerular 
permselectivity and glomerular lesions in humans.
154
 Urinary IgG (uIgG) was increased in 
dogs with CKD,
155
 XLHN,
156 
leishmaniasis,
157,158
 pyometra,
159
 and leptospirosis.
160
 Urinary 
IgG was increased compared to age-matched healthy control dogs and present prior to 
azotemia, thereby suggesting a role for early detection of altered glomerular 
permselectivity.
156
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In analogy with IgG, urinary IgA was found to be increased in dogs with 
leishmaniasis,
158,161
 leptospirosis,
162
 and pyometra
159
 compared to healthy dogs. However, 
quantification of IgA was not performed and results were based on gel electrophoreses of 
urine. Recently, urinary C-reactive protein (CRP, 115 kDa) was demonstrated to be increased 
in urine of dogs with leptospirosis.
162
  
 
1.4.3.2 Tubular markers 
Retinol-binding protein and other urinary low molecular weight proteins 
Retinol-binding protein (RBP, 21 kDa) is a low molecular weight (LMW) plasma 
protein synthesized in the liver and is the major carrier of retinol.
163
 Uncomplexed RBP is 
freely filtered by the glomeruli and efficiently reabsorbed by megalin-mediated endocytosis in 
the proximal tubules.
164
 Therefore, urine of healthy dogs is normally almost devoid of RBP 
and increased urinary RBP (uRBP) indicates impaired tubular reabsorption.
165,166
 Higher 
concentrations of  uRBP were observed in dogs with CKD and urolithiasis compared with 
healthy controls.
155,167,168
 The potential of  uRBP to diagnose kidney dysfunction at an early 
stage has recently been evaluated in two studies. In one study, increased uRBP was detected 
before the onset of azotemia in dogs with XLHN.
169
 In addition, results of the latter study 
support the correlation of uRBP with progression of CKD. In contrast, a second study 
reported uRBP concentrations not to be significantly associated with plasma creatinine 
clearance in non-azotemic dogs with CKD. Consequently, the authors concluded that uRBP 
might not be useful for detection of a mildly decreased GFR in early stages of renal disease.
153
 
Although to date uRBP seems to be a promising marker for proximal tubular dysfunction in 
dogs, further research is warranted. 
 
Other urinary LMW proteins such as α1-microglobulin and β2-microglobulin have 
been intensively studied as tubular markers in human kidney diseases.
170,171
 Only one study 
demonstrated these proteins in urine of dogs with XLHN and they were found to increase 
with renal disease progression.
156
 
 
Tubular enzymes 
N-acetyl-β-D-glucosaminidase (NAG, 150 kDa), alkaline phosphatase (AP), γ-
glutamyl transferase (GGT), alanine aminopeptidase (AAP), and lactate dehydrogenase 
(LDH) are enzymes primarily located in the lysosomes (NAG, AP), brush border (GGT, 
AAP) or cytoplasm (LDH) of proximal tubular cells. These tubular enzymes are excreted in 
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urine after tubular dysfunction or damage.
172,173
 The magnitude of urinary NAG (uNAG), AP, 
and GGT concentrations was correlated with severity of lesions in proximal tubular cells in 
dogs with pyometra.
174
 Furthermore, early onset of acute renal damage was accurately 
reflected by two- to threefold increases of urinary NAG and GGT in dogs with gentamicin-
induced nephrotoxicosis.
175,176
 In contrast, uNAG-, GGT- and LDH-to-urinary creatinine 
ratios were higher but not significantly increased compared to baseline after cisplatin-induced 
acute kidney injury in dogs, despite presence of azotemia and histological evidence of tubular 
injury.
177
 No explanation for this finding was given, although high inter-individual variation 
may have played a role. Increased uNAG and GGT concentrations compared to healthy 
controls were shown in dogs with CKD.
178
 Urinary NAG activity was increased in dogs with 
pyelonephritis when compared to patients with uncomplicated lower urinary tract 
infections.
179
 So far, uNAG is one of the most studied tubular markers in dogs. 
 
Table 4. Overview of urinary biomarkers for kidney dysfunction in dogs. 
 
Urinary biomarker Nephron segment  
Clinical conditions in which the 
biomarker has been studied in dogs 
IMW/HMW proteins 
 
ALB Glomerulus and 
proximal tubule 
CKD, acute renal failure, 
hypercortisolism, diabetes mellitus, 
critical care, anesthesia, urinary tract 
inflammation, 
 
IgG and IgA 
Glomerulus 
Leishmaniasis, leptospirosis, pyometra, 
hypercortisolism, diabetes mellitus, X-
Linked Hereditary Nephropathy 
(XLHN) 
LMW proteins 
RBP Proximal tubule CKD, XLHN, urolithiasis 
β2-microglobulin Proximal tubule XLHN 
α1-microglobulin Proximal tubule XLHN 
Tubular enzymes 
NAG Proximal > distal 
tubule 
Aminoglycoside-nephrotoxicosis, 
maleate administration, pyometra, 
hypercortisolism, diabetes mellitus, 
CKD, acute renal failure, leishmaniasis, 
urinary tract inflammation 
GGT Proximal tubule 
AAP Proximal tubule 
AP Proximal > distal 
tubule 
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1.5 Conclusion  
There is an extensive connection between GCs and renal function. Excess cortisol in 
Cushing’s syndrome may have detrimental effects on renal function by inducing vascular and 
hemodynamic alterations as well as glomerular and tubular dysfunction. In addition, 
exogenous GCs are widely used in human and veterinary medicine for a myriad of 
indications. 
Because of its similarity with the syndrome in humans and its high estimated 
incidence compared to the low incidence in people, canine Cushing’s syndrome is an 
interesting animal model for its human counterpart.  
Studies evaluating renal consequences of Cushing’s syndrome in human and canine 
patients are scarce. Better characterization of renal involvement may have implications for 
therapy as well as the general well-being of the canine and human Cushing patient. 
Since routine markers such as screat and urea are insensitive indicators of renal 
function, there is a need for sensitive markers that allow early detection of renal dysfunction. 
Measurement of GFR is considered the best index of overall renal function, whereas urinary 
markers may allow early and site-specific indication of renal dysfunction. Only few studies 
have described the use of urinary markers in veterinary medicine. 
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Excess cortisol in Cushing’s syndrome may affect renal function by inducing vascular 
and hemodynamic alterations as well as glomerular and tubular dysfunction. Fifty-nine to 
86% of canine Cushing patients have hypertension and 44 to 75% have proteinuria. However, 
studies evaluating renal consequences of Cushing’s syndrome or exogenous GCs are scarce in 
human as well as in veterinary medicine.  
  
Therefore, the general aim of this thesis is to assess effects of Cushing’s syndrome on 
renal function in dogs. Routine renal markers, namely serum creatinine and urea, will only be 
increased when 75% of renal function is already compromised. Hence, more sensitive 
methods, such as measurement of glomerular filtration rate (GFR) and urinary markers are 
necessary to detect renal dysfunction at an earlier stage. 
 
Specific objectives of the thesis are: 
 
1. To evaluate sampling methods and storage conditions of canine urine samples for 
measurement of urinary albumin (uALB), retinol-binding protein (uRBP) and N-acetyl-β-
D glucosaminidase (uNAG) 
2. To validate precision, accuracy and sensitivity of a commercially available uALB ELISA 
and uNAG colorimetric assay and to determine glomerular (uALB) and tubular (uRBP, 
uNAG) marker concentrations in urine samples of healthy young and aged dogs, and dogs 
with chronic kidney disease 
3. To assess renal function in dogs with Cushing’s syndrome using GFR and uALB, urinary 
immunoglobulin G (uIgG), uRBP and uNAG, before treatment and during a 12 month 
follow-up period after medical or surgical therapy of hypercortisolism 
4. To evaluate renal function and morphology using GFR, urinary markers and renal biopsies 
in aged Beagle dogs before and after inducing hypercortisolism 
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Summary 
Urinary markers for renal dysfunction are gaining interest, but effects of sampling 
method, storage conditions, and urinary tract inflammation or infection on these markers are 
unclear. Therefore, the objectives of the current study were to determine the difference in 
urinary albumin (uALB), urinary retinol-binding protein (uRBP), and urinary N-acetyl-β-D-
glucosaminidase (uNAG) concentrations in cystocentesis and voided samples and to 
investigate concentration changes after storage at –20°C and at –80°C. Effects of a protease 
inhibitor were also assessed in samples stored at –80°C for 12 months. In a pilot experiment, 
influence of in vitro hematuria, pyuria, and bacteriuria on the urinary markers was evaluated. 
A mixed model was used to calculate mean differences and 95% confidence intervals.  
Urinary ALB, uNAG, and uRBP concentrations were similar in voided and 
cystocentesis samples. After storage for 4 months at –20°C, uALB concentration was not 
affected, and uRBP concentration showed a mild and clinically irrelevant decrease, whereas 
uNAG activity was significantly lower compared to fresh samples. After storage for 12 
months at –80°C, uALB and uRBP concentrations did not differ from fresh samples, but 
uNAG activity was severely decreased. Protease inhibitor addition did not preserve uNAG 
activity. Experimental hematuria, pyuria, and bacteriuria did not seem to affect urinary 
markers, although further research is needed.  
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Introduction 
Early diagnosis of decreased kidney function remains a challenge in veterinary 
medicine because of limitations of current diagnostic tests. Traditional diagnostic markers 
such as serum creatinine (screat) and ureum will only be increased when already 75% of 
functional renal mass is lost.
1
 Measurement of glomerular filtration rate (GFR) is a more 
sensitive technique, but usually requires labor-intensive and time-consuming clearance tests.
2
 
Therefore, novel urinary markers that have demonstrated their potential for early and site-
specific detection of renal dysfunction in human studies are gaining interest in companion 
animal medicine.
3-6
 Among others, these urinary markers include intermediate weight proteins 
such as albumin (ALB), low molecular weight proteins such as retinol-binding protein (RBP), 
and urinary enzymes such as N-acetyl-β-D-glucosaminidase (NAG). Glomerular dysfunction 
causes increased filtration of ALB, whereas tubular dysfunction leads to excessive urinary 
excretion of RBP and NAG due to disturbed reabsorption or structural damage of tubule cells, 
respectively.
7
 These markers may not only allow early diagnosis of primary renal disease, 
they are also able to detect subclinical renal dysfunction secondary to infectious or endocrine 
disorders (e.g. pyometra, leishmaniasis, hyperthyroidism, and Cushing’s disease).8-11 
  
In order to perform reliable clinical studies using urinary markers, urine samples need 
to be collected and stored in optimal conditions to preserve protein integrity and enzyme 
activity. Studies evaluating the effect of sampling method and storage conditions on 
determination of urinary markers are lacking in veterinary medicine and therefore mandatory. 
Hence, the first objective of the current study was to determine whether urinary (u) ALB, 
uRBP, and uNAG concentrations differ between samples collected by cystocentesis or by free 
catch. The second aim was to investigate whether urinary marker concentrations decrease 
over time depending on storage duration and freezing temperature and if a protease inhibitor 
(PI) cocktail preserves protein concentrations in samples stored at –80°C for 12 months. In a 
pilot experiment, effects of in vitro hematuria, pyuria, and bacteriuria on urinary marker 
concentrations were assessed.  
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Material and Methods 
Urine samples 
The present study was performed at the Faculty of Veterinary Medicine, Ghent 
University (Merelbeke, Belgium), after approval by the Local Ethical Committee (number 
2008/066) and written owner consent. Eleven privately owned dogs were included (2 neutered 
males, 5 intact females, and 4 spayed females), diseased as well as healthy, to ensure a broad 
range of urinary marker concentrations. The study group consisted of 3 healthy dogs, 1 dog 
with diabetes mellitus, 1 dog with combined diabetes mellitus and Cushing’s disease, 1 dog 
with Cushing’s disease, and 5 dogs with chronic kidney disease. Immediately after morning 
urine samples were obtained by ultrasound-guided cystocentesis, dogs were walked, and a 
voided urine sample was collected from each dog. During cystocentesis, care was taken to 
avoid peripheral blood contamination, and none of the samples showed macroscopic 
discoloration possibly leading to falsely increased uALB concentrations.
12  
After centrifugation (3 min, 447 × g), a complete urinalysis (dipstick,
a
 urine specific 
gravity, urine protein-to-creatinine ratio (UPC), sediment analysis, and bacterial culture) was 
done on cystocentesis samples. Dipstick and sediment analysis of the voided samples were 
also performed. The remaining supernatant was divided into aliquots of 0.5 ml and frozen at  
–20°C and –80°C. Sufficient aliquots were frozen to avoid multiple freeze–thaw cycles during 
future analyses. Fifty µl of PI cocktail
b
 was added to 1 ml of cystocentesis and voided urine, 
and 4 aliquots of each were frozen at –80°C. One aliquot of both cystocentesis and voided 
samples was used immediately for measurement of uALB, uRBP, and uNAG in fresh 
samples. 
 
Analysis of urinary markers 
Urinary ALB, uRBP, and uNAG concentrations were measured in cystocentesis and 
voided samples, within 3 hr after collection (time 0: T0) and after 4 months of storage at –
20°C (time 4 months: T4 months). Furthermore, urinary markers were determined in 
cystocentesis samples after 12 months of storage at –20°C and at –80°C (time 12 months: T12 
months) and in PI samples stored at –80°C. Urinary ALB concentration was determined with a 
commercial canine-specific sandwich enzyme-linked immunosorbent assay (ELISA) kit,
c
 
uRBP with a human ELISA kit,
d
 and uNAG activity using a colorimetric assay,
e
 as previously 
validated and descreatibed.
3,6
 Mean interassay coefficient of variation was 12.0% for uALB 
analysis, 8.5% for uRBP, and 8.1% for uNAG.
3,6 
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Effect of hematuria, pyuria, and bacteriuria 
Cystocentesis urine samples of 2 healthy dogs were used to evaluate the effect of 
experimental hematuria, pyuria, and bacteriuria on uALB, uRBP, and uNAG concentrations. 
A heparinized blood sample of 1 healthy dog was used to mimic hematuria and to isolate 
white blood cells. Whole blood was diluted 4,000- and 16,000-fold in the urine samples, 
yielding a 3+ and 1+ hematuria on dipstick analysis,
f
 respectively. Furthermore, white blood 
cells were isolated after gradient centrifugation on Percoll.
g,13
 Briefly, 2 ml of blood was 
layered carefully on Percoll with a density of 1.077. The tube was centrifuged at 340 × g for 
30 min at room temperature. Then plasma was discarded, and the opaque band at the interface 
between plasma and the Percoll layer, containing the white blood cells, was aspirated with a 
Pasteur pipette and transferred into a conical tube. After 3 washing steps in a phosphate 
buffered saline solution, the white blood cells were counted.
h
 Cytospin preparations
i
 were 
stained
j
 and showed isolated white blood cells to consist mainly of neutrophils (74%) and 
further of lymphocytes (21%) and monocytes (5%). White blood cells were added to the urine 
samples until a final concentration of approximately 80 white blood cells per µl was obtained, 
corresponding with 1+ pyuria on dipstick analysis. 
For the bacteriura experiment, Escherichia coli bacteria were grown overnight, and 
bacterial concentration was determined using a standard curve plotting the colony forming 
units (CFUs) as a function of the absorbance at 550 nm. Bacteria were diluted in the urine 
samples until a final concentration of 10
5
 CFU per ml was obtained. 
All urine samples (i.e., 1+ and 3+ hematuria, 1+ pyuria, and bacteriuria) and blank 
urine samples were incubated at 38°C for 2 hr to simulate a retention period in the bladder at 
body temperature. After centrifugation (3 min at 447 × g), the supernatant was divided into 
aliquots of 1 ml and stored at –80°C until analysis within 2 weeks. Additionally, blank urine 
samples without incubation at 38°C were also centrifuged and stored at –80°C as negative 
controls. Urinary ALB, uRBP, and uNAG concentrations were compared between blank 
samples and hematuria, pyuria, and bacteriuria samples of the 2 dogs to assess the effect of 
red blood cell, white blood cell, and bacterial contamination. 
 
Statistical analysis 
Analyses were performed with a commercial software program
k
 using a mixed model 
with dog as random effect, and with collection method, storage time, freezing temperature, 
and addition of PI as categorical fixed effects. Urinary ALB, uRBP and uNAG concentrations 
were compared between cystocentesis and voided samples at T0 and at T4 months. Urinary 
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marker concentrations at T4 months and T12 months were compared to concentrations at T0. At T12 
months, uALB, uRBP, and uNAG concentrations in samples stored at –80°C with and without 
PI were compared to each other and to T0 samples. All tests were performed at 5% 
significance level. 
Mean differences between sampling techniques, storage time, and temperature with 
95% confidence intervals (CI) were derived. Equivalence between sampling techniques or 
between storage conditions can be claimed when the confidence interval is contained in a 
region of differences, which is considered to be clinically irrelevant. To calculate the mean 
percentage change of uALB, uRBP, and uNAG over time, a simple regression analysis was 
performed with difference at 2 time points as response variable and the value at earliest time 
point as covariate. 
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Results 
There was no statistically significant difference in uALB, uRBP, and uNAG 
concentrations between cystocentesis and voided urine samples at T0 or T4 months (P > 0.05). 
Mean differences between cystocentesis and voided samples at T0 and T4 months are presented 
in Figure 1. 
Differences in uALB, uRBP, and uNAG concentrations after storage at –20°C and  
–80°C are also shown in Figure 1. At T4 months after storage at –20°C, uALB concentration was 
not significantly different from T0 (P > 0.05), with a mean difference of 29.96 mg/l (95% CI: 
[–18.55; 51.48]). Urinary RBP concentration was significantly but mildly decreased (P = 
0.02), with a mean difference of 40.11 µg/l (95% CI: [12.51; 67.71]). Urinary NAG activity 
was significantly lower compared to T0, with a mean decrease of 0.61 U/l (95% CI: [0.27; 
0.95]; P = 0.005). Mean percentage decrease ± standard error (SE) was 15 ± 3% for uRBP 
and 20 ± 11% for uNAG, respectively. 
At T12 months after storage at –20°C, uALB and uNAG concentrations were 
significantly lower than at T0 (P = 0.006 and P < 0.0001, respectively). Mean difference was 
99.83 mg/l (95% CI: [44.25; 155.4]) and 2.87 U/l (95% CI: [2.13; 3.6]) for uALB and uNAG, 
respectively. For uALB, mean percentage decrease ± SE was 20 ± 6% and for uNAG 92 ± 
4%. Urinary RBP was not significantly different compared to T0 (P > 0.05), with a mean 
difference of 37.92 µg/l (95% CI: [–2.13; 77.97]). 
At T12 months after storage at –80°C, only uNAG activity showed a significant decrease 
of 2.7 U/l (95% CI: [2.09; 3.3]) compared to T0 (P < 0.0001), with a mean decrease of 89 ± 
5%. Urinary ALB and uRBP concentrations did not differ significantly from T0 (P > 0.05), 
with a difference of 42.89 mg/l (95% CI: [–15.33; 101.1]) and 7.3 µg/l (95% CI: [–4.84; 
19.44]), respectively. 
Samples with addition of PI were analyzed only at T12 months after storage at –80°C. 
Urinary ALB, uRBP, and uNAG concentrations were not statistically different in samples 
with PI compared to samples stored without PI (P > 0.05). Urinary NAG activity remained 
significantly lower compared to T0 (P < 0.0001), regardless of PI addition. 
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Figure 1. Mean differences in urinary albumin (uALB; A), urinary retinol-binding protein 
(uRBP; B), and urinary N-acetyl-β-D-glucosaminidase (uNAG; C) concentrations between 
cystocentesis and voided samples in fresh urine and after storage for 4 months at –20°C, and 
between fresh urine samples and samples stored at –20°C and at –80°C for 4 and 12 months.  
PI, protease inhibitor. 
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Figure 1 (continued). Mean differences in urinary albumin (uALB; A), urinary retinol-binding 
protein (uRBP; B), and urinary N-acetyl-β-D-glucosaminidase (uNAG; C) concentrations 
between cystocentesis and voided samples in fresh urine and after storage for 4 months at –20°C, 
and between fresh urine samples and samples stored at –20°C and at –80°C for 4 and 12 months. 
PI, protease inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 As presented in Table 1, uALB, uRBP, and uNAG concentrations did not differ between 
blank samples and urine samples with 1+ hematuria, 1+ pyuria, and bacteriuria. Urinary ALB 
and uRBP, but not uNAG concentration, showed a very mild increase in samples with 3+ 
hematuria. 
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Table 1. Urinary marker concentrations in blank urine samples and urine samples with 
experimental hematuria, pyuria, and bacteriuria.  
uALB, urinary albumin; uRBP, urinary retinol-binding protein; uNAG, urinary N-acetyl-β-D-
glucosaminidase. BDL, below detection limit; RBC, red blood cells. 
 
  Dog 1 Dog 2 
              
  uALB  uRBP  uNAG  uALB  uRBP uNAG  
  (mg/l) (µg/l) (U/l) (mg/l)  (µg/L) (U/l) 
              
Blank samples 
     
  
 0h incubation 25.9 161.6 1.8 2.9 BDL BDL 
 2h incubation  34.2 163.7 1.4 3.5 BDL BDL 
Hematuria 
      
 RBC 1+ 34.1 183.7 1.9 3.4 BDL BDL 
 RBC 3+ 40.5 217.1 1.9 8.1 58.3 BDL 
Pyuria 1+ 35.7 160.9 2.1 3.6 BDL BDL 
Bacteriuria 34.9 164.4 1.9 4.4 BDL BDL 
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Discussion 
Results of the present study demonstrate that uALB, uRBP, and uNAG concentrations 
do not differ significantly between cystocentesis and voided urine samples. In contrast, 
storage conditions may affect uALB and uRBP concentrations and uNAG enzyme activity. 
Results also suggest that the addition of a PI cocktail does not preserve uNAG activity after 
long-term storage at –80°C. Effects of experimental microscopic hematuria, pyuria, and 
bacteriuria on these urinary marker concentrations seem to be minimal, although these in vitro 
results do not reflect the complexity of an inflammatory process in vivo, and further research 
is needed. 
 
In human medicine, there are many reports on urine sample storage conditions, their 
effect on protein concentrations and on subsequent data interpretation.
14-18
 To the authors’ 
knowledge, the effect of sampling method on urinary marker concentrations has never been 
reported in dogs or cats. In reports on uALB, uRBP, or uNAG in canine or feline urine, 
cystocentesis as well as catheterization and midstream voided urine have been used.
9,19-20
 In 
contrast to voided samples, cystocentesis avoids contamination with lower urinary tract 
epithelial cells, proteases, and bacteria that may affect urinary markers.
21
 When performing 
cystocentesis, care must be taken to avoid peripheral blood contamination leading to grossly 
discolored urine samples, since this may cause a falsely increased urinary albumin 
concentration.
12 
However, results of the present study did not indicate a statistically 
significant difference in uALB, uRBP, or uNAG concentrations between cystocentesis and 
voided samples at T0 and at T4 months after storage at –20°C.  
Despite this general finding, 1 dog with combined diabetes mellitus and Cushing’s 
disease, and a negative urine culture, had increased uALB, uRBP, and uNAG concentrations 
in the voided sample (voided: uALB, 183.17 mg/l; uRBP, 71.1 µg/l; uNAG, 5.86 U/l; 
cystocentesis: uALB, 33 mg/l; uRBP, 29.8 µg/l; uNAG, 1.51 U/l). In this male castrated dog, 
macroscopic hematuria was not present in either the cystocentesis or voided sample. Sediment 
analysis of the cystocentesis sample did not reveal pyuria or inflammation. However, in the 
sediment of the voided sample, an increased amount of red blood cells, white blood cells, and 
epithelial cells were detected. Therefore, one hypothesis might be that urethral inflammation 
or preputial disease caused severe contamination of the urine sample, which affected the 
urinary markers. This finding suggests that other components of the inflammatory response, 
not mimicked by the in vitro experiment, may also play a role. Although, in general, a 
CHAPTER III: Sampling method and storage conditions for urinary markers 
 
56 
 
significant difference between cystocentesis and voided samples was not detected, possible 
interindividual variations should be considered. 
 
To the authors’ knowledge, there are no reports in the veterinary literature on stability 
of uRBP, uALB, and uNAG after frozen storage. At T4 months after storage at –20°C, uALB 
concentration was comparable to T0. In human medicine, there are contradictory reports on 
uALB stability. Results of the present study are in agreement with previous studies that 
describe no significant change in uALB concentration after storage at –20°C for up to 6 
months.
22-23
 However, others detected a decrease of 20% in uALB concentration after 6 
months at –20°C.18 In the present study, uRBP was significantly lower at T4 months compared to 
T0. Nevertheless, this decrease was mild (40.11 µg/l), and the entire 95% CI was within a 
clinically acceptable range. Moreover, the RBP ELISA range of analytical variation for 
canine urine is 15.6% (mean interassay coefficient of variation + 2*SD) and mean percentage 
decrease of uRBP reported herein was 15%.
3
 Therefore, the decrease in uRBP may be due to 
assay variation. Urinary NAG was significantly lower at T4 months compared to T0, with a mean 
percentage decrease of 20%. This finding corresponds to results of studies in human 
medicine, which demonstrated a 25.6% decrease in uNAG after 2 months of storage at  
–20°C.24 
 
While both uALB concentration and uNAG activity were significantly decreased at 
T12 months after storage at –20°C, only uNAG was significantly lower compared to T0 after 
storage at –80°C. For uALB, these findings are similar to previous results demonstrating a 
significant decline in human uALB after 12 months at –20°C, but not at –80°C.15 In the 
present study, uNAG was dramatically decreased at T12months with losses of 92% at –20°C and 
of 89% at –80°C. Addition of a PI cocktail had no effect on the preservation of uNAG. The 
decrease at –80°C was unexpected because studies in human medicine indicated a largely 
preserved uNAG activity (84.6 %) after storage for 12 months at –70°C.17 Still, components 
of canine urine differ from human urine, and enzyme activities are influenced by many 
factors, such as temperature, pH, specific inhibitors, creatinine, urea, and electrolytes.
25
 
Alkaline pH (> 8) causes a rapid decrease of uNAG, but urinary pH values in the present 
study ranged from 5.5 to 8, and only 1 sample had a pH of 8.
25-26 
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At T12 months after storage at –20°C, uRBP was not significantly lower compared to T0. 
This may seem contradictory because uRBP was mildly decreased at T4 months. However, the 
former decline is probably due to assay variability, and none of the observed differences is so 
large as to have clinical relevance. In the current study, storage at –20°C for 4–12 months 
seems to have only minimal effects on uRBP concentration. This finding is in contradiction 
with results obtained from human samples demonstrating decreased uRBP concentrations 
after storage at –20°C for 6–8 months. However, it must be noted that only a minority of 
samples in the latter study showed substantial underestimation.
18
 At T12 months after storage at  
–80°C, the present study indicated no significant difference in uRBP compared to T0. This is 
in accordance with data from human medicine demonstrating no significant change in uRBP 
when stored at –70°C for 8 months.18 
 
Guidelines advise diagnosticians to exclude urinary tract inflammation or infection 
(UTI) before identifying the origin of proteinuria because it influences UPC.
27-28
 However, 
the effect on other urinary markers is currently unclear. In human medicine, there is no 
evidence that asymptomatic UTI causes proteinuria or albuminuria.
29
 Results of the present 
pilot experiment suggest that experimental pyuria, 1+ and 2+ hematuria, and bacteriuria do 
not affect uALB, uNAG, and uRBP concentrations. However, these findings have to be 
interpreted with caution, because in vitro addition of leucocytes or bacteria to urine does not 
fully reflect an in vivo inflammatory process, with its complex interactions between 
stimulated leucocytes and bacteria involving inflammatory cytokines, bacterial products, and 
urinary molecules released from various sources. Samples with 3+ hematuria had a negligible 
increase in uALB and uRBP, probably caused by contamination of plasma albumin and RBP 
through addition of whole blood to the urine samples. These results are in agreement with 
previous data from canine urine samples showing no increased uALB in the majority of 
pyuric samples and a uALB above normal range only in macroscopically hematuric 
samples.
12
 Two studies report similar canine uNAG activity in samples with or without 
hematuria, asymptomatic bacteriuria, or positive urine cultures.
9,30
 One report showed 
increased uNAG concentration in dogs with pyelonephritis but not in dogs with lower UTI.
31
 
Effects of UTI on uRBP have not been reported in veterinary medicine. Data from human 
medicine, however, showed increased uRBP in patients with acute pyelonephritis, but not in 
patients with cystitis or asymptomatic bacteriuria.
32 
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Limitations of the present study are that data were obtained at only 3 time points (0, 4, 
and 12 months) in a relatively small sample group and that the effect of a PI was examined 
after 12 months at –80°C, but not at –20°C. The pilot experiment to assess effects of 
hematuria, pyuria, and bacteriuria is limited because it does not fully mimic the complexity of 
an in vivo cystitis. Therefore, further work is needed to evaluate the true influence of UTI on 
these urinary markers. The study was not designed to clarify underlying mechanisms of 
storage effects on the markers, but provides essential information regarding storage conditions 
for further research in the domain of urinary markers. 
 
In conclusion, samples for analysis of uALB and uRBP can be stored at –20°C for up 
to 4 months, whereas –80°C is preferred for storage up to 12 months. Urinary NAG enzyme 
activity is less stable at –20°C as well as –80°C, with already substantial losses after 4 months 
at –20°C and a more severe decline after 12 months at –80°C. 
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b.  Calbiochem protease inhibitor cocktail set n° III, Merck KGaA, Darmstadt, Germany 
c.  Canine albumin ELISA, Immunology Consultants Laboratory, Newberg, OR 
d. Retinol binding protein ELISA, Immundiagnostik AG, Bensheim, Germany 
e.  β-N-Acetylglucosaminidase Assay Kit, Sigma-Aldrich, St. Louis, MO 
f.  Multistix 8 SG, Bayer AG, Leverkusen, Germany 
g.  Percoll, Sigma-Aldrich, St. Louis, MO 
h.  Coulter Counter, Coulter Electronics Ltd., Buckinghamshire, England, United Kingdom 
i.  Shandon Cytospin cytocentrifuge and Shandon Cytoclip slide clips, Thermo Scientific, 
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Summary 
Serum creatinine (screat) and urea concentrations only detect a decrease of  > 75% of 
renal functional mass. Therefore, there is a need for markers that allow early detection and 
localization of renal damage. The objective was to investigate urinary albumin (uALB), C-
reactive protein (uCRP), retinol binding protein (uRBP) and N-acetyl-β-D-glucosaminidase 
(uNAG) concentrations in dogs with chronic kidney disease (CKD) compared with healthy 
controls and in healthy older dogs compared with young dogs. Ten dogs with CKD, 10 
healthy young dogs (age 1-3 years) and 10 healthy older dogs (age > 7 years) without 
clinically relevant abnormalities on physical examination, hematology, biochemistry and 
urinalysis were included. Urinary markers were determined using an enzyme linked 
immunosorbent assay (ELISA) (uALB, uCRP and uRBP) or a colorimetric test (uNAG). 
Results were related to urinary creatinine (c). The fixed effects model or the Wilcoxon rank 
sum test were used to compare the different groups of dogs.  
Urinary ALB/c, uRBP/c and uNAG/c were significantly higher in CKD dogs than in 
healthy dogs. No significant difference was found for uCRP, which was not detectable in the 
healthy dogs and only in 3 of the CKD dogs. Between the healthy young and older dogs, no 
significant difference was detected for any of the markers. 
 The urinary markers uALB/c, uRBP/c and uNAG/c were significantly increased in 
dogs with CKD compared to healthy controls. Additional studies are needed to evaluate the 
ability of these markers to detect renal disease before the onset of azotemia. 
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Introduction 
Chronic kidney disease (CKD) is an important cause of morbidity and mortality in 
dogs. The prevalence of CKD increases with age, with 15% of dogs over 10 years old being 
affected.
1
 Early diagnosis may allow therapeutic intervention that prevents further damage 
and progressive decline of renal function. However, only a decrease of > 75% of renal 
functional mass will be detected by current diagnostic tests such as urea and serum creatinine 
(screat) concentrations.
2
  
 
Unlike these insensitive serum tests, urinary markers are sensitive indicators of renal 
injury and also have the potential to reflect the site and severity of damage.
3
 They include 
proteins categorized according to their molecular weight: high molecular weight (HMW), 
intermediate molecular weight (IMW) and low molecular weight (LMW) proteins.
4
 In 
general, renal pathologic proteinuria may be due to increased glomerular filtration or tubular 
dysfunction causing impaired reabsorption of normally filtered protein.    
 
Glomerular dysfunction leads to higher filtration of IMW proteins such as albumin and 
in more advanced stages to the presence of HMW proteins in the ultrafiltrate.
4
 A urinary 
albumin concentration above normal, but below the limit of detection of conventional dipstick 
analysis (i.e. between 1 and 30 mg/dl) is defined as microalbuminuria. Several studies suggest 
that microalbuminuria may be an early indicator of glomerular disease in dogs.
5-6
 An example 
of a HMW protein is C-reactive protein (CRP), an acute phase protein with an increased 
serum concentration in many inflammatory diseases.
7
 To the authors’ knowledge, urinary 
CRP (uCRP) has only recently been evaluated in 1 study, reporting an increased CRP-to-
creatinine ratio (uCRP/c) in dogs with renal damage secondary to pyometra.
8
  
 
Tubular dysfunction is reflected by urinary loss of LMW proteins or urinary enzymes.
9
 
Retinol binding protein (RBP) is a LMW protein associated with tubular impairment in 
humans and dogs with renal disease and in hyperthyroid cats.
10-12
 Excessive amounts of 
urinary enzymes appear in urine due to leakage from damaged tubular cells.
13
 One such 
enzyme is N-acetyl-β-D-glucosaminidase (NAG), a lysosomal glycosidase present in 
proximal tubular cells. Urinary NAG has proven to be a useful tool in early detection of renal 
injury in various human diseases as reviewed by Skalova.
14
 In veterinary medicine, an 
increased urinary NAG-to-creatinine ratio (uNAG/c) has been observed in dogs in various 
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stages of CKD
15-16
, leishmaniasis
17
 and pyometra
18
 and in dogs treated with nephrotoxic 
antibiotics
19
, non-steroidal anti-inflammatory drugs or glucocorticoids
20
. 
 
Most studies in dogs have focused on 1 urinary marker, whereas reports on the 
combined measurement of glomerular and tubular markers in healthy and CKD dogs are 
scarce. Data about urinary marker assay validation likewise are scarce, especially for NAG.
21
 
Finally, little information exists on the urinary concentration of these markers in aging dogs.
22
 
Therefore, the aims of this study were first to validate a commercial canine albumin ELISA 
and NAG colorimetric test. Secondly, we wanted to compare 2 glomerular markers, urinary 
albumin (uALB) and uCRP, and 2 tubular markers, urinary RBP (uRBP) and NAG (uNAG) 
between healthy and CKD dogs. A third objective was to detect a possible age-related 
difference in these markers between healthy young and older dogs.
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Material and Methods 
Dogs 
The current study was performed at the Faculty of Veterinary Medicine, Ghent 
University, after approval by the Local Ethical Committee (approval number 2008/066). All 
owners agreed to participate in the study and signed an informed consent form. 
In this cross-sectional study, 20 staff- and student-owned healthy dogs were recruited 
and divided into 2 groups according to their age: a group of young dogs (age 1-3 years) and a 
group of healthy older dogs (≥ 7 years). Dogs were judged healthy based on history, physical 
examination, complete blood count, biochemistry profile and urinalysis (negative bacterial 
culture and urine protein-to-creatinine ratio, UPC < 0.5). Dogs were excluded when 
medication possibly influencing renal function had recently been administered. Descriptive 
statistics for both groups of healthy dogs are presented in Table 1. 
Ten privately owned dogs with CKD of all ages, breeds and both sexes were included. 
Diagnosis was based on clinical signs compatible with CKD (e.g., polyuria, polydipsia, 
weight loss, inappetence, vomiting), laboratory findings such as anemia, azotemia, electrolyte 
disturbances and urine specific gravity (USG) < 1.030. Dogs with CKD were classified 
according to the International Renal Interest Society (IRIS) into stages I to IV.
23
 Exclusion 
criteria were the presence of concurrent infectious, neoplastic or endocrine diseases. 
Descriptive statistics for the CKD dogs are presented in Table 1. 
Clinical signs were polyuria and polydipsia (8/10), lethargy (6/10), weight loss (5/10), 
decreased appetite or anorexia (5/10), vomiting (5/10) and diarrhea (2/10). Fecal examination 
of 1 dog with diarrhea indicated a Giardia and Strongyloides stercoralis infection. Two dogs  
had positive urine cultures (Escherichia coli). CKD dogs were IRIS stage I (n=2), III (n=2) or 
IV (n=6) and all were proteinuric (UPC > 0.5). The 2 dogs in stage I had screat concentrations 
of 1.39 mg/dl and 1.37 mg/dl and UPC ratios of 2.33 and 3.06, respectively. Ultrasound 
findings were hyperechoic renal cortices and a renal cortical cyst of 3 mm diameter in 1 dog 
and decreased kidney size (3.8 cm), hyperechoic parenchyma and decreased corticomedullary 
demarcation in the other dog. Juvenile renal disease was found as underlying cause for CKD 
in 4 dogs: a Leonberger, a Boxer, a Bull Mastiff and a Schapendoes (ages 2.3, 0.7, 2.6 and 0.5 
years, respectively). The Boxer had a littermate that had been euthanized because of end-stage 
renal disease and the Schapendoes was diagnosed with polycystic kidney disease. 
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Table 1. Group descriptive statistics (median, range) for the healthy and CKD dogs.
  
**
 indicates a significant difference (p < 0.0001); M, male intact; F, female intact; FN, female 
neutered; MN, male neutered; screat, serum creatinine;  UPC, urine protein-to-creatinine ratio;  USG, 
urine specific gravity. 
 
    Healthy dogs     
Variable Young dogs Older dogs Total CKD dogs 
number  
10 10 20 10 
of dogs 
age (years) 2.4 (1.1-2.9)
**
 8.3 (7-10.9)
**
 5 (1.1-10.9) 4.7 (0.5-10.5) 
gender 
2 M, 5 F, 1 MN, 2 M, 4 F, 2 MN, 4 M, 9 F, 3 MN, 2 M, 4 F, 2 MN, 
2 FN 2 FN 4 FN 2 FN 
bodyweight 
(kg) 
23.8 (8.8-36.0) 24.6 (8.7-39) 24.5 (8.7-39) 17.4 (4.2-40.1) 
screat (mg/dl) 0.99 (0.69-1.24) 0.92 (0.42-1.10) 0.94 (0.42-1.24)
**
 5.51 (1.37-15.94)
**
 
urea (mg/dl) 
33.99 26.13 29.52 362.52 
(26.01-43.00) (18.98-43.00) (18.98-43.00)
**
 (95.98-689.01)
**
 
UPC 0.08 (0.06-0.11) 0.1 (0.06-0.47) 0.08 (0.06-0.47)
**
 1.9 (0.63-3.39)
**
 
USG 
1.040 1.030 1.035 1.010 
(1.008-1.050) (1.016-1.049) (1.008-1.050)
**
 (1.008-1.017)
**
 
 
  
 Concurrent heart disease was present in 1 dog with aortic and pulmonary valve 
stenosis (Cairn Terrier) and in 2 dogs with mitral valve disease, International Small Animal 
Cardiac Health Council (ISACHC) class Ia (Maltese) and class II (Cavalier King Charles). 
Nine dogs were newly diagnosed and referred to our clinic for further diagnostic work-up. In 
1 dog, the diagnosis of CKD had been made 13 months earlier but the owner had stopped 
feeding the renal diet and stopped the ACE inhibitor therapy for several months. Six dogs had 
not yet received any treatment and 4 dogs had already been treated with anti-emetics, 
gastroprokinetics, antibiotics or fluid therapy by their referring veterinarians. The dog with 
ISACHC class II mitral valve disease was the only dog on an ACE inhibitor (benazepril) for 
12 months. 
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Sample collection 
Morning urine samples were collected by cystocentesis (10 ml, 22 gauge needle). 
Urinalysis consisting of dipstick analysis
a
, USG, UPC, sediment analysis and bacterial 
culture, was performed. After centrifugation (3 min at 447 x g), the supernatant was divided 
into aliquots of 0.5 ml and stored at -80°C until analysis of each marker after thawing on ice. 
 
Laboratory methods 
Because spot urine samples were used, urinary concentration of each biomarker was 
related to urinary creatinine (c) and expressed as a ratio.
19
 Urinary creatinine concentration 
was measured by the modified Jaffé reaction using picric acid.
24 
  
Validation of the albumin ELISA and NAG colorimetric assay 
As an indication of assay precision, within-day coefficient of variation (CV) was 
calculated from 30 duplicate samples assayed on the same day and between-day CV from 15 
samples assayed on separate days, respectively. In addition, between-day variation was 
assessed using Lin’s sample concordance correlation coefficient (Lin’s CCC, ρc), which 
indicates the degree of deviation from total agreement between 2 repetitive measurements of 
the same sample.
25
 
Accuracy of the assays was assessed by evaluation of linearity under serial dilution.
26
 
Urinary concentration in diluted samples was plotted against dilution factor and linear 
regression analysis was performed. 
Assay sensitivity was determined using the mean and standard deviation (SD) of blank 
samples to define the lowest concentration of albumin and NAG that can be reliably 
distinguished from a blank measurement. The limit of detection (LOD) was calculated as 
mean blank result + 2.6*SD.
27
 
 
ALB, CRP and RBP ELISA  
UALB and uCRP concentration were measured with commercial canine specific 
sandwich ELISA kits
b 
and uRBP with a human ELISA kit
b
, previously validated in our 
laboratory for use with canine urine.
28
 A microtiter plate precoated with affinity-purified 
antibodies for canine albumin, CRP or human RBP was used. Wells were filled with 100 μl of 
diluted urine samples or standards (albumin, 12.5-400 ng/ml; CRP, 3.125-200 ng/ml; RBP, 
7.8-250 ng/ml) and incubated. After several wash steps, peroxidase-labeled albumin, CRP or 
RBP antibody conjugate was added. After incubation and wash steps, each well was filled 
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with 100 μl of tetramethylbenzidin substrate and incubated. Addition of sulfuric acid stopped 
the colorimetric reaction and absorbance was measured using an ELISA plate reader
c
 at a 
wavelength of 450 nm with 650 nm as a reference. A 4 parameter logistic curve fitting 
program
d
 was used to generate the standard curve and calculate albumin, CRP or RBP 
concentrations in the urine samples.  
 
NAG colorimetric activity assay 
Urinary NAG activity was calculated with a colorimetric assay
e
. The NAG enzyme 
hydrolyzes the 4-nitrophenyl-N-acetyl-β-D-glucosaminide substrate and releases p-
nitrophenol (PNP). Addition of the basic stop solution causes ionization of the PNP to the p-
nitrophenylate ion. The  absorbance of the latter ion was measured at 405 nm with a plate 
reader
c
. NAG activity was calculated using a standard formula and divided by urinary 
creatinine concentration to determine the uNAG/c (U/g) = NAG activity (U/l) / urinary 
creatinine (g/l).
15,19  
 
Statistical analysis 
Analyses were performed with a commercial software program
f
. For normally 
distributed data, the linear model with normally distributed random error term and dog group 
(healthy and CKD) and age category (young and older) as categorical fixed effects was fitted. 
An F-test was used to compare the 2 dog groups. When the normal distribution assumption 
did not hold, the Wilcoxon rank sum test stratified for age category was performed to 
compare the CKD dogs with the healthy dogs. 
In a 2nd analysis, the young healthy dogs were compared with the old healthy dogs 
using the same analysis techniques as above, but only for the healthy dogs and without 
including age category as an adjusting covariate.    
A global significance level of 5% was used to test, leading to a Bonferroni-adjusted 
significance level of 2.5% for each of the 2 comparisons above.   
Correlations between different urinary markers and between the markers and other 
variables (screat, urea, UPC and IRIS classification) were determined using Pearson’s 
correlation coefficient for normally distributed data or Kendall’s τ for the other data. Results 
are expressed as median (range).
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Results 
Validation of the albumin and NAG assays 
Precision and sensitivity of the albumin ELISA and NAG colorimetric assay are 
presented in Table 2. Both assays had satisfactory variability with within-day CV < 10% and 
a between-day CV < 15%. Moreover, a ρc > 0.95 indicated substantial agreement between 
repetitive measurements of samples on separate days. Regression analysis after serial dilution 
of urine samples showed a linear relationship between albumin concentration or NAG activity 
and dilution factor (Figure 1).  
 
Table 2. Assay characteristics for canine albumin ELISA and NAG colorimetric assay.  
ALB, albumin ELISA; NAG, N-acetyl-β-D-glucosaminidase colorimetric assay; LOD, limit of 
detection; CV, coefficient of variation;. ρc, Lin’s concordance correlation coefficient. 
 
                          
Assay characteristic 
 
ALB 
 
NAG 
 
 
Sensitivity :     LOD 
 
15.1 ng/ml 
 
0.84 U/l 
 
 
Precision:        Within-day CV (%) 
 
                        Between-day CV (%) 
 
                        ρc 
 
 
5.2 
 
4.9 
 
12.0 
 
8.1 
 
0.98 
 
0.98 
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Figure 1. Sequential dilution of a urine sample from a dog with CKD. (A) urinary albumin 
concentration (ng/ml) plotted against dilution factor (x 10
-6
). The linear regression equation was y = 
0.8812x – 0.3507 (r2 = 0.9995). (B) urinary NAG activity (U/l) plotted against dilution factor (x 10-1). 
The linear regression equation was y = 1.0296x + 0.3107 (r
2 
= 0.995).  
CKD, chronic kidney disease; NAG, N-acetyl-β-glucosaminidase. 
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 Urinary markers 
Results for uALB/c, uRBP/c and uNAG/c in healthy and CKD dogs are presented in 
Figure 2 and Table A1 and A2. There was a highly significant difference between healthy and 
CKD dogs for uALB/c, uRBP/c and uNAG/c (p < 0.001), but not for uCRP (p = 0.07). In the 
healthy dogs, median uALB/c was 7.3 mg/g (1.5-296.5) and in the dogs with CKD uALB/c 
was 1868.6 (12.7-4594.6). None of the healthy dogs had any detectable uCRP, whereas 3 of 
the CKD dogs did, with uCRP/c of 84.3 µg/g, 179.8 µg/g and 236.9 µg/g. uRBP/c was 0.10 
mg/g (0-0.89) in the healthy dogs whereas dogs with CKD had a median ratio of 53.4 (6.8-
1372.2). The healthy dogs had a median uNAG/c of 2.2 U/g (1.2-5.5) and the CKD dogs had 
a uNAG/c of 5.7 U/g (1.5-9.5). 
When comparing the healthy young with the healthy older dogs, no significant 
differences were found for uALB/c, uCRP/c, uRBP/c or uNAG/c (p > 0.025). uALB/c in the 
young dogs was 4.7 mg/g (1.5-46.3) and in the older dogs 17.8 (3.3-296.5). In the young 
dogs, median uRBP/c was 0.1 mg/g (0-0.2) and in the older dogs also 0.1 (0-0.9). Median 
uNAG/c was 2.5 U/g (1.6-5.5) in the young dogs and in the older dogs it was 2 (1.2-5.2).  
 
Figure 2. Scatter plot of uALB/c (mg/g) (A) and uRBP/c (mg/g) (B) in healthy and CKD dogs. All 
three markers were significantly different (p < 0.001) between groups.  
uALB/c, urinary albumin-to-creatinine ratio; uRBP/c: urinary retinol-binding protein-to-creatinine 
ratio; CKD, chronic kidney disease. 
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Figure 2 (continued). Scatter plot of uNAG/c (U/g) (C) in healthy and CKD dogs. This marker 
was also significantly different (p < 0.001) between both groups.  
uNAG/c, urinary N-acetyl-β-glucosaminidase-to-creatinine ratio; CKD, chronic kidney disease. 
 
 
 
 
Correlations between different urinary markers and between the markers and other 
variables are shown in Table 3. The highest correlations were found between uALB/c and 
UPC (r = 0.96, p < 0.001), uALB/c and uRBP/c (r = 0.65, p < 0.001), uRBP/c and UPC (r = 
0.74, p < 0.001) and uRBP/c and IRIS stage (r = 0.72, p < 0.001). uRBP/c also showed 
moderate correlations to screat (r = 0.51, p < 0.001) and urea (r = 0.56, p < 0.001), and 
uALB/c to IRIS stage (r=0.53, p < 0.025), but not to screat and urea. uCRP/c was weakly to 
moderately associated with screat (r = 0.38, p < 0.025), IRIS stage (r=0.52, p < 0.025) and 
urea (r=0.41, p < 0.025), but not with UPC (p > 0.025). uNAG/c was moderately correlated to 
IRIS stage (r=0.49, p < 0.025), urea (r = 0.42, p < 0.025) and UPC (r=0.51, p < 0.025), but not 
to screat. 
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Table 3. Correlations (r) for the urinary markers, screat, IRIS stage, urea and UPC.
  
*
 indicates a significant correlation (p < 0.025); 
**
 indicates a significant correlation (p < 0.001); screat, 
serum creatinine; IRIS, International Renal Interest Society; UPC, urine protein-to-creatinine ratio; 
uALB/c, urinary albumin-to-creatinine ratio; uCRP/c, urinary CRP-to-creatinine  ratio; uRBP/c,  
urinary retinol binding  protein-to-creatinine ratio; uNAG/c, urinary N-acetyl-β-D-glucosaminidase-to-
creatinine ratio.  
 
 screat 
IRIS 
stage 
UREA UPC uALB/c uCRP/c uRBP/c uNAG/c 
 
uALB/c 
 
 
r=0.27 
 
 
r=0.53
* 
 
 
r=0.35 
 
 
r=0.96
** 
 
 
r=1 
 
r=0.27 
 
 
r=0.65
** 
 
 
r=0.56
* 
 
uCRP/c 
 
 
r=0.38
* 
 
 
r=0.52
* 
 
 
r=0.41
* 
 
 
r=0.32
 
 
 
r=0.27 
 
 
r=1 
 
r=0.43
* 
 
 
r=-0.02 
 
 
uRBP/c 
 
 
r=0.51
** 
 
 
r=0.72
** 
 
 
r=0.56
** 
 
 
r=0.74
** 
 
 
r=0.65
** 
 
 
r=0.43
* 
 
 
r=1 
 
r=0.49
* 
 
 
uNAG/c 
 
r=0.33 
 
 
r=0.49
* 
 
 
r=0.42
* 
 
 
r=0.51
* 
 
 
r=0.56
* 
 
 
r=-0.02 
 
 
r=0.49
* 
 
 
r=1 
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Discussion 
Results of the present study indicate satisfactory assay characteristics of the 
quantitative canine albumin ELISA and NAG colorimetric assay when applied for evaluation 
of urine. Furthermore, uALB, uCRP, uRBP concentrations and uNAG activity were found to 
be significantly higher in dogs with CKD compared to healthy controls. No age-related 
difference in urinary markers was detected between young and older healthy dogs. 
 
The assays used in this study were able to measure canine uALB and uNAG in a linear 
manner with within- and between-run imprecision of 5.2 and 12%, and 4.9 and 8.1%, 
respectively. As a comparison, for uALB ELISA’s, other studies have reported within- and 
between-run imprecision ranging between 2 to 17% and 4.5 to 21.7%, respectively.
29-30
 For 
the NAG colorimetric assay, within- and between-run CV’s of 2.8% and 11.9% have been 
reported.
31
 In research settings, where samples frequently are analyzed in the same run, these 
levels of imprecision are considered acceptable, but for diagnostic purposes steps to decrease 
between-run variability should be taken.  
 
In the current study, both quantitative as well as the qualitative aspects of proteinuria 
were evaluated by measuring several proteins as candidate urinary markers for glomerular and 
tubular damage. Because albuminuria is the earliest detectable form of proteinuria and all 
dogs with CKD had a UPC > 0.5, the strong correlation between uALB/c and UPC was 
expected.
32
 This strong correlation also was found in a study in cats with CKD, in which UPC 
also was predictive for survival.
30 
The use of microalbuminuria as a marker of early CKD is supported by several studies 
in dogs predisposed to glomerular disease because of a genetic cause or a heartworm 
infection.
5-6
 In these dogs, microalbuminuria reflected the onset of disease more rapidly than 
the UPC. However, in the present study, most of the dogs had advanced renal disease and it 
was not the objective to prospectively evaluate uALB/c as an early marker of CKD.  
 
This study is the first to describe uCRP concentrations in dogs with CKD. To the 
authors’ knowledge, increased uCRP/c ratios only have been described in dogs with 
pyometra, and uCRP has never been evaluated in humans.
8
 uCRP was not detected in the 
healthy dogs and increased uCRP/c ratios were present in 3 out of 10 CKD dogs. No increase 
in uCRP/c was detected in the 2 dogs with positive urine cultures or in the dog with a positive 
fecal examination. Although no statistically significant difference could be detected between 
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CKD and control dogs, the presence of uCRP in dogs with CKD still is an interesting finding. 
For CRP to appear in urine, its plasma concentration must be increased and the glomerular 
barrier must be sufficiently damaged to allow HMW protein filtration. Thus, 1 possible 
hypothesis is that the increased uCRP/c in these 3 CKD dogs reflects an inflammatory 
response leading to increased plasma concentrations and subsequent leakage of CRP through 
the damaged glomerular barrier.  
In humans, inflammation and oxidative stress start early in the process of failing 
kidney function and mild increases in CRP concentration are present even in patients with 
moderate renal impairment.
33-34
 Among other causes, decreased renal clearance of CRP, pro-
inflammatory cytokines such as interleukin-6 or both, and uremia are suggested reasons for 
chronic inflammation in these human patients.
35
 This might also have been the cause in 1 dog 
with  increased uCRP/c, which was in an advanced staged of CKD (IRIS stage IV) with 
severe clinical signs (e.g. vomiting, hemorrhagic diarrhea). In humans, serum CRP 
concentration also is a predictor of cardiovascular disease, such as congestive heart failure.
36
 
Interestingly, 2 of the dogs with increased uCRP/c were older dogs that also had mitral valve 
disease. One dog with aortic and pulmonary valve stenosis had a normal uCRP/c. To obtain 
better insight into the role of inflammation in canine CKD, plasma and urinary concentrations 
of CRP and other pro-inflammatory mediators should be evaluated in a larger number of 
dogs.  
 
URBP was measured as a 1st marker of tubular dysfunction. In most mammals, this 
LMW protein circulates in plasma complexed with a second protein (transthyretin) and binds 
vitamin A, which prevents RBP excretion. However, dogs have high concentrations of 
transthyretin-uncomplexed RBP that is filtered by the glomeruli. Under physiologic 
conditions, the filtered RBP is almost completely reabsorbed by megalin-mediated 
endocytosis in the proximal tubular cells, but tubular dysfunction leads to excessive amounts 
of uRBP.
10,37
 In our study, uRBP/c was significantly higher in dogs with CKD compared to 
healthy controls and highly correlated with screat, urea, UPC and IRIS-stage, which 
corroborates results from previous studies documenting increased uRBP/c ratios in CKD 
dogs.
10,38
 
 
As a second marker for tubular dysfunction, uNAG was determined. Indeed, in 
humans increased uNAG/c in renal disease does not originate from filtration due to 
glomerular damage but from tubular epithelial cells.
39-40
 This enzyme was found to be 
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significantly higher in the CKD than in the healthy dogs, although there was large overlap in 
uNAG/c ratios between the 2 groups. In the present study, uNAG/c in CKD dogs (median, 5.5 
U/g; range, 1.5-9.5 U/g) was lower than observed in 2 previous reports in 9 CKD dogs (mean 
± SD, 17.1 ± 7.9 U/g) and 7 CKD dogs (median, 25.4 U/g; range, 15.7-136.8 U/g), 
respectively.
15-16
 Possible explanations for this difference include variation in laboratory 
techniques for NAG analysis and dog-related factors, such as stage of CKD. Enzymuria may 
be a marker of active disease damaging the renal cells. When the primary cause of the damage 
has disappeared, enzymuria might become minimal despite pronounced structural damage and 
permanent loss of tubular cells.
40
 To further investigate this hypothesis, additional studies are 
needed to determine uNAG/c in dogs with acute renal failure as well as in dogs with various 
stages of CKD. 
 
Urinary tract infection (UTI) was an exclusion criterion for the healthy dogs, but 2 of 
the CKD dogs had positive urine cultures. The effect of lower UTI on microalbuminuria and 
uNAG/c seems to be minimal in dogs, but an increased uNAG/c ratio is reported in the 
presence of pyelonephritis.
15,41
 In these 2 dogs, no ultrasonographic signs of pyelonephritis 
were detected. To the authors’ knowledge, the effect of UTI on uRBP and uCRP is unknown 
in dogs. In humans, microalbuminuria and uCRP, uRBP and uNAG concentrations are 
increased in patients with upper UTI, but not in patients with cystitis or asymptomatic 
bacteriuria.
42-45  
 
The degree of correlation between the urinary markers and routine variables such as 
screat, urea and UPC differed for each urinary marker. This is not unexpected, because these 
markers might be more sensitive indicators of renal damage and some may reflect renal 
dysfunction at another site rather than serving as an indirect glomerular marker as does screat. 
Different markers each may reflect different pathophysiologic processes. UALB/c was not 
correlated with screat and urea whereas uRBP/c was strongly correlated with both. 
Progression of CKD in humans and dogs, respectively, may be initiated by glomerular 
changes subsequently leading to interstitial injury.
4,46-47
 It is mainly the tubulointerstitial 
inflammatory process that precedes renal scarring and is associated with a decreased renal 
function. In this more advanced stage, large amounts of LMW proteins such as RBP appear in 
urine. Negatively-charged IMW proteins such as albumin are a sign of mildly altered 
glomerular permeability and already appear in urine in an early stage. Although uCRP/c was 
moderately to weakly correlated to screat, urea and UPC, this finding needs to be interpreted 
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with caution because only 3 dogs had positive results. As in the present study, a report on 
urinary enzymes in humans with glomerulonephritis also demonstrated a correlation between 
uNAG/c and proteinuria and the absence of an association between uNAG/c and screat.
48
 The 
current hypothesis is that urinary enzymes correlate better with tubulointerstitial damage than 
with an indirect measurement of glomerular filtration rate such as screat. 
 
In the healthy dogs, a median uALB/c of 7.3 mg/g (range, 1.5-296.5) was measured. 
Cut-off values for uALB/c ratios remain to be properly established in a large number of 
healthy dogs. Usually, a normal range is calculated as mean uALB/c + 2*SD of the healthy 
control group.
49
  In 2 previous reports, uALB/c either ranged from 5 to 82 mg/g (n=6) or 
mean uALB/c ± SD was 40 ± 80 mg/g (n=10).
49-50
 Three of 20 healthy dogs in the current 
study had uALB/c ratios above the upper limit of 42 mg/g (mean + 2*SD of the healthy 
young dogs). Interestingly, 2 of these 3 dogs were older dogs with uALB/c ratios well above 
the cut-off (152.6 and 296.5 mg/g) and another 2 older dogs had uALB/c ratios near the cut-
off (40.4 mg/g and 41.5 mg/g). Previous data indicated a higher prevalence of 
microalbuminuria with increasing age.
22
 This finding might be related to the higher 
prevalence of glomerular lesions and CKD in aging dogs.
1,51
 However, in the present study no 
renal biopsies were taken due to ethical considerations. As for the CKD dogs, knowledge of 
the histopathologic lesions would unlikely have therapeutic or prognostic implications in 
advanced disease stages.  
 
  
UNAG/c ratios in the healthy dogs (median, 2.2 U/g; range, 1.2-5.5 U/g) were in 
agreement with previous reports.
15,20,52
 The present study is the first to report uNAG/c ratios 
in older healthy dogs. No significant difference was found between the young and older 
healthy dogs. Nevertheless, the true effect of age is best assessed in a longitudinal follow-up 
of the same individuals. In humans, uNAG is higher in children than in adults.
53 
This is 
mainly due to changes in muscle mass and consequently in creatinine excretion.
54
 Therefore, 
in human medicine each laboratory establishes its own reference ranges for different age 
categories and patients then are compared against age-matched controls.
53,55 
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In conclusion, combined use of glomerular and tubular markers in conjunction with 
traditional tests may provide more detailed information about the extent and location of renal 
damage. The urinary markers discussed in this study appear to be promising as non-invasive 
tools for the diagnosis of CKD in dogs. Age-related differences seem to be minimal between 
young adult and older healthy dogs. These results should encourage in-depth investigation of 
urinary markers in larger numbers of dogs classified according to their etiology and stage of  
renal disease. 
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Addendum 
 
Table A1. Individual data of the healthy dogs. Dogs 1-10 belong to the group of young dogs and 
dogs 11-20 to the group of older dogs.  
screat, serum creatinine; UPC, urinary protein-to-creatinine ratio; uRBP/c, urinary retinol-binding 
protein to-creatinine ratio; uNAG/c, urinary N-acetyl-β-D-glucosaminidase-to-creatinine ratio; 
uALB/c, urinary albumin-to-creatinine ratio; uCRP/c, urinary C-reactive protein-to-creatinine ratio; 
BDL, below detection limit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Healthy 
dogs 
Age                     
(years) 
screat           
(mg/dl) 
ureum           
(mg/dl) 
UPC 
uRBP/c        
(mg/g) 
uNAG/c    
(U/g) 
uALB/c    
(mg/g) 
uCRP/c    
(µg/g) 
Dog 1 2.9 0.90 29.01 0.08 0.10 2.7 2.8 BDL 
Dog 2 1.5 0.89 26.01 0.08 0.07 2.8 1.5 BDL 
Dog 3 2.9 1.02 30.99 0.07 0.14 3.0 5.7 BDL 
Dog 4 1.1 0.82 32.97 0.07 0.12 5.5 46.3 BDL 
Dog 5 1.7 0.69 43.00 0.11 0.14 3.3 15.7 BDL 
Dog 6 2.9 1.24 37.00 0.06 BDL 2.1 1.7 BDL 
Dog 7 1.9 1.14 41.98 0.11 0.19 2.3 31.7 BDL 
Dog 8 2.9 0.95 35.02 0.07 BDL 1.6 3.1 BDL 
Dog 9 2.9 1.11 41.02 0.08 BDL 1.9 3.7 BDL 
Dog 10 1.25 1.15 27.03 0.08 0.14 2.0 8.6 BDL 
Dog 11 7.2 0.89 30.03 0.07 BDL 1.2 3.3 BDL 
Dog 12 8.3 0.87 18.98 0.07 0.04 1.9 13.2 BDL 
Dog 13 8.1 1.01 25.23 0.17 0.89 2.8 152.6 BDL 
Dog 14 10.8 0.93 41.02 0.12 0.13 1.5 40.4 BDL 
Dog 15 10 0.95 27.03 0.06 BDL 2.0 5.1 BDL 
Dog 16 10.9 0.76 21.98 0.07 BDL 1.9 6.0 BDL 
Dog 17 8.3 0.98 21.98 0.08 BDL 2.0 5.0 BDL 
Dog 18 8.7 1.09 43.00 0.19 0.23 5.2 41.5 BDL 
Dog 19 7.5 0.90 19.22 0.11 0.43 2.3 22.5 BDL 
Dog 20 7 0.42 27.03 0.47 0.44 2.4 296.5 BDL 
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Table A2. Individual data of the dogs with CKD.  
CKD, chronic kidney disease, screat, serum creatinine; UPC, urinary protein-to-creatinine ratio; 
uRBP/c, urinary retinol-binding protein to-creatinine ratio; uNAG/c, urinary N-acetyl-β-D-
glucosaminidase-to-creatinine ratio; uALB/c, urinary albumin-to-creatinine ratio; uCRP/c, urinary C-
reactive protein-to-creatinine ratio; BDL, below detection limit. 
 
Dogs with 
CKD 
Age     
(years) 
screat    
(mg/dl) 
 ureum    
(mg/dl) 
UPC 
uRBP/c    
(mg/g) 
uNAG/c   
(U/g) 
uALB/c    
(mg/g) 
uCRP/c    
(µg/g) 
IRIS Stage 
Dog 1 2.6 15.94 689.01 0.90 392.88 4.9 444.9 179.8 IV 
Dog 2 0.9 4.64 370.03 0.63 56.62 9.5 624.2 BDL III 
Dog 3 10.5 1.41 190.99 2.33 11.80 7.0 2959.2 BDL I 
Dog 4 2.3 5.66 215.02 3.39 50.24 5.3 3900.0 BDL IV 
Dog 5 9.5 1.37 95.98 3.06 6.77 7.9 4594.6 BDL I 
Dog 6 10.25 5.35 447.45 3.34 421.92 1.5 2924.9 236.9 IV 
Dog 7 0.7 2.31 140.00 0.92 13.78 6.1 812.4 BDL III 
Dog 8 6.7 7.40 483.00 1.46 1372.18 4.8 658.3 84.3 IV 
Dog 9 7.4 7.18 355.02 2.67 98.61 6.5 3364.5 BDL IV 
Dog 10 0.5 7.73 455.98 0.97 9.25 3.0 12.7 BDL IV 
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Renal function was assessed in 25 dogs with Cushing’s syndrome and in 12 healthy 
controls. Routine renal parameters and glomerular filtration rate (GFR) were measured and 
urinary biomarkers such as urinary albumin (uALB), urinary immunoglobulin G (uIgG), and 
urinary retinol-binding protein (uRBP) were assessed by ELISA. Urinary N-acetyl-β-D-
glucosaminidase (uNAG) was determined colorimetrically. All urinary markers were indexed 
to urinary creatinine concentration (c). Plasma exo- (Clexo) and endo-iohexol (Clendo) 
clearance were used to measure GFR.  
Based on a Mann-Whitney U-test, urea and Clexo did not differ, serum creatinine 
(screat) was significantly lower, and urinary protein-to-creatinine ratio (UPC), uALB/c, 
uIgG/c, uRBP/c, uNAG/c and Clendo were higher in the dogs with Cushing’s syndrome when 
compared with controls.  
The findings indicate that both glomerular and tubular function are altered in dogs 
with Cushing’s syndrome. A longitudinal study to further investigate renal functional changes 
before and after treatment of hypercortisolism will be described in § 5.2.  
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 Introduction  
Cushing’s syndrome is one of the most common endocrine disorders, with an 
estimated incidence of 1 to 2 cases/1000 dogs/year.
1
 In 80 to 85% of cases, chronic 
glucocorticoid excess is caused by increased adrenocorticotrophic hormone (ACTH) secretion 
by a pituitary tumor, while adrenal or ACTH-independent hypercortisolism accounts for about 
15 to 20% of cases of spontaneous hypercortisolism in dogs.
2
 Forty-four to 75% of dogs with 
untreated Cushing’s syndrome have proteinuria and 59 to 86% have systemic hypertension. 3-5 
Frequently, neither of these disease processes respond to treatment of hypercortisolism.
3-4
 
Proteinuria and hypertension are central to the development and progression of chronic 
kidney disease (CKD), and are associated with increased morbidity and mortality in dogs with 
naturally-occurring CKD.
6-8
 Dogs with Cushing’s syndrome may thus be at risk of developing 
renal complications. In human patients with Cushing’s syndrome, decreased GFR and CKD, 
focal segmental glomerulosclerosis, nephrotic syndrome and an increased prevalence of 
nephrolithiasis have been observed.
9-12
 Despite these associations, effects of spontaneous 
Cushing’s syndrome on renal function remain poorly documented in humans as well as in 
dogs.
13-14
 
Routine diagnostic markers such as screat and urea allow detection of kidney 
dysfunction only when at least 75% of renal functional mass is lost.
15
 Measurement of GFR is 
considered a more sensitive index of renal function.
16
 Additionally, new urinary markers, 
proposed for early and site-specific detection of renal dysfunction in human studies, are 
gaining interest in companion animal medicine.
17-20
 They include high molecular weight 
(HMW) proteins such as immunoglobulin G (IgG), intermediate weight proteins such as 
albumin (ALB), low molecular weight proteins such as retinol-binding protein (RBP) and 
urinary enzymes such as N-acetyl-β-D-glucosaminidase (NAG). Glomerular dysfunction 
causes increased filtration of IgG and ALB, whereas tubular dysfunction leads to excessive 
urinary excretion of RBP and NAG, due to disturbed reabsorption or increased protein 
trafficking and structural damage of tubule cells, respectively.
21
 Several studies in dogs and 
cats demonstrated these markers’ ability to detect subclinical renal dysfunction secondary to 
infectious or endocrine disorders, e.g. pyometra, leishmaniasis and hyperthyroidism.
20,22-24
  
 
This study was established to assess renal function in dogs with Cushing’s syndrome 
prior to treatment compared with healthy control dogs, using routine variables as well as 
GFR, glomerular and tubular urinary markers.  
Material and methods 
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Animals 
This study was performed at the Faculty of Veterinary Medicine of Ghent University 
(Belgium) and the University Clinic for Companion Animals of Utrecht University (The 
Netherlands), after approval by the Local Ethical Committee of both institutions (approval 
numbers  2008/066 and 2008.III.06.052). All owners signed informed consent prior to 
inclusion. 
 Twenty-five client-owned dogs with Cushing’s syndrome were included in the study 
(Cushing group). Cushing’s syndrome was diagnosed based on history, clinical signs, 
physical examination, biochemical changes and consistent resulst on a combination of 
screening methodologies: low dose dexamethasone suppression test (LDDST), urinary 
corticoid-to-creatinine ratio (UCCR) in two consecutive morning urine samples, or ACTH-
stimulation test. Pituitary-dependent hypercortisolism (PDH) was diagnosed when at least two 
of the following five test results were present: LDDST results indicative for PDH, UCCR 
suppression of 50% or more after oral administration of dexamethasone, increased plasma 
ACTH concentration, ultrasonographic evidence of two equal-sized adrenal glands or 
presence of a pituitary mass on computed tomography. Adrenal tumor hypercortisolism 
(ATH) was diagnosed when the LDDST result showed no suppression or when the UCCR 
was not suppressed after oral administration of dexamethasone, in combination with 
ultrasonographic evidence of an adrenal mass. A complete blood count, biochemistry profile 
and urinalysis including bacterial culture were performed in all dogs. Exclusion criteria were 
presence of concurrent systemic infectious, neoplastic, or endocrine diseases. Dogs treated 
with drugs affecting kidney function were also excluded.  
Twelve privately-owned healthy dogs, aged seven years or older, were recruited as 
control subjects (control group). Dogs were judged healthy based on history, physical 
examination, complete blood count, biochemistry profile and urinalysis (negative bacterial 
culture). Recent administration of drugs possibly influencing renal function (e.g. non-steroidal 
anti-inflammatory drugs, glucocorticoids) was an exclusion criterion.  
To avoid any potential confounding effect due to size-dependent variations in GFR, 
the number of healthy dogs was matched proportionally to the number of dogs with Cushing’s 
syndrome in each of the following bodyweight classes: small (< 10 kg), medium (10-25 kg), 
large (> 25-45 kg) and giant (> 45 kg). Two Cushing dogs and one control dog weighed < 10 
kg (small), 10 Cushing dogs and four controls weighed between 10 and 25 kg (medium), 11 
Cushing dogs and six healthy dogs weighed more than 25 to 45 kg (large), and two Cushing 
dogs and one control dog weighed more than 45 kg (giant).  
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Sampling procedures 
All dogs were fasted for at least 10 h prior to the test day and fed immediately after 
ending the sampling period. Water was provided ad libitum. Systolic blood pressure (SBP) 
was measured indirectly by Doppler method
a
 after acclimatization to the environment, 
according to the American College of Veterinary Internal Medicine guidelines.
25
 Five 
consistent consecutive measurements were averaged. Morning urine samples were taken by 
cystocentesis (10 mL, 22 G needle). Urinary dipstick analysis
b
, urine specific gravity (USG), 
urine protein-to-creatinine ratio (UPC), sediment analysis and bacterial culture were 
performed. After centrifugation, the urine supernatant was stored at –80°C until analysis of 
urinary markers. 
Glomerular filtration rate was measured by plasma clearance of exo- and endo-iohexol 
(Clexo and Clendo), using a protocol adapted from van Hoek and coworkers.
26
 Briefly, a 15 mL 
blood sample was collected from the jugular vein (22 G needle) for hematology and 
biochemistry, including screat and urea. A 22 G catheter was placed in the cephalic vein, 64.7 
mg/kg (0.1 mL/kg) iohexol
c
 was injected and a timer was started at the end of the injection. 
Afterwards, dead space in the catheter was rinsed with 3 mL of sodium chloride 0.9%. The 
catheter was removed and 2.5 mL EDTA blood samples were collected from the jugular vein 
at 5, 15, 60, 120, 240, 360 and 480 min after injection. Samples were centrifuged within 2 h 
and stored in aliquots of 300 µL at –20°C until assayed.  
 
Exo- and endo-iohexol assays 
Plasma concentrations of exo- and endo-iohexol were determined by high- 
performance liquid chromatography with ultraviolet detection, as previously validated and 
described.
26
 Percentage of exo- and endo-iohexol measured in the Omnipaque
®
 solution were 
83.5% and 16.5%, respectively. This ratio was used to determine the dose of each isomer for 
clearance calculations. Plasma concentrations below the limit of quantification (LOQ) were 
not taken into account. The LOQ was 0.06 and 0.43 µg/ml for endo- and exo-iohexol, 
respectively. 
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Pharmacokinetic analysis  
Pharmacokinetic analyses were performed using WinNonlin
d
. For clearance 
calculation, individual plasma data were subjected to noncompartmental analysis, as 
described by Watson and coworkers.
16
 The area under the plasma exo- and endo-iohexol 
concentration versus time curve (AUC) was calculated using the trapezoidal rule with 
extrapolation to infinity. Plasma Clexo and Clendo were determined by dividing the actually 
administered dose of respectively exo- and endo-iohexol by the corresponding AUC, and 
indexed to bodyweight (mL/min/kg).  
 
Urinary marker assays 
Urinary ALB and uIgG concentrations were determined with a commercial canine 
specific enzyme-linked immunosorbent assay (ELISA)
e
, uRBP with a human ELISA
e
 and 
uNAG activity using a colorimetric assay
f
, as previously described and validated by our 
group.
19,27
 Because spot urine samples were used, urinary concentration of each marker was 
indexed to urinary creatinine (c) and expressed as a ratio.
28
 Urinary creatinine concentration 
was measured by a modified Jaffé reaction using picric acid.     
 
Statistical analysis 
Analyses were performed with a commercial software program
g
. Results are expressed 
as median and range. Bodyweight, age, SBP, screat, urea, UPC, USG, uALB/c, uIgG/c, 
uRBP/c, uNAG/c, Clexo and Clendo were compared between Cushing patients and healthy dogs 
using a Mann-Whitney U-test with a significance level of 5%. Results are expressed as 
median (range). 
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Results 
Dogs 
Most frequently represented breeds in the Cushing group were: Beagle (4/25), Boxer 
(3/25), Basset breeds (one Grand Basset Griffon Vendéen, one Basset Hound, one Basset 
Fauve de Bretagne) and mixed breed dogs (3/25). Typical clinical signs included polyuria and 
polydipsia (24/25), polyphagia (19/25), skin abnormalities (18/25), pot-belly (16/25), muscle 
weakness (10/25) and exercise intolerance (10/25). Pituitary-dependent hypercortisolism was 
diagnosed in 22/25 and ATH in 3/25 dogs. A Briard was diagnosed with combined ATH and 
CKD and one Beagle had concomitant PDH and CKD. One dog with PDH had a positive 
urine culture (Escherichia coli) and another dog with PDH had renal glucosuria. Age, body 
weight, and gender of the Cushing and control groups are presented in Table 1.  
 
Renal variables 
Systolic blood pressure and renal variables in the Cushing and control group are 
presented in Table 1. When the Cushing group was compared to the control group, screat (p = 
0.003) and USG (p < 0.001) were significantly decreased, and UPC (p < 0.001) was 
significantly increased in the dogs with Cushing’s syndrome. Urea (p = 0.85) and SBP (p = 
0.49) were not different between groups. Urinary ALB/c, uIgG/c, uRBP/c and uNAG/c were 
significantly higher in the Cushing group than in healthy dogs (p < 0.001).  
Plasma exo- and endo-iohexol concentration-time curves in the Cushing and control 
groups are shown in Figure 1. Plasma exo-iohexol concentration (expressed as mean ± SD) in 
each dog over the entire sampling period represents 76.4 ± 7.2 % to 87.9 ± 2.2 % of the 
overall concentration of iohexol, i.e. a ratio similar to that observed in the iohexol 
formulation. Plasma Clendo (p = 0.046), but not Clexo (p = 0.416), was significantly higher in 
the Cushing group (Table 1). The two dogs with concurrent CKD and PDH or ATH, had a 
Clexo of 1.1 and 0.5 ml/min/kg, and a Clendo of 0.9 and 0.4 ml/min/kg, respectively. 
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Table 1. Details of the descriptive statistics (median, range) for the Cushing and control group. 
* 
P < 0.05 between Cushing and control group.  
** 
P < 0.001 between Cushing and control group. 
F, female (intact); FN, female (neutered); M, male (intact); MN, male (neutered). SBP, systolic blood 
pressure; screat, serum creatinine; USG, urine specific gravity; UPC, urine protein-to-creatinine ratio; 
uALB/c, urinary albumin-to-creatinine ratio; uIgG/c, urinary immunoglobulin G-to-creatinine ratio; 
uRBP/c, urinary retinol-binding protein-to-creatinine ratio; uNAG/c, urinary N-acetyl-β-D-
glucosaminidase-to-creatinine ratio; Clexo, plasma clearance of exo-iohexol; Clendo, plasma clearance of 
endo-iohexol 
 
Variable  Cushing group Control group 
Number of dogs 25 12 
Age (years) 10.6 (6.7-13.3) 8.5 (7-10.9) 
Bodyweight (kg) 25.1 (4.1-56.5) 29.6 (9.5-51.2) 
Sex 4 F, 9 FN, 10 M, 2 MN 2 F, 4 FN, 3 M, 3 MN 
SBP (mmHg) 166 (103-230) 165 (102-200) 
screat (µmol/L) 60 (35-182)
*
 84 (67-132)
* 
urea (mmol/L) 4.7 (2-19.5) 5.4 (3.2-7.3) 
USG 1.008 (1.004-1.015)
**
 1.033 (1.016-1.050)
** 
UPC 3.4 (0.01-16.8)
**
 0.1 (0.06-0.19)
** 
uALB/c (mg/g) 2593 (45.4-15717.3)
** 
9.6 (2.3-152.6)
** 
uIgG/c (mg/g) 521.6 (4.2-3468.2)
** 
2.7 (0.8-17.7)
** 
uRBP/c 2.6 (0.2-485.6)
** 
0.06 (0-0.89)
** 
uNAG/c (U/g) 8.6 (1.8-31.8)
** 
2.0 (1.2-5.2)
** 
Clexo (mL/min/kg) 2.3 (0.5-3.7) 2.2 (1.7-3.6) 
Clendo (mL/min/kg) 2.7 (0.4-5.1)
*
 1.9 (1.3-2.8)
* 
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Figure 1. Plasma concentration-time curves of exo-iohexol (A) and endo-iohexol (B) in dogs with 
Cushing’s syndrome (black squares) and in control dogs (white circles).  
Plasma concentrations are expressed as mean +/- SD. 
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Discussion 
This is the first study to determine GFR and urinary marker concentrations in dogs 
with Cushing’s syndrome. Results indicate altered glomerular and tubular function in dogs 
with Cushing’s syndrome, as evidenced by increased UPC, uALB/c, uIgG/c, uRBP/c and 
uNAG/c compared to healthy dogs. Plasma Clendo, but not Clexo was higher in the Cushing 
group than in the control dogs. 
 
Regarding routine renal variables, results were similar to previous studies.  Serum 
creatinine was decreased by 29% in the Cushing group, as previously reported.
29
 Not only 
renal function affects screat concentration, but also production of creatinine from creatine in 
skeletal muscle, as shown in dogs with CKD
16
 and with experimental hypothyroidism.
30-31
 In 
Cushing patients, both decreased muscle mass and increased GFR might contribute to a lower 
screat. Urea is usually within or in the lower part of the reference range in dogs with 
Cushing’s syndrome.32 Urinary specific gravity was also significantly lower in the Cushing 
patients, as a result of polyuria and polydipsia. Excess cortisol indeed disturbs osmoregulation 
of vasopressin release and causes resistance to its renal action, leading to a decreased urinary 
concentrating ability.
33-34
   
In the Cushing group, UPC was markedly increased compared to controls. This result 
is comparable to previously reported mean UPCs of 1.47 in dogs with untreated PDH, 2.7 in 
dogs with untreated ATH and an overall mean of 1.9 in dogs with either PDH or ATH.
5,35
 In 
our study, the highest UPC was 16.8 in a dog with concomitant PDH and CKD, although one 
dog with only ATH and two dogs with only PDH also had surprisingly high UPC’s (10.16, 
10.05 and 16.32, respectively), with a normal urine sediment. It is difficult, however, to 
elucidate whether this proteinuria is related solely to the Cushing's syndrome or to underlying 
glomerular disease. 
 
Renal proteinuria can be caused by increased glomerular permeability, impaired 
tubular reabsorption of filtered protein, or both. Marked increases in UPC, uALB/c and 
uIgG/c in the diseased group indicates proteinuria of glomerular origin which may result from 
glomerular hypertension or altered glomerular permselectivity. High uIgG/c suggests the 
latter, since the glomerular barrier is normally impermeable to this HMW protein.
36
 Although 
the SBP was not increased in the Cushing compared to the control group, this does not 
preclude the possibility that glomerular hypertension contributed to the proteinuria.
3,5
 Despite 
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the measures taken to reduce stress-induced hypertension, we cannot completely exclude the 
influence of handling stress in dogs of both groups. 
 
Furthermore, increased uRBP/c and uNAG/c in the Cushing group indicate proteinuria 
of tubular origin. Glomerular-filtered RBP is reabsorbed through megalin-mediated 
endocytosis by proximal tubular cells, causing urine of healthy dogs to contain very little 
RBP.
37-38
 Increased urinary excretion of RBP, associated with tubular dysfunction, has been 
described in humans and dogs with CKD, in dogs with pyometra and in hyperthyroid cats.
19-
20,24,38-39
 This may result from impairment of megalin-mediated endocytosis due to tubulo-
interstitial damage.
38
  
Urinary NAG/c may be increased because of tubular damage and leakage from tubular 
cell lysosomes or higher lysosomal activity due to increased protein processing, as was 
demonstrated in rats.
40
 In humans with glomerulonephritis, in geriatric cats with azotemia and 
in dogs with CKD, it has been demonstrated that uNAG/c is correlated with UPC and/or 
albuminuria, but not with screat concentration in dogs and cats, or with GFR in humans.
19,41-42
 
Therefore increased uNAG/c may reflect alteration of tubular function rather than tubular 
damage. In people, the isoenzyme NAG A is physiologically excreted in urine by exocytosis, 
whereas NAG B is part of the lysosomal membrane and released when there is actual damage 
to the tubular cell.
43
 Identification of similar NAG isoenzymes in the dog could contribute to 
differentiation between upregulated NAG activity and tubular cell damage.  
 
Plasma Clexo was not significantly different between the two groups of dogs, whereas 
Clendo was higher in the Cushing group. Differences in plasma clearance of the two stereo-
isomers have previously been described and indicate that dispositions of exo- and endo-
iohexol may vary in different clinical settings for reasons that currently remain unclear.
 44
 The 
dose calculation of both isomers is unlikely to be responsible for the observed differences, 
since the exo/endo-iohexol ratio in plasma was similar to that observed in the iohexol 
formulation. The only way to identify the underlying mechanisms would be to perform 
specific pharmacokinetic studies by administering each stereoisomer separately. A direct 
consequence is that measurement of total iohexol is misleading for GFR assessment, since it 
is the sum of two stereo-isomers with different kinetics.  
Exo-iohexol is the major stereo-isomer and is typically considered a marker of GFR in 
dogs.
45
 No statistically significant difference in plasma Clexo was observed between the 
Cushing and control group. A previous pilot study in a smaller group of dogs with Cushing's 
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syndrome showed a higher plasma Clexo and Clendo compared to control dogs.
46
 However, 
bodyweight may have been a confounding factor in the latter study, because dogs of both 
groups were not bodyweight matched. Plasma clearance of iohexol can indeed be higher in 
small dogs compared to large dogs.
47
 Another explanation could be the duration of exposure 
to high plasma cortisol concentrations. Short term administration of ACTH or glucocorticoids 
increases GFR in rats, dogs and humans.
48-50
 On the contrary, long-term effects of Cushing’s 
syndrome in human patients may decrease GFR, as shown in a study by Haentjens and 
coworkers
12
, in which four out of 18 patients were identified with CKD.  
 
Urinary tract infection (UTI) was an exclusion criterion for the healthy dogs, but one 
dog with Cushing’s syndrome had a positive urine culture (E. coli). Information about effects 
of UTI on urinary markers in dogs is scarce. Experimentally induced cystitis increased UPC 
in one study, and another study demonstrated that not pyuria alone, but the combination of 
pyuria, hematuria and bacteriuria leads to higher urinary albumin concentrations.
51-52
 The 
effect of lower UTI on uNAG/c seems to be minimal in dogs, but an increased uNAG/c ratio 
is reported in the presence of pyelonephritis.
53
 To the authors’ knowledge, the effect of UTI 
on uRBP/c and uIgG/c is largely unknown in dogs. In one pilot experiment, addition of white 
blood cells, red blood cells and bacteria to urine samples did not affect uALB/c, uRBP/c and 
uNAG/c, but this does not fully mimic an in vivo inflammatory response.
54
 
 
 
Conclusion 
This study found evidence of both renal glomerular and tubular dysfunction in dogs 
with untreated Cushing's syndrome. A longitudinal study to further investigate renal 
functional changes before and after treatment of hypercortisolism will be described in § 5.2.  
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Sources and manufacturers 
a
Parks Medical Electronics Inc., Aloha, OR, USA  
b
Combur stick, Roche Diagnostics, Burgess Hill, UK 
c
Omnipaque 300, GE Healthcare, Amersham Health, Wemmel, Belgium 
d
WinNonlin version 4.0.1, Pharsight 
e
Dog albumin, Dog IgG and Human RBP ELISA kit, Immunology Consultants Laboratory, 
 Newberg, OR, USA 
fβ-N-Acetylglucosaminidase Assay kit, Sigma-Aldrich, St.-Louis, MO, USA 
g
Systat, version 12.00.08
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Summary 
Systemic arterial hypertension and proteinuria are frequent complications in dogs with 
Cushing’s syndrome and do not always resolve after treatment of hypercortisolism. Therefore, 
dogs with Cushing’s syndrome may be at risk for renal dysfunction before and after treatment. 
Objectives were to assess renal function in dogs with pituitary-dependent hypercortisolism 
(PDH) before and after treatment.  
Nineteen dogs with PDH and 12 control dogs were included in the study. Renal 
function was assessed before, and at 1, 3, 6 and 12 months after treatment. Twelve dogs were 
treated with trilostane and 7 dogs by transsphenoidal hypophysectomy. Routine renal markers 
were measured and urinary albumin (uALB), immunoglobulin G (uIgG), and retinol-binding 
protein (uRBP) were assessed by ELISA. Urinary N-acetyl-β-D-glucosaminidase (uNAG) 
was determined colorimetrically. All urinary markers were indexed to urinary creatinine 
concentration (c). Plasma clearance of creatinine (Clcreat), exo-iohexol (Clexo), and endo-
iohexol (Clendo) were used to measure GFR. Data were analyzed using a general linear model. 
Serum creatinine and urea increased post-treatment, but remained within reference 
ranges. Plasma Clcreat and Clendo were significantly lower post-treatment, whereas Clexo was 
not different. Urinary protein-to-creatinine ratio (UPC), uALB/c, uIgG/c and uRBP/c were 
decreased post-treatment, but at 12 months 5/13 dogs remained proteinuric. Urinary NAG/c 
did not change significantly.  
Post-treatment GFR decline and persistent proteinuria may warrant the clinician’s 
attention. Future research including kidney histopathology of patients with persistent 
proteinuria or a low GFR is needed to further assess renal outcome. 
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Introduction 
Cushing’s syndrome  is a frequent endocrine disorder in middle-aged and older dogs,1 
and is treated with trilostane, a reversible inhibitor of cortisol synthesis, or by transsphenoidal 
hypophysectomy.
2-3
 Up to 86% of dogs with untreated Cushing’s syndrome have systemic 
arterial hypertension and 44-75% have proteinuria, which may persist despite successful 
treatment of hypercortisolism.
4-6
 Proteinuria and systemic arterial hypertension are major 
factors in development and progression of chronic kidney disease (CKD) and  associated with 
increased morbidity and mortality in dogs with CKD.
7-9
 Therefore, dogs with Cushing’s 
syndrome could be considered at risk for renal complications. In human patients with 
Cushing’s syndrome, decreased glomerular filtration rate (GFR), focal segmental 
glomerulosclerosis, nephrotic syndrome and an increased prevalence of nephrolithiasis have 
been reported.
10-13
 However, effects of spontaneous hypercortisolism on renal function is 
poorly documented in humans and dogs.
14-15 
 
Use of sensitive and direct methods is needed to detect subtle changes in renal 
function. Measurement of GFR is considered the best overall indicator of renal function.
16
 In 
addition, urinary markers may allow early and site-specific detection of renal dysfunction.
17-20
 
These include high molecular weight (HMW) proteins, e.g. immunoglobulin G (IgG), 
intermediate molecular weight proteins (IMW), e.g. albumin (ALB), low molecular weight 
(LMW) proteins, e.g. retinol-binding protein (RBP) and urinary enzymes, e.g. N-acetyl-β-D-
glucosaminidase (NAG). Glomerular dysfunction causes increased filtration of IgG and ALB, 
whereas tubular dysfunction leads to increased urinary excretion of RBP and NAG.
21
 These 
markers allow detection of subclinical renal dysfunction secondary to infectious or endocrine 
disorders in dogs and cats, e.g. pyometra 
22-23
, leishmaniasis 
24
 and hyperthyroidism.
25
 Urine 
(u) ALB-to-creatinine (c) ratio (uALB/c), uIgG/c, uRBP/c and uNAG/c are increased in 
untreated dogs with Cushing’s syndrome  compared to 12 healthy controls.26  
 
This prospective longitudinal study aimed to assess renal function in dogs with 
pituitary-dependent hypercortisolism (PDH) before and after medical or surgical treatment of 
hypercortisolism, using routine renal variables as well as GFR, glomerular and tubular urinary 
markers.  
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Materials and methods 
Animals and study design 
This study was performed at the Faculty of Veterinary Medicine of Ghent University 
(Belgium) and the University Clinic for Companion Animals of Utrecht University (The 
Netherlands). Following approval by the Ethical Committee of both institutions (EC2008/066 
and 2008.III.06.052) and informed owner consent, 19 client-owned dogs with pituitary-
dependent hypercortisolism (PDH) were included in the study. Cushing’s disease was 
suspected based on history, clinical signs, physical examination, biochemical changes and a 
result consistent with hypercortisolism on at least 1 of these screening tests: low dose 
dexamethasone suppression test (LDDST), urinary cortisol-to-creatinine ratio (UCCR) in 2 
consecutive morning urine samples or ACTH-stimulation test. Diagnosis of PDH was 
confirmed when at least 2 of the following 5 test results were present: LDDST results 
indicative for PDH, UCCR suppression for 50% or more after oral administration of 
dexamethasone, increased plasma ACTH concentration, ultrasonographic evidence of 2 equal-
sized adrenal glands or presence of a pituitary mass on computed tomography. Exclusion 
criteria were presence of concurrent systemic infectious, neoplastic, or endocrine diseases, 
and treatment with drugs potentially affecting kidney function. Cardiac disease was an 
exclusion criterion except for dogs with subclinical disease (International Small Animal 
Cardiac Health Council class Ia and Ib). 
Twelve dogs (Mx group) were treated medically with trilostane
a
 at a starting dose of 2 
mg/kg every 24h (sid) or 1 mg/kg every 12h (bid). Response to treatment was based on 
control of clinical signs and an ACTH
b
-stimulation test. Dogs were considered to be 
adequately controlled when clinical signs were resolved and post-ACTH cortisol was between 
40 and 150 nmol/L.  
Seven dogs (Hx group) underwent a transsphenoidal hypophysectomy and received 
replacement therapy with cortisone acetate (1 mg/kg bid starting dose tapered over 4 weeks to 
0.25 mg/kg bid), levothyroxine (15 µg/kg) and desmopressin (0.01% 1 drop into the 
conjuctival sac every 8h, tapered tailored to individual patient) (Hx group).
27
 Response to 
treatment was assessed based on clinical signs and UCCRs with additional evaluation of 
serum total thyroxine concentration. Hypercortisolism was considered to be in remission 
when clinical signs were resolved and UCCR’s were below 8.3*10-6.28 Choice of therapy 
relied on the owners’ decision and randomization of the 2 treatment groups was not 
performed. 
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All dogs were evaluated 1 day before treatment (T0) and at 1 (T1), 3 (T3), 6 (T6) and 
12 (T12) months after treatment. Tested variables at all time points were body weight (BW), 
systolic blood pressure (SBP), serum creatinine (screat), serum urea, urine specific gravity 
(USG), urine protein-to-creatinine ratio (UPC), uALB/c, uIgG/c, uRBP/c and uNAG/c. 
Complete blood count (CBC), biochemistry profile and urine cultures were performed at T0, 
T6 and T12, or for urine culture more often when indicated based on sediment analysis. At the 
end of the study, owners were interviewed by telephone to document clinical outcome of the 
patients.  
Because control values for plasma clearance of creatinine (Clcreat), exo- and endo-
iohexol (Clexo and Clendo), are currently not well established and often different analytical 
methods are used, 12 healthy BW matched control dogs ≥ 7 years old were included for 
measurement of GFR. For Clcreat a lower limit of 2 mL/min/kg has been previously 
suggested.
29-31
 Dogs were judged healthy based on history, physical examination, CBC, 
biochemistry profile and urinalysis (negative bacterial culture). Recent administration of 
drugs possibly affecting renal function was an exclusion criterion.  
 
Sampling procedures 
SBP was measured indirectly by Doppler method
c
, according to the American College 
of Veterinary Internal Medicine guidelines.
32
 Morning urine samples were taken by 
cystocentesis. Urinary dipstick analysis
d
, USG, UPC, sediment analysis and bacterial culture 
were performed. After centrifugation, the urine supernatant was stored at  –80°C until 
assayed.  
Glomerular filtration rate was simultaneously measured by Clcreat, Clexo and Clendo, as 
described in a previous study and in paragraph 5.1.
33
  
 
Assays and pharmacokinetic analysis  
Serum urea (reference interval 1.16-8.49 mmol/L) was measured using an enzymatic 
method
f
. Urinary protein was determined with a turbidimetric method using benzethonium 
chloride and urinary creatinine with a modified Jaffé reaction. Urinary ALB, IgG and RBP 
were determined with an ELISA
g
 and uNAG with a colorimetric assay
h
, as previously 
validated, and indexed to urinary creatinine (c).
17,34
  
Enzymatic analysis of plasma creatinine, and measurement of iohexol stereo-isomers 
(exo- and endo-iohexol) with high performance liquid chromatography were performed as 
previously described.
29,33
 A noncompartmental analysis was performed using software
i
 as 
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previously described, with calculation of the area under the plasma creatinine, exo- and endo-
iohexol concentration versus time curve (AUC).
16
 Plasma Clcreat, Clexo and Clendo were 
determined by dividing the administered dose by the corresponding AUC, and indexing to 
BW (mL/min/kg).  
 
Statistical analysis 
Analyses were performed with commercial software
j
.  Level of significance was set at 
5%. A general linear model was used to test the effect of time on the selected variables. When 
a significant effect of time was detected, a Tukey post hoc hypothesis test was performed to 
analyze which time points differed significantly.  
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Results 
Dogs 
All 19 dogs were followed-up for at least 6 months. The baseline examination of most 
of these dogs was also used in the study in § 5.1. Thirteen of 19 dogs underwent the final 
check-up at T12 (7 dogs in the Mx group and 6 dogs in the Hx group). Between T6 and T12, 
3 dogs died or were euthanized due to cardiac disease (n=1), central nervous signs (n=1) or 
severe respiratory disease (n=1) and 3 dogs were lost to follow-up because of owners 
withdrawing them from the study (n=3). At the time of submission 10/19 dogs had died or 
were euthanized because of non-renal related causes, with a mean survival time of 523 days.  
At T0, mean ± standard deviation (SD) age and BW were 10.1 ± 1.6 years and 27.2 ± 
11.4 kg in the complete group, 10.5 ± 1.9 years and 24.8 ± 12.1 kg in the Mx group, and 9.4 ± 
0.6 years and 31.3 ± 9.8 kg in the Hx group, respectively. Age and BW in the control group 
were 8.7 ±1.6 years and 27.9 ± 14.2 kg. Bodyweight and SBP did not change significantly 
post-treatment (Table 1). Systolic BP was ≥ 160 mmHg in 7/19 dogs at T0, in 6/19 at T6 and 
in 5/13 dogs at T12.  
In the Mx group, adequate control of PDH was achieved by T1. At T3, 1/12 dogs was 
poorly controlled and at T12 1/7 dogs had clinical signs caused by concurrent diabetes 
mellitus. Total starting dose of trilostane was 1.8 ± 0.5 mg/kg bid in 9/12 dogs and 2.4 ± 0.2 
mg/kg sid in 3/12 dogs. At T12, trilostane dose was 1.6 ± 0.7 mg/kg bid in 6/7 dogs and 3 
mg/kg sid in 1 dog. 
In the Hx group, control of PDH in all dogs was achieved by T3. At T6 2/7 dogs had 
recurrence of PDH with increased UCCRs (45.0 and 44.8*10
-6
; 5.0 and 7.4*10
-6
). The latter 
two dogs were subsequently treated with trilostane with good clinical control at T12.  
 
Post-treatment course of renal variables 
Descriptive statistics for the complete group are presented in Table 1. Screat was 
increased post-treatment in the complete group at T6 ( p= 0.011) and in the Hx group at T3 (p 
= 0.037), but not in the Mx group. Two dogs had a mildly elevated screat (> 125 µmol/L) at 
T0 and T6 (126 and 132 µmol/L, respectively). Urea was higher in the complete group and 
the Mx group at T1 (p = 0.020 and p = 0.041, respectively) and T6 (p = 0.019 and p = 0.007), 
but did not differ post-treatment in the Hx group.   
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Plasma Clcreat, Clexo and Clendo in the control dogs were 2.6 ± 0.5, 2.4 ±0.6, 2.6 ±0.9 
mL/min/kg, respectively. Plasma Clcreat was unavailable at baseline in 3/19 PDH patients. 
Pretreatment Clcreat, Clexo and Clendo are presented in Table 1 and were higher than plasma 
clearance values of the controls in 10/16, 11/19 and 14/19 PDH patients, respectively. Post-
treatment Clcreat was significantly lower than pretreatment values at T6 and T12 in the 
complete group (p < 0.001) and the Hx group (p = 0.001 and p = 0.002, respectively) (Figure 
1). In the Mx group, Clcreat was decreased at T6 (p = 0.014), but not at T12 (Figure 1). At T0 
and T12, respectively, 1/16 and 4/13 dogs had a Clcreat below the previously suggested lower 
limit of 2.0 mL/min/kg. There was a mild, non-significant post-treatment decline in Clexo, 
whereas Clendo was lower in the complete group at T12 (p = 0.024) (Figure 1). 
Post-treatment USG increased in the complete group and the Mx group at T3 (p = 
0.005 and p = 0.004), T6 (p < 0.001) and T12 (p < 0.001), but there was no significant change 
in the Hx group. In all groups, UPC (Figure 1) decreased significantly after treatment (p < 
0.001) at all timepoints except for T1 and T12 in the Mx group. At T0, T6 and T12, UPC was 
above the cut-off (> 0.5) in 13/19 (9/12 Mx, 4/7 Hx), 7/19 (5/12 Mx, 2/7 Hx) and 5/13 (3/7 
Mx, 2/6 Hx) dogs, respectively. At T12, the 3 proteinuric dogs in the Mx group had UPCs of 
0.78, 1.72 and 7.74. The latter dog was diagnosed with concurrent diabetes mellitus at T12. 
Previous blood and urinary examinations did not show hyperglycemia and glucosuria. The 2 
dogs in the Hx group with mild proteinuria at T6 (0.62 and 0.72) and T12 (0.64 and 0.52) 
were those with recurrence of PDH at T6. At T12 they were treated with trilostane with good 
clinical control and optimal dosage as assessed by an ACTH-stimulation test. 
A decrease in uALB/c at T3 (p = 0.015) and T6 (p = 0.013), in uIgG/c at T3 (0.0049) 
and in uRBP/c (p = 0.033) at all time points in the complete group was observed (Figure 2), 
but inversely urine NAG/c did not change significantly. While uALB/c (p = 0.004) and 
uIgG/c (0.002) were decreased in the Hx group at all time points and uRBP/c (p = 0.021) at 
T1, T3 and T6, there was no statistically significant difference in these markers post-treatment 
in the Mx group. 
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Table 1. Median (range) of tested variables pre- and post-treatment in 19 dogs with PDH. 
T0, pretreatment; T1, T3, T6, T12:1, 3, 6 and 12 months post-treatment; SBP, systolic blood pressure; 
screat, serum creatinine; USG, urine specific gravity; UPC, urine protein-to-creatinine ratio; uALB/c, 
urinary albumin-to-creatinine ratio; uIgG/c urinary albumin-to-creatinine ratio uRBP/c, urinary 
retinol-binding protein-to-creatinine ratio; uNAG/c, urinary N-acetyl-β-D-glucosaminidase-to-
creatinine ratio; Clcreat, plasma clearance of creatinine; Clexo plasma clearance of exo-iohexol; Clendo, 
plasma clearance of endo-iohexol; NA, not assessed; 
*
 indicates a significant difference versus T0 (p < 
0.05). 
 
Tested variable 
Time point 
T0 T1 T3 T6 T12 
BW (kg) 28.2 28.0 28.0 29.3 30.2 
 (9.5-47.0) (9.6-47.7) (9.6-48.6) (9.2-48.7) (13.9-45.2) 
SBP (mmHg) 155 138 155 140 155 
 (103-230) (122-180) (124-207) (110-220) (120-195) 
screat (µmol/L) 53 62 
(46-117) 
63 65
* 
67 
(37-126) (44-119) (48-132) (56-100) 
urea (mmol/L) 3.8 4.3
*
 
(3.2-8.0) 
4.0 4.7
* 
4.5 
(2.0-8.3) (2.3-7.3) (2.7-6.7) (1.3-6.2) 
USG 1.009 1.011 1.013
* 
1.023
* 
1.020
* 
(1.003-1.022) (1.003-1.025) (1.004-1.039) (1.004-1.039) (1.002-1.045) 
UPC 1.66 0.41
* 
0.27
* 
0.25
* 
0.28
* 
(0.01-16.32) (0.06-4.96) (0.06-4.01) (0.09-4.7) (0.08-7.47) 
uALB/c (mg/g) 951.44 263.39 131.65
* 
129.60
* 
159.54 
(31.19-13713) (2.03-6659.04) (1.45-4483.08) (3.47-5236.51) (4.73-12903.48) 
uIgG/c (mg/g) 189.35 17.59 12.1
* 
24.74 27.03 
(0.71-6186.11) (0-1410.03) (0.75-700.33) (1.18-712.93) (1.29-1365.10) 
uRBP/c (mg/g) 0.63 0.10
* 
0.12
* 
0.11
* 
0.10
* 
(0.21-37.87) (0-1.59) (0-1.35) (0-0.82) (0-4.77) 
uNAG/c (mg/g) 4.03 2.27 2.39 3.19 3.21 
(0-58.30) (0-58.45) (0-22.57) (0-13.56) (0-11.78) 
Clcreat (mL/min/kg) 3.2 
NA NA 
2.2
* 
2.2
* 
(1.8-4.3) (1.6-2.8) (1.4-3.2) 
Clexo (mL/min/kg) 3.0 
NA NA 
2.5 2.5 
(1.8-4.5) (1.7-3.9) (1.9-3.0) 
Clendo (mL/min/kg) 2.8 
NA NA 
2.6 2.3
* 
(1.9-4.9) (1.6-4.3) (1.8-3.2) 
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Figure 1. Post-treatment course of Clcreat (A), Clexo (B), Clendo (C)  and UPC (D) in the complete 
group (n=19), and subgroups of dogs that were treated with trilostane (n=12) or 
hypophysectomy (n=7).  
Dark grey box: complete group, white box: trilostane group, yellow box, hypophysectomy group. Box: 
interquartile range, o: outlier, *: significant difference (p < 0.05) compared to time point 0. 
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Figure 1 (continued). Post-treatment course of Clcreat (A), Clexo (B), Clendo (C)  and UPC (D) in the 
complete group (n=19), and subgroups of dogs that were treated with trilostane (n=12) or 
hypophysectomy (n=7).  
Dark grey box: complete group, white box: trilostane group, yellow box, hypophysectomy group. Box: 
interquartile range, o: outlier, black square: extreme value, *: significant difference (p < 0.05) 
compared to time point 0. 
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Figure 2. Post-treatment course of uALB/c (A), uIgG/c (B), uRBP/c (C) and uNAG/c (D) in the 
complete group (n=19), and subgroups of dogs that were treated with trilostane (n=12) or 
hypophysectomy (n=7).   
Dark grey box: complete group, white box: trilostane group, yellow box, hypophysectomy group. Box: 
interquartile range, o: outlier, *: significant difference (p < 0.05) compared to time point 0. 
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Figure 2 (continued). Post-treatment course of uALB/c (A), uIgG/c (B), uRBP/c (C) and uNAG/c 
(D) in the complete group (n=19), and subgroups of dogs that were treated with trilostane (n=12) 
or hypophysectomy (n=7).   
Dark grey box: complete group, white box: trilostane group, yellow box, hypophysectomy group. Box: 
interquartile range, o: outlier, black square: extreme value, *: significant difference (p < 0.05) 
compared to time point 0. 
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Post-mortem kidney histopathological examination was available for two dogs that 
had died between T6 and T12. The first dog was an 11 year old Boxer that died of a 
ventricular tachycardia. Light microscopic evaluation revealed mild thickening of Bowman’s 
capsule, tubular deposits (presumably protein) and focal accumulation of lymphocytes, 
plasma cells and macrophages. The second dog was a 13 year old Jack Russell Terrier 
euthanized because of severe respiratory distress (diffuse interstitial pneumonia). Kidney 
histopathology showed  diffuse glomerular lesions including mild hypercellularity, thickening 
of the glomerular basement membrane and granular deposits in the glomerular tuft. Multifocal 
cystic glomerular atrophy and glomerulosclerosis were also found. Tubulo-interstitial lesions 
included tubular atrophy, thickening of the tubular basement membrane, mild interstitial 
fibrosis and few mononuclear cell infiltrates. 
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Discussion 
This study is the first to prospectively assess long-term effects of canine  on renal 
function, using both routine renal markers and more sensitive tests such as GFR and urine 
markers. Main findings are that GFR is increased pretreatment and decreases post-treatment. 
Furthermore, UPC and urinary markers significantly decline post-treatment, although after 12 
months of treatment, proteinuria persisted in 5/13 (38%) dogs. 
 
Pretreatment Clcreat, Clexo and Clendo in PDH patients were above the mean values of 
healthy controls in 10/16 (63%), 14/19 (74%) and 11/19 (58%) dogs, respectively. Post-
treatment values were 27% and 26% lower after 6 and 12 months for Clcreat, 13 and 11% for 
Clexo, and 15% and 23% for Clendo. Between-day coefficient of variation (CV) for Clcreat in our 
department in healthy dogs is 14.1%, for Clexo between-day CV is 9.9% and for Clendo it is 
13.1%. This means that the significant decrease of Clcreat at T6 and T12 and of Clendo at T12 
are true changes in GFR not due to between-day measurement variability.  
 
In the present study, 4/13 dogs had a Clcreat < 2.0 mL/min/kg at T12, which is 
compatible with renal impairment. As in previous studies, pretreatment screat was low and 
increased post-treatment, but no dog developed azotemia within 12 months.
26,35
 Also, of the 
10 dogs that died or were euthanized, none died of renal failure, although 2 dogs did have 
glomerular and tubulo-interstitial renal lesions at post-mortem examination. Nevertheless, it is 
inconclusive whether these lesions were caused by concomitant renal disease or by PDH. 
 
In human patients with Cushing’s syndrome, post-treatment GFR is decreased, leading 
to clinical CKD in some patients. Monitoring of GFR therefore seems mandatory in these 
patients.
11
 Contrary to humans, cardiovascular risk factors do not seem to play an important 
role in development of renal dysfunction in dogs with Cushing’s syndrome.11,36-37 The clinical 
relevance of GFR changes in dogs with PDH is currently unclear, as in hypothyroid dogs.
29,31
 
Patients in the present study were middle-aged to old and part of the observed decline in GFR 
during the 12-month period could have been age-related, as described in aging humans, and 
suggested in aging dogs.
38-39
  
 
Discrepancies between Clcreat, Clexo and Clendo were observed, as previously reported in 
healthy dogs
40
, dogs with Cushing’s syndrome26 and healthy cats.41 Potential explanations 
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could be the disposition of the marker, laboratory technique, the animal’s characteristics and 
the clinical setting. Simultaneous injection of both markers limits animal-dependent 
influences. Whatever the explanation, dispositions of exo- and endo-iohexol differ from each 
other and from creatinine so that they should be considered as different markers. 
 
Following hypophysectomy, dogs were supplemented with cortisone acetate and 
levothyroxine, because of very low endogenous ACTH- and thyroid-stimulating 
hormoneproduction.
27
 Exogenous glucocorticoids
42
 and levothyroxin
29,31
 affect GFR, but a 
"physiologic dose" (0.25mg/kg bid) of cortisone was given and none of the dogs had a serum 
thyroxine concentration below the reference range at the time GFR was performed. Therefore, 
these factors are unlikely to influence GFR in the Hx group. 
 
In agreement with a previous study,
4
 SBP did not change significantly following 
treatment. At T3 and all later time points, USG was significantly higher in the Mx group, but 
not in the Hx group. This may be explained by impaired release of vasopressin post-
hypophysectomy. All Hx dogs were supplemented with desmopressine and urine samples 
were taken after their morning dose. 
 
Pretreatment UPC was increased in 68% of dogs, which is a higher percentage than in 
earlier studies (44 to 46%)
5-6
, but in accordance with more recent reports (71%).
43
 Different 
cut-off values for proteinuria partly explain this difference (UPC > 1.0 in initial studies and > 
0.5 in recent reports). Post-treatment proteinuria has previously been reported in 21-31% of 
cases with well controlled PDH and is found in 38% of dogs in the current study at T12.
5-6
  
 
Because no randomization was performed, Mx and Hx groups differ at T0 and it is 
difficult to compare between-group post-treatment changes. In addition, both groups consist 
of a small number of dogs. In the Mx group, however, UPC tended to decline slower than in 
the Hx group. At T12 3/7 Mx dogs had an increased UPC, whereas the only 2 dogs in the Hx 
group with proteinuria at T6 and T12 were dogs with recurrence of PDH. These findings 
might suggest: 1) that recurrence of PDH is associated with recurrence of proteinuria, and 2) 
that surgically treated dogs may be less likely to remain proteinuric post-treatment than 
medically treated dogs. Therefore, proteinuria in a dog after hypophysectomy may either 
suggest (pending) recurrence of PDH or a concurrent disease and definitely warrants the 
clinician’s attention.  
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Parallel to UPC, uALB/c, uIgG/c and uRBP/c decreased following treatment in the 
complete group. In a previous study comparing untreated dogs with Cushing’s syndrome to 
healthy controls, these markers are increased, suggesting altered glomerular and tubular 
function.
26
 A combined HMW (IgG) and LMW (uRBP) proteinuria indicates increased 
glomerular permeability with decreased tubular protein reabsorption. The latter may be due to 
protein overload in the tubular lumen with saturation of the tubular reabsorption capacity.
44
 
Results of the present study also indicate that these changes are reversible in most dogs. As 
for UPC, post-treatment course of uALB/c, uIgG/c and uRBP/c may differ in the Mx and Hx 
group. In the latter, uALB/c, uIgG/c and uRBP/c were lower following treatment, whereas no 
significant difference was found in the former. In medically treated dogs with PDH, clinical 
signs of hypercortisolism are controlled without removing its primary cause. Thus serum 
cortisol may still exceed physiological levels during a certain period of the day. Therefore, 
this “temporary hypercortisolism” might contribute to proteinuria in these patients, as 
opposed to dogs that underwent hypophysectomy and are substituted with a low dose of 
cortisone. 
 
 In the current study, pretreatment uNAG/c was high and decreased post-treatment, 
although not statistically significant. In humans with glomerulonephritis
45
, in geriatric cats 
with azotemia
46
 and in dogs with CKD
20
, uNAG/c is correlated with UPC and/or albuminuria, 
but not with screat concentration (or GFR in humans). Therefore, high uNAG/c may reflect 
high lysosomal activity rather than active tubular damage and remains high in the dogs with 
persistent proteinuria or albuminuria because of increased tubular processing. However, 
additional unknown factors also play a role, since some of the dogs with a UPC < 0.5 also 
have mild increases in uNAG/c. 
 
Urinary tract infection (UTI) is known to affect UPC and may also influence urinary 
marker concentrations.
47-48
 However, UTI is unlikely to affect results of the present study 
since only one dog had a positive urine culture prior to treatment and post-treament and only 
one other dog had a cystitis at T3 and T6. 
 
  Limitations of the present study are the low number of dogs in both subgroups and not 
using the gold standard of urinary inulin clearance for measurement of GFR. However, this is 
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a time-consuming, stressful and potentially harmful procedure, with increased risk of UTI. 
Moreover, both Clcreat and Cliohexol show good correlation with urinary inulin clearance.
16,49
  
 In conclusion, although none of the patients developed CKD over 12 months, post-
treatment decline of GFR and persistent proteinuria in 38% of dogs warrant the clinician’s 
attention. Future research with longer follow-up and kidney histopathology of patients with 
persistent proteinuria or a low GFR is needed to further assess renal outcome. 
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Summary 
Objectives of this study were to evaluate glomerular filtration rate (GFR), renal 
structural changes and proteinuria in aged Beagle dogs before and after hydrocortisone 
administration. Eleven Beagle dogs ≥ 10 years old were treated with either hydrocortisone 
(HC group, n=6) or placebo (control group, n=5). Urinary markers, GFR and kidney biopsies 
were evaluated before (T0), during (T16wks) and after discontinuing HC administration 
(T24wks). 
Results indicate that HC administration causes a significant increase in GFR. At all 
time points except T16wks, proteinuria was higher in the control group than in the HC group, 
and there was no significant difference in urinary markers between groups. At T16wks, 
proteinuria, urinary albumin-to-creatinine (c) ratio, immunoglobulin G/c and retinol-binding 
protein/c were higher compared to baseline in the HC group. At T0, rare to mild renal lesions 
were detected in all HC dogs and rare to moderate changes in all control dogs. 
Glomerulosclerosis progressed in both groups until T24wks. Tubular atrophy was detected in 
three HC dogs at T16wks and T24wks, but also in five control dogs throughout the study. At 
every time point, five HC dogs and all control dogs had rare to moderate interstitial 
inflammation. Rare to mild interstitial fibrosis was found in up to three HC dogs at T16wks 
and T24wks, and severe fibrosis in one HC dog at T24wks. Up to four control dogs had rare 
to mild fibrosis at all time points.  
These findings indicate that clinically healthy, aged Beagle dogs may have 
considerable renal lesions and proteinuria, which could have implications for experimental or 
toxicological studies. Additional research is needed to elucidate glucocorticoid effects on 
renal structure, but functional changes such as hyperfiltration and proteinuria warrant 
attention to kidney function of canine patients with Cushing's syndrome or receiving 
exogenous glucocorticoids.  
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Introduction  
 Proteinuria has been described in 44-75% of dogs with Cushing’s syndrome and 
sometimes persists or even develops after successful treatment of hypercortisolism.
1-2
 An 
increased urinary albumin excretion has also been demonstrated in more than 80% of human 
Cushing patients prior to treatment of hypercortisolism.
3
 Whereas short-term administration 
of exogenous glucocorticoids (GC) seems to increase GFR in humans and dogs, one study 
indicates a decreased glomerular filtration rate (GFR) in people with Cushing’s syndrome and 
suggests that renal compromise in these patients warrants more attention.
4-6
 Therefore, human 
and canine Cushing patients could be considered at risk for renal complications, but 
information about effects of GC on renal function is scarce.  
 
 Canine endogenous hypercortisolism or Cushing’s syndrome is considered a good 
animal model for its human counterpart, because of similarities in the pathogenesis : 80–85% 
of cases are caused by a pituitary tumor and ACTH-dependent, while 15–20% are ACTH-
independent.
7
 Moreover, middle-aged to old individuals are typically affected in both species 
and similar clinical signs include fatigue, weight gain and central obesity with muscle atrophy 
of the limbs, with polyuria, polydipsia and polyphagia being most pronounced in the dog.
8-9
  
 Previous experimental studies evaluating GC effects on renal function often differed 
from the in vivo situation in spontaneous Cushing’s syndrome. For example, many 
experiments included young animals.
10-11
 Aging itself has marked effects on renal structure 
and function in humans, but also in laboratory animals, dogs and cats.
12-16.
 Therefore, in aged 
individuals GC will act on kidneys with an already decreased renal functional reserve.
17-18 
 
 In addition to serum renal markers and GFR, urinary markers are gaining interest in 
veterinary medicine, because of their potential for early detection of renal dysfunction and 
ability to localize the insult to a particular part of the nephron.
19-21
 These markers include high 
molecular weight (HMW) proteins such as immunoglobulin G (IgG), intermediate molecular 
weight (IMW) proteins such as albumin (ALB), low molecular weight (LMW) proteins such 
as retinol-binding protein (RBP) and urinary enzymes such as N-acetyl-β-D-glucosaminidase 
(NAG).
22-23
 Glomerular dysfunction leads to higher filtration of ALB and in more advanced 
stages to presence of IgG in the ultrafiltrate.
24
 Tubular dysfunction is reflected by urinary loss 
of RBP and NAG, due to disturbed reabsorption or increased protein trafficking and structural 
damage of tubule cells, respectively.
25-26 
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 Information about GC effects on renal function and morphology is rare, and often 
limited to case reports, despite their frequent therapeutic use and the occurrence of Cushing’s 
syndrome in humans and dogs.
11,27-30
 Therefore, the objectives of this study were to evaluate 
GFR, renal light microscopic and ultrastructural changes, and proteinuria in old Beagle dogs 
before and after administration of hydrocortisone.  
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Material and methods 
Animals 
 This study was approved by the Ethical Committee of Ghent University (EC: 
2008/146). Eleven female spayed Beagle dogs, age 8.4 to 11 years (median: 10 years), with a 
body weight ranging from 10.9 to 14 kg (median 12.9 kg) were included in the study. Dogs 
were housed in pairs in two adjacent indoor kennels of 2.6 m
2
 each, with free access to water, 
fed a standard dry food
a
 (25.0% protein, 15.3% fat, 52.0% carbohydrates, 2.6% fiber) twice a 
day, and allowed outdoor activity in a secured area. They were judged healthy based on 
physical examination, hematology, biochemistry profile, abdominal ultrasound and two 
consecutive morning urinary corticoid-to-creatinine ratio’s (< 10*10-6) to exclude endogenous 
Cushing’s syndrome. A urinalysis consisting of sediment and dipstick analysis, urine specific 
gravity (USG), urinary protein-to-creatinine ratio (UPC), and bacterial culture were 
performed, but proteinuria (UPC > 0.5) was not an exclusion criterion. 
 
Study design 
 Five dogs were randomly assigned to the placebo group (control group) and six to the 
hydrocortisone treatment group (HC group). After baseline sampling (T0), the control group 
received a gelatin capsule containing lactose and the HC-group received a capsule containing 
lactose and a median dose of 9.6 mg/kg HC (range from 8.7 to 11.0 mg/kg) every 12 hours 
(h). Hydrocortisone was used because it is the synthetic glucocorticoid most closely 
resembling endogenous cortisol and dosage was based on two previous publications.
10-11
 Dogs 
were monitored for development of clinical signs of GC excess such as polyuria, polydipsia 
and polyphagia, and for skin abnormalities using a scoring sheet. Treatment period was 16 
weeks (end of treatment period: T16wks), then the HC dose was tapered over 4 weeks (one 
week 10 mg/kg once a day, two weeks 5 mg/kg once a day, and one week 2.5 mg/kg once a 
day, end of tapering period: T20wks) and the study ended four weeks after completely 
stopping treatment (end of study: T24wks). Plasma exogenous creatinine-iohexol clearance 
tests (PEC-ICT), kidney biopsies and urine sampling were performed in both groups at 
baseline, at T16wks and at T24wks. Blood and urine samples were additionally collected 
during treatment after 4 wks (T4wks) and at T20wks. 
 At T16wks and T24wks, an ACTH-stimulation test was performed in all dogs by 
collecting serum for measurement of cortisol before and 60 minutes (min) after intramuscular 
injection of 0.25 mg of synthethic ACTH
b
. Cortisol concentrations were measured using an 
immunoassay
c
 validated for use in the dog.   
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Sampling methods  
 Morning urine samples were taken by cystocentesis (10 mL, 22 G needle). Urinary 
dipstick analysis
d
, urine specific gravity (USG), urinary protein-to-creatinine ratio (UPC), 
sediment analysis and bacterial culture were performed. After centrifugation, the urine 
supernatant was stored at –80°C until analysis of urinary markers. 
 
Plasma exogenous creatinine-iohexol clearance test (PEC-ICT) 
 All dogs were fasted for at least 10 h prior to the test day and fed immediately after 
ending the sampling period. Water was provided ad libitum. GFR was measured by plasma 
clearance of exogenous creatinine (Clcreat), exo- and endo-iohexol (Clexo and Clendo), adapted 
from a protocol previously proposed in cats and described in Chapter V.
31-32
  
 Plasma creatinine concentrations were analysed using an enzymatic method
f
. This 
technique was validated by measuring samples with increasing creatinine concentration 4 
times per day, on each of three consecutive days. The upper limit of quantification was 1202 
µmol/L. Within- and between-day coefficients of variation were < 3% in the lower, middle, 
and high concentration range (80, 530 and 1160 µmol/L, respectively), and there was linear 
correlation between theoretical and measured concentrations within quantification limits. The 
basal plasma creatinine concentration measured on the day of PEC-ICT testing was subtracted 
from the creatinine concentrations measured in the samples from that dog.  
 Plasma concentrations of iohexol stereo-isomers (exo- and endo-iohexol) were 
determined by a validated high-performance liquid chromatographic method with ultraviolet 
detection, as described in previous studies and in Chapter V.
33
 Pharmacokinetic analyses were 
performed using WinNonlin
g
. For clearance calculation, individual plasma data were 
subjected to noncompartmental analysis, as described by Watson and coworkers.
34
 Plasma 
Clcreat, Clexo and Clendo were determined as mentioned in Chapter V. 
 
Serum and urinary  renal markers 
 Serum creatinine (screat)
f
 and urea
h
 were measured using an enzymatic method. 
Urinary protein was determined with a turbidimetric method using benzethonium chloride
h
 
and urinary creatinine with a modified Jaffé reaction using picric acid
g
. As markers of 
glomerular function, uALB and uIgG concentrations were determined with a commercial 
canine specific enzyme-linked immunosorbent assay (ELISA)
i
. As an indication of tubular 
function, uRBP was determined with a human ELISA
i
 and uNAG activity using a 
colorimetric assay
j
. All assays have been previously described and validated in our 
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laboratory.
22,35
 Within- and between-day coefficients of variation were 5.2 and 12.0% for the 
uALB ELISA, 6.1 and 7.7% for the uIgG ELISA, 4.3 and 5.5% for the uRBP ELISA, and 4.9 
and 8.1% for the uNAG colorimetric assay. Because spot urine samples were used, urinary 
concentration of each marker was indexed to urinary creatinine (c) and expressed as a ratio: 
uALB/c, uIgG/c, uRBP/c and uNAG/c.
36,37
  
  
Kidney biopsies 
 Coagulation was checked in all dogs by measurement of buccal mucosal bleeding 
time, and activated partial thromboplastin and prothrombin time
k
. Ultrasound guided 
percutaneous kidney biopsies were taken under general anesthesia at T0, T16wks and 
T24wks. Dogs were premedicated intravenously (IV) with a combination of acepromazine
l
 
(0.01 mg/kg) and butorphanol
m
(0.01 mg/kg). Afterwards, dogs received IV diazepam
n
 (0.2 
mg/kg) immediately followed by propofol
o
 to effect until endotracheal intubation could be 
performed. Anesthesia was maintained with isoflurane
p
 (2% vaporized in 100% oxygen).  
 Ultrasound guided kidney biopsies were taken by an experienced radiologist, 
according to a previously described technique.
38
 Large-bore 14-gauge needles
q
 with 9cm 
length and 20 mm specimen notch were used to take two consecutive biopsies > 10 mm long 
(or three biopsies < 10 mm long) from the left kidney. Biopsy cores were collected and 
transported according to a standardized protocol adapted from Lees and co-workers.
39
 
Specimens were transversely divided in three parts and transferred into a standard container 
with 3% glutaraldehyde for EM within 5 min after collection, in 10% buffered formalin for 
LM and in Michel’s transport medium for IF. Biopsies were cooled and transported to a 
nephropathology service within 24 h.  
 Three µm sections from each biopsy sample were stained with hematoxylin and eosin 
(HE), periodic acid-Schiff (PAS), Masson’s trichrome and periodic acid methenamine silver. 
All biochemical stains were performed according to standard procedures.
39
 Slides were 
evaluated using light microscopy for presence of glomerular, tubular, interstitial and vascular 
lesions, using a tie-grade system from 1 to 4 (1=rare lesion, 2=mild, 3=moderate, 4=severe).                                                                                                                      
 For direct immunofluorescence (IF) examination, fresh unfixed renal specimens were 
embedded in OCT compound, snap-frozen in liquid nitrogen and stored at –80°C. 
Subsequently, five µm thick sections were fixed with acetone for 15 min. After washing with 
PBS (two passages), slides were incubated with FITC-labelled sheep anti-dog IgG
r
, goat anti-
dog IgM
r
, goat anti-canine IgA
r
, goat anti-dog C3
r
,
 
rabbit anti-human κ light chains, rabbit 
anti-human λ light chains, and rabbit anti-human complement factor C1Qs. Primary antibodies 
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were omitted as negative controls and substituted with PBS.
40
 Fluorescence findings were 
classified according to the pattern seen on immunofluorescent examination (granular or 
linear), which included the localization of the deposit (mesangium, GBM, tubules and 
vessels), the distribution (focal, diffuse, segmental and global) and the intensity. 
 For transmission electron microscopy (EM), the tissue was post-fixed in 2% osmium 
(in distilled water) for 1.5 h, dehydrated in graded acetone and embedded in epon. Semi-thin 
sections were stained with azure methylene blue. Ultrathin sections were counterstained with 
uranyl acetate and lead citrate. For ultrastructural studies, a Philips EM 420 was used. All 
histological sections were examined in a blinded fashion by three pathologists. 
 
Statistical analysis 
 Analyses were performed with a commercial software program
t
. Level of significance 
was set at 5%. A general linear model was used to test the effect of HC treatment, time point 
and their interaction between the control and the HC group. When a statistically significant 
interaction between treatment and time point was detected, a post hoc hypothesis test was 
performed to compare the two groups at each period. 
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Results 
Dogs 
 All dogs assigned to the HC group developed clinical signs of hypercortisolism, such 
as polyuria, polydipsia and skin changes (atrophy of abdominal skin with phlebectasia, no 
regrowth of clipped haircoat, comedones, ecchymose) and complementary laboratory changes 
(increased alkaline phosphatase and alanine aminotransferase, ALT). Additionally, some dogs 
also developed muscle atrophy and abdominal distention, but no significant changes in 
bodyweight were detected throughout the study. At T16wks, 36 h after HC withdrawal, all 
dogs in the HC group failed to respond adequately to ACTH-stimulation; median (range) 
serum cortisol concentrations before and after ACTH-injection were 18 nmol/L (6-30 nmol/L) 
and 25 nmol/L (17-86 nmol/L). At T16wks serum ALT was significantly increased in the HC 
group compared to the control group (p < 0.001). 
 At T24wks, 4 weeks after complete HC withdrawal, clinical signs were resolved, 
except for skin changes in some dogs, and laboratory changes returned to baseline (alkaline 
phosphatase and ALT within reference interval). Response to an ACTH-stimulation test was 
within normal range in all dogs; median (range) serum cortisol concentrations before and after 
ACTH-injection were 32 nmol/L (25-60 nmol/L) and 330 nmol/L (246-516 nmol/L).  
 
Plasma exogenous creatinine-iohexol clearance test 
 As presented in Table 1, plasma Clcreat and Clexo were significantly higher in the HC 
group than in the control group at T16wks (p < 0.001). There was no significant difference 
between groups either at baseline or at T24wks. Plasma Clendo was not significantly different 
between groups at any time point (p=0.21). Figure 1 shows the plasma creatinine (A), exo-
iohexol (B) and endo-iohexol concentration (C) versus time curves in the control and HC 
groups at baseline, T16wks and T24wks.  
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Figure 1. Plasma concentration versus time curves.  
Plasma creatinine (A1, A2), exo-iohexol (B1, B2) and endo-iohexol concentration (C1, C2) versus 
time curves in the hydrocortisone (HC) group (6 dogs) and the control group (5 dogs) at T0, T16wks 
and T24wks. Mean ± standard deviation is displayed. The asterisk indicates a statistically significant 
difference (p<0.001) in plasma clearance between groups at T16wks, for creatinine and exo-iohexol 
clearance. 
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Figure 1 (continued). Plasma concentration versus time curves. 
Plasma creatinine (A1, A2), exo-iohexol (B1, B2) and endo-iohexol concentration (C1, C2) versus 
time curves in the hydrocortisone (HC) group (6 dogs) and the control group (5 dogs) at T0, T16wks 
and T24wks. Mean ± standard deviation is displayed. The asterisk indicates a statistically significant 
difference (p<0.001) in plasma clearance between groups at T16wks, for creatinine and exo-iohexol 
clearance. 
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Serum and urinary renal markers  
 As shown in Table 1, no significant differences were detected between groups for 
screat (p = 0.74), urea concentration (p = 0.32) and USG (p = 0.30) throughout the study, 
despite a decrease of USG during treatment in the HC group. UPC was significantly higher in 
the control group than in the HC group (p = 0.003) at baseline, T4wks, T20wks and T24wks, 
but not at T16wks. Figure 2 presents the median and 75-25
th
 percentiles of UPC, uALB/c, 
uIgG/c, uRBP/c and uNAG/c in the HC and control groups before, during and after HC 
administration, with the grey area representing the treatment period. Differences between HC 
and control groups in glomerular markers uALB/c (p = 0.05) and uIgG/c (p = 0.26) did not 
reach statistical significance, although they progressively increased within the HC group 
during treatment and decreased afterwards. Also for tubular markers uRBP/c (p = 0.07) and 
uNAG/c (p = 0.20), there was no significant difference between the HC and control groups at 
any time point, despite the fact that uRBP/c seemed to increase within the HC group, with 
highest concentrations at T16wks, and declined again after discontinuation of HC.  
 
Figure 2. Urinary markers.  
Median and 75-25
th
 percentiles of urinary albumin-to-creatinine ratio (uALBc) (A), immunoglobulin 
G-to-creatinine ratio (uIgG/c) (B), retinol-binding protein-to-creatinine ratio (uRBP/c) (C) and N-
acetyl-β-D-glucosaminidase ratio (uNAG/c) (D) at T0, T16wks and T24wks in the hydrocortisone 
(HC) group (black circles) and in the control (C) group (white squares). The grey area indicates the 
hydrocortisone administration period. 
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Figure 2 (continued). Urinary markers.  
Median and 75-25
th
 percentiles of urinary albumin-to-creatinine ratio (uALBc) (A), immunoglobulin 
G-to-creatinine ratio (uIgG/c) (B), retinol-binding protein-to-creatinine ratio (uRBP/c) (C) and N-
acetyl-β-D-glucosaminidase ratio (uNAG/c) (D) at T0, T16wks and T24wks in the hydrocortisone 
(HC) group (black circles) and in the control (C) group (white squares). The grey area indicates the 
hydrocortisone administration period. 
 
 
  
 C 
 B 
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Figure 2 (continued). Urinary markers.  
Median and 75-25
th
 percentiles of urinary albumin-to-creatinine ratio (uALBc) (A), immunoglobulin 
G-to-creatinine ratio (uIgG/c) (B), retinol-binding protein-to-creatinine ratio (uRBP/c) (C) and N-
acetyl-β-D-glucosaminidase ratio (uNAG/c) (D) at T0, T16wks and T24wks in the hydrocortisone 
(HC) group (black circles) and in the control (C) group (white squares). The grey area indicates the 
hydrocortisone administration period. 
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Table 1. Glomerular filtration rate and routine renal markers in the control and HC group. 
T0, baseline; T16wks, at the end of the 16 weeks hydrocortisone treatment period; T24 wks, at 4 
weeks after complete cessation of hydrocortisone treatment; Clcreat, plasma clearance of creatinine; 
Clexo, plasma clearance of exo-iohexol, Clendo, plasma clearance of endoiohexol; screat, serum 
creatinine, USG urinary specific gravity; UPC, urinary protein-to-creatinine ratio. The asterisk 
indicates in which group results are significantly increased (p < 0.05) compared to the other group at 
that timepoint. 
 
  
Renal 
Marker 
T0 T16wks T24wks 
Control HC Control HC Control HC 
Clcreat 
(mL/min/kg) 
3.3 
(2.8-3.7) 
3.3 
(2.6-3.7) 
3.0 
(2.1-3.4) 
3.7 
(2.5-4.2)* 
2.8 
(2.0-3.0) 
2.7 
(2.3-3.3) 
Clexo 
(mL/min/kg) 
2.9 
(2.7-3.6) 
3.2 
(2.5-3.7) 
2.9 
(2.1-3.4) 
4.0 
(2.5-4.5)* 
2.9 
(2.1-3.1) 
2.8 
(2.0-3.3) 
Clendo 
(mL/min/kg) 
3.1 
(2.8-3.9) 
2.9 
(2.3-4.5) 
2.5 
(1.6-2.9) 
3.2 
(1.8-3.9) 
2.3 
(1.8-2.4) 
2.3 
(1.6-2.7) 
screat 
(µmol/L) 
72 
(58-92) 
80 
(75-84) 
86 
(75-113) 
88 
(68-111) 
90 
(76-119) 
90 
(68-107) 
urea 
(mmol/L) 
13.1 
(7.3-17.2) 
11.0 
(9.9-14.6) 
10.3 
(8.1-25.9) 
9.2 
(6.0-20.4) 
11.8 
(7.7-27.4) 
10.8 
(8.1-16.3) 
USG 1.018 1.024 1.018 1.003 1.012 1.019 
(1.008-1.035) (1.012-1.050) (1.011-1.020) (1.000-1.013) (1.006-1.050) (1.007-1.029) 
UPC 1.77 
(0.12-10)* 
0.18 
(0.13-1.56) 
1.93 
(0.11-6.55) 
3.04 
(0.28-6.19) 
1.95 
(0.15-6.67)* 
0.16 
(0.02-0.33) 
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Kidney histopathology  
 Most important light microscopic findings in HC and control dogs are presented in 
Table 2 and 3. Affected dogs in both groups and the score ranges of severity at different time 
points are mentioned.  
 Commonly observed glomerular lesions were global endocapillary and mesangial 
hypercellularity, with increase of mesangial matrix. Increase of mesangial matrix progressed 
in both the HC and control group at T16wks and T24wks, with an increasing number of 
affected dogs and highest scores at T24wks (Figure 3a, 3b and 3c). Obsolescent glomeruli 
were detected in one control dog at T0, in 4 HC dogs and all control dogs at T16wks, and in 
all dogs at T24wks (Figure 4a). Asymmetrical thickening and splitting of Bowman’s capsule 
was most pronounced in two control dogs especially at T24wks, whereas only rare to mild 
changes were seen in the HC group, mainly at T16wks (Figure 4b). Tubular lesions included 
tubular atrophy, tubular macro- and micro-vesiculation and cellular pigment. In the HC group 
there was no tubular atrophy at T0, whereas mild to severe atrophy was detected in three dogs 
at T16wks and T24wks. Rare to moderate tubular atrophy was present throughout the study in 
three to five control dogs. At every time point, up to five HC dogs and all control dogs had 
rare to moderate interstitial inflammation (Figure 3d). Rare to mild interstitial fibrosis was 
found in up to three HC dogs at T16wks and T24wks, and severe fibrosis in one HC dog at 
T24wks. Up to four control dogs had rare to mild fibrosis at all time points.  
 Ultrastructural lesions included changes of the glomerular basement membrane 
(GBM) such as thickening, rarefaction, wrinkling and irregular jagged profile (Figure 5a). At 
T0, EM detected GBM changes in only 2/6 HC dogs, but they were prominent in the entire 
HC group at T16wks and T24wks. In the control group mild to moderate GBM lesions were 
found at all time points. Multifocal to diffuse podocyte foot process fusion was found in 5/6 
HC dogs and all five control dogs at every time point (Figure 5b and 5c). Degenerative 
tubular cells and/or degenerative changes in podocytes, endothelial and mesangial cells were 
detected in dogs from both groups and were most pronounced at T24wks.  
 Immunofluoresence staining was unremarkable with coarse, segmental deposits of Ig 
G (1+ to 2+) in the capillary wall in 1/6 HC dogs and 2/5 control dogs at T16wks. Mesangial 
Ig M deposits (1+ to 2+) were detected in 4/6 HC dogs and 3/5 control dogs at T16wks, and in 
one control dog at T24wks. This was probably a nonspecific finding due to entrapment of Ig 
M in sclerotic glomeruli. Coarse λ light chain deposits (1+ to 2+) were seen in the capillary 
walls and mesangium of one  dog from each group at T16wks, and in one control dog at 
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T24wks. One dog from the HC group had 1+ coarse, diffuse, segmental deposits of C3 at 
T24wks. 
 In summary, glomerular, tubular and interstitial lesions presented in Table 2 and 3 
progressed over time in both groups, with most severe lesions detected at T24wks. At 
T16wks, a marked increase was seen in the number of HC dogs with obsolescent glomeruli 
and tubular atrophy compared to baseline. No significant vascular changes (hypertrophic and 
hyaline arteriosclerosis, arteritis, fibrinoid necrosis, thrombosis) were present at baseline or at 
any of the other time points. 
 
Figure 3. Light microscopic lesions.  
(A) Glomerulus, Dog 11 at T0. Early glomerular lesions including minimal increase of mesangial 
matrix. Periodic acid-Schiff staining (x400); (B) Glomerulus, Dog 11 at T16 weeks. Moderate 
hypercellularity of mesangial and endothelial cells and one synechia. There is segmental to global 
increase of mesangial matrix and Bowman's capsule is symmetrically thickened with proliferation of 
parietal epithelial cells. Periodic acid-Schiff staining (x400); (C) Glomerulus, Dog 11 at T24 weeks. 
Moderate hypercellularity of mesangial and endothelial cells associated with global increase of 
mesangial matrix. Visceral epithelial cells are hypertrophic. Periodic acid-Schiff staining (x400); (D) 
Tubulo-interstitium, Dog 11 at T24 weeks. Moderate inflammation widely separating tubules and 
atrophic tubules. Periodic acid-methenamine silver staining (x400). 
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Figure 4. Glomerular lesions.  
(A) Glomerulus, Dog 8 at T16 weeks. Obsolescent glomerulus. Periodic acid-Schiff staining (x400). 
(B) Glomerulus, Dog 5 at T24 weeks. Accentuated lobulation, increase of mesangial and endothelial 
cellularity of the tuft, and synechiae. Splitting of Bowman's capsule is visible. Periodic acid-Schiff 
staining (x400). 
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Figure 5. Electron microscopic glomerular lesions.  
(A) Glomerulus, Dog 10 at T16 weeks. Sub-endothelial widening and rarefaction of the glomerular 
basement membrane associated with foot process effacement. EM x5000; (B) Glomerulus, Dog 9 at 
T24 weeks. Multifocal foot process effacement (arrow) and endothelial cell swelling with reduction of 
the capillary lumens. Increased mesangial matrix. EM x4000; (C) Glomerulus, Dog 11 at T24 weeks. 
Diffuse and severe foot process effacement (arrow). EM x400. 
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Table 2. Glomerular lesions in the hydrocortisone and control group. 
Endocap., endocapillary; Prim.mesang., primary mesangial; T0, baseline; T16wks, at the end 
of the 16 weeks hydrocortisone treatment period; T24 wks, at 4 weeks after complete 
cessation of hydrocortisone treatment; HC, hydrocortisone. Score: 1=rare lesion, 2=mild, 
3=moderate, 4=severe. 
  
Dog 
number 
Global endocap. 
hypercellularity 
Prim. mesang. 
hypercellularity 
Diffuse 
glomerulosclerosis 
Global 
glomerulosclerosis 
Number of 
obsolescent glomeruli 
T0 
T16 
wks 
T24 
wks 
T0 
T16 
wks 
T24 
wks 
T0 
T16 
wks 
T24 
wks 
T0 
T16 
wks 
T24 
wks 
T0 
T16 
wks 
T24 
wks 
HC 
group                               
Dog 1 0 0 2 0 0 2 2 2 4 2 3 2 0 5/94 5/39 
Dog 2 0 0 0 0 0 2 0 0 4 0 0 2 0 0 4/63 
Dog 3 2 2 2 2 3 2 0 2 4 0 2 3 0 3/55 9/90 
Dog 4 0 0 0 0 0 0 1 1 3 1 1 2 0 3/52 2/26 
Dog 5 0 0 0 0 2 1 2 2 3 2 2 2 0 4/56 4/35 
Dog 6 0 0 2 0 0 2 2 2 3 2 0 2 0 0 4/37 
Control 
group 
               
Dog 7 2 2 2 3 3 2 3 3 4 3 3 2 0 6/44 6/83 
Dog 8 0 2 2 0 2 2 2 4 3 2 4 2 5/12 18/79 4/19 
Dog 9 0 0 0 0 0 0 0 0 2 0 0 2 1/22 3/47 5/42 
Dog 10 3 2 2 2 3 3 3 2 2 3 2 2 6/39 8/57 4/46 
Dog 11 0 0 0 0 0 0 0 2 2 0 1 1 0 2/69 1/45 
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Table 3. Tubular and interstitial lesions in the hydrocortisone and control group.  
T0, baseline; T16wks, at the end of the 16 weeks hydrocortisone treatment period; T24 wks, 
at 4 weeks after complete cessation of hydrocortisone treatment; HC, hydrocortisone. Score:  
1=rare lesion, 2=mild, 3=moderate, 4=severe. 
 
Dog 
number 
Tubular atrophy Tubular cell pigment Interstitial fibrosis 
Interstitial 
inflammation 
T0 T16wks T24wks T0 T16wks T24wks T0 T16wks T24wks T0 T16wks T24wks 
HC 
group 
                   
Dog 1 0 3 2 2 2 2 0 2 2 0 2 2 
Dog 2 0 0 0 1 1 1 0 0 2 1 0 2 
Dog 3 0 2 4 1 1 1 0 1 4 1 2 3 
Dog 4 0 3 3 2 2 2 0 0 2 0 2 2 
Dog 5 0 0 0 2 2 2 0 0 0 0 1 0 
Dog 6 0 0 0 1 0 2 0 0 0 0 0 1 
Control 
group 
            
Dog 7 1 2 0 0 2 1 0 2 2 1 3 2 
Dog 8 3 3 2 2 2 2 2 2 2 2 3 2 
Dog 9 0 2 2 0 0 2 0 2 2 1 2 2 
Dog 10 2 2 2 2 2 2 2 0 2 2 2 2 
Dog 11 0 2 0 2 2 2 0 2 0 1 2 2 
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 Discussion  
This study demonstrates that HC administration reversibly increases GFR in aged 
Beagle dogs. Plasma Clcreat and Clexo were both significantly increased in the HC group at 
T16wks, but no longer differed between groups eight weeks after tapering and cessation of 
treatment. This is in agreement with previous reports showing that synthetic GC augment 
GFR in dogs, with an increase in renal plasma flow (RPF), renal vasodilation and a decrease 
in filtration fraction (FF).
5,41
 The mechanism for this increase is most likely at least partly 
species-specific, since GC also increase GFR in humans, but with little effect on RPF and an 
increase instead of a decrease in FF.
42 
Suggested mechanisms include hemodynamic factors, 
interaction of GC with vaso-active hormones and catabolic effects leading to an increase in 
plasma amino acids, which in turn augments RPF and GFR.
43,44
 Glucocorticoids can also 
mediate GFR changes through an increased blood pressure, leading to a higher 
intraglomerular pressure, although they do not always cause hypertension in dogs.
10 
However, 
blood pressure measurements were not available in the current study. 
 
Although all dogs included in the study were clinically healthy with no abnormalities 
on hematology, biochemistry profile and abdominal ultrasound, two dogs from the HC group 
and four dogs from the control group had an increased UPC at baseline. Proteinuria, which 
did not progress over a two year follow-up period, has been previously described in otherwise 
healthy Beagles by Stuart and coworkers.
45
 In the latter study, LM and EM changes were 
similar to our results and degree of proteinuria correlated with the severity of glomerular 
lesions.
45
 In the present study, dogs with most severe glomerular changes also had the highest 
UPC (n° 3: 1.56, n° 7: 1.77, n° 8: 10 and n° 10: 6.4; reference range < 0.5). The dog with the 
highest UPC had severe glomerulosclerosis, was the only dog with obsolescent glomeruli at 
baseline and had the highest percentage of obsolescent glomeruli throughout the study. Pre-
existing renal lesions and proteinuria, independent of GC administration, in these healthy 
aged Beagle dogs raise questions for interpretation of similar findings in dogs with glomerular 
diseases. Moreover, this important observation has to be kept in mind when using Beagle 
dogs as a model for human renal disease or toxicological studies.
46
 
Proteinuria was significantly higher in the control group than in the HC group at all 
time points, except for T16wks. This could be caused by an increase in UPC in the HC group 
at the end of the treatment period. Table 1 en Figure 2 indicate that UPC was increased in the 
HC group at T16wks and progressively decreased again at T20wks and T24wks. Figure 2 also 
suggests an increase followed by a decline within the HC group for uALB/c, uIgG/c and 
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uRBP/c, but not for uNAG/c. Nevertheless, dogs with the highest UPC also had the highest 
uNAG/c, which could be an indication of increased tubular lysosomal protein degradation. 
Interestingly, changes in the lysosomal degradation pattern with altered distribution of 
lysosomes from the perinuclear to the apical tubular cell region were also detected in 
proteinuric X-linked Alport Syndrome affected dogs.
24 
 
 
Possible mechanisms causing glomerular proteinuria include glomerular hypertension 
and structural alterations of the glomerular barrier.
47
 A GC-induced increase in GFR together 
with hemodynamic alterations could augment glomerular pressure and contribute to 
proteinuria. This hypothesis is supported by the parallel increase of both GFR and proteinuria 
at the end of the HC treatment period and their simultaneous decline after cessation of 
treatment in the HC group. Structural alterations that may contribute to proteinuria were 
glomerulosclerosis, podocyte foot process effacement, and GBM changes such as wrinkling, 
thickening, delamination and rarefaction. Whereas proteinuria and hyperfiltration were 
rapidly reversible after cessation of treatment in the HC group, the structural changes seemed 
to persist at T24wks. Possible explanations for this are three-fold: 1) the lesions are not 
related to GC administration, but are age-dependent and continue their physiological 
progression over time, 2) the lesions are GC-induced and there is a longer lag-time than eight 
weeks between tapering and cessation of HC administration and normalization of structural 
changes, and 3) the lesions are irreversible. Because it was not possible to repeat kidney 
biopsies at a later time in the current Beagle colony, the present study cannot confirm or 
dispute any of these hypotheses. 
 
At baseline, many dogs had mild to moderate pre-existing renal lesions. 
Glomerulosclerosis has been described to be age-related in dogs and in people.
46,48
 Tubular 
atrophy, and interstitial inflammation and fibrosis have also been shown to increase with 
aging in both species.
46,49,50
 The brownish cellular pigment detected throughout the study in 
many dogs is most likely lipofuscin accumulation, which again may be an age-related 
phenomenon as previously suggested in rats and dogs.
49,51
 Interestingly, no vascular 
morphological changes were found throughout the current study period in any of the groups, 
whereas in people vascular changes are part of age-related renal lesions.
52,53
 
At the end of the HC administration period, most striking LM findings in the HC 
group, not detected at baseline, were obsolescent glomeruli and tubular atrophy. However, 
there was a higher prevalence of renal lesions at baseline than expected and glomerular, 
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tubular and interstitial changes also progressed in the control group. Therefore, it is not 
possible to separate HC effects from progression of pre-existing renal lesions. It is possible 
that HC administration accelerated age-related glomerulosclerotic and tubular changes in the 
HC group, but definitive conclusions cannot be drawn from these data.  Another limitation of 
the study is the lack of IF examination at baseline. However, IF findings at T16wks and 
T24wks were either mild or non-specific.  
 
In conclusion, this study shows that HC administration reversibly increases GFR, with 
a similar trend for proteinuria. Results indicate that clinically healthy aged Beagle dogs have 
renal lesions and proteinuria, which could have implications for experimental or toxicological 
studies. Although further research is needed to elucidate whether morphological renal changes 
are GC-induced, hyperfiltration and proteinuria are and warrant attention to kidney function in 
human and canine patients with Cushing's syndrome or receiving exogenous GC. 
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 β-N-Acetylglucosaminidase Assay kit, Sigma-Aldrich, St Louis, MO, USA 
j.
 
CA 7000, Siemens, Brussels, Belgium   
k.
 
Placivet, Codiphar, Wommelgem, Belgium 
l.
 
Dolorex, Intervet NV, Mechelen, Belgium 
m.
 
Valium, Rosch, Brussels, Belgium 
n.
 
Propovet, Abbott Animal Health, Queenborough, UK
 
o.
 
Isoflo, Abbott Animal Health, Queenborough, UK 
p.
 
Vet-Core
TM
, Surgivet, USA  
q.
 
Bethyl Laboratories Inc., Montgomery, TX, USA 
r.
 
Dako, Glostrup, Denmark 
s.
 
Systat, version 12.00.08 
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Fifty-five to 80% of human and up to 86% of canine patients with Cushing’s 
syndrome have systemic hypertension, and about 40% of the cases are resistant to treatment 
of hypercortisolism.
1-5
 In addition, 44 to 75% of affected dogs have proteinuria, which also 
persists post-treatment in around 30% of cases.
4,6
 Systemic hypertension can cause target-
organ damage to the kidney and contribute to renal proteinuria.
7
 Proteinuria is a sign of renal 
dysfunction, but may also play a role in progression of kidney disease.
8,9
    
Consequently, dogs with Cushing’s syndrome could be considered at risk for renal 
complications. Current knowledge on the link between GCs and kidney function is reviewed 
in Chapter I. Surprisingly, information on renal function in human and canine patients with 
Cushing’s syndrome was found to be scarce. Only two studies in the nineties described 
hypertension and proteinuria in dogs with Cushing’s syndrome. However, their cut-off for 
proteinuria was higher than the one currently defined, further long-term follow-up post-
treatment was not available and dogs were treated with mitotane, while nowadays trilostane is 
used for medical treatment.
4,6
 
Screat and urea are known to be insensitive markers of renal function, hence the need 
for markers that allow early detection of renal dysfunction. Glomerular filtration rate is 
considered the best overall index of renal function. In human medicine, some urinary markers 
might allow early and site-specific indication of renal dysfunction.
10
 
Therefore, the main objective of this thesis was to evaluate renal function in dogs with 
Cushing’s syndrome using routine renal markers as well as GFR and urinary markers. 
 
1. Measurement of urinary markers in dogs  
At the start of this research, only few studies had described measurement of uALB, 
uRBP and uNAG in veterinary medicine.
11-17
 Moreover, uIgG and uCRP had never been 
measured in canine patients. Therefore a solid assay validation was mandatory, as well as 
more information about urine sampling procedures and sample storage conditions for these 
“new” urinary markers. 
 
In a first study, we evaluated effects of sampling method and storage temperature  
(-20° compared to -80°) on concentrations of uALB, uRBP and uNAG (Chapter III).  
To avoid lower urinary tract contamination, urinary samples for bacterial culture are 
generally taken in a sterile manner by cystocentesis in dogs and cats.
18
 Midstream voided 
samples are contaminated with lower urinary tract epithelial cells, proteases and bacteria, but 
have the advantage they can easily be collected by the owner at home. We collected morning 
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urine samples by cystocentesis and midstream free catch in client-owned dogs, healthy as well 
as diseased, and found no significant difference in urinary marker concentrations in 
cystocentesis compared to voided samples. Therefore, analysis of urinary markers generally 
does not seem to be influenced by sample type. Caution is still warranted, because one dog 
had markedly elevated uALB, uRBP and uNAG in the voided sample. Urine culture was 
negative, but it was hypothesized that preputial disease or urethral inflammation caused 
contamination of the voided sample that may have affected the urinary markers.  
It is still unknown whether urinary tract inflammation or infection (UTI) affects 
urinary marker concentrations. Experimental cystitis and urinary blood contamination have 
been shown to increase UPC in dogs and therefore guidelines advise to exclude UTI before 
evaluating the source of proteinuria.
7,19
 In this first study, we conducted a pilot experiment to 
assess effects of in vitro hematuria, pyuria, and bacteriuria on urinary marker concentrations. 
Results suggested minimal effects of experimental hematuria, pyuria and bacteriuria on 
uALB, uNAG, and uRBP concentrations. However, these findings have to be interpreted with 
caution, because in vitro addition of leucocytes or bacteria to urine does not fully reflect an in 
vivo inflammatory process. To date, there are no studies evaluating urinary marker 
concentrations in dogs during and after resolution of UTI. 
Our study was the first to investigate effects of storage temperature and time on 
urinary marker concentration in canine samples. In conclusion, samples for analysis of uALB 
and uRBP can be stored at –20°C for up to 4 months, whereas –80°C is preferred for storage 
up to one year. Urinary NAG enzymatic activity is less stable at –20°C as well as –80°C, with 
already substantial losses after 4 months at –20°C and a more severe decline after one year at    
–80°C.  
This first study (Chapter III) provided us with important practical information for our 
subsequent research. In the following studies we decided to collect urine samples by 
cystocentesis, to be able to perform bacterial cultures, and all urine samples were stored at -
80°C. 
 
In the second study (Chapter IV), the first objective was to validate a canine ALB 
ELISA and a uNAG colorimetric test. Secondly, we wanted to compare two glomerular 
markers, uALB and uCRP, and two tubular markers, uRBP and uNAG between healthy and 
CKD dogs. A last objective was to detect a possible age-related difference in these markers 
between healthy young and older dogs.  
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Assay characteristics (limit of detection, within- and between day-variability, and 
linearity after serial dilution) of the uALB ELISA and uNAG colorimetric test were all 
satisfactory. Validation of ELISA kits for measurement of uIgG, uCRP and uRBP was 
performed in cooperation with the Laboratory of Biochemistry and is described elsewhere by 
Maddens and coworkers.
20
 
Urinary ALB/c, uRBP/c and uNAG/c were significantly higher in dogs with CKD than 
in healthy controls. These results indicate that combined use of glomerular and tubular 
markers in conjunction with traditional tests may provide more detailed information about the 
extent and location of renal damage. Urinary markers appear to be promising as non-invasive 
tools for the diagnosis of CKD in dogs. An important question is how “early” can urinary 
markers detect a decreased renal function, in other words, how sensitive are they? One recent 
study has attempted to answer this question by investigating uALB/c and uRBP/c in healthy 
dogs and dogs with different stages of CKD, separated into five groups based on screat, UPC 
and GFR.
21
 Urinary ALB and uRBP could not differentiate between healthy control dogs and 
nonazotemic, nonproteinuric dogs with reduced Clcreat. Therefore, the authors concluded that 
uALB/c and uRBP/c were not diagnostically useful in detecting a mildly decreased Clcreat at 
an early stage of renal disease. However, GFR measurement and Clcreat reference values in the 
former study can be questioned. Plasma Clcreat was measured using a limited sampling 
technique (3 samples) “during the period from 4 to 9 hours after injection”. When using a 
limited sampling strategy, choice of blood sampling times is critical.
22
 For plasma Clcreat it has 
been shown that sampling within the first hour after injection is required to minimize 
considerable errors in GFR calculation.
23
 Furthermore, in dogs with CKD, samples at a later 
time than 9 hours post-injection may be required for accurate GFR calculation.
23
 The lower 
limit of normal for Clcreat was based on values obtained in six Beagle dogs, that were only six 
months old.
24
  It has been shown that GFR in two month old Beagle puppies is higher than 
that in adult dogs, so it is warranted to use an age-matched control group when defining 
“normal range” Clcreat.
25
 Consequently, further research in dogs classified according to stage 
of renal disease is necessary to investigate the urinary markers’ ability for early detection of 
CKD.  
In this study (Chapter IV), no significant difference was found between healthy dogs 
and dogs with CKD for uCRP/c. C-reactive protein is an important positive acute phase 
protein in dogs and differs from the other urinary markers. For CRP to appear in urine, its 
plasma concentration must be increased and the glomerular barrier must be sufficiently 
damaged to allow HMW protein filtration. None of the healthy dogs had any detectable uCRP 
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and only three of the CKD dogs did. Thus, one possible hypothesis is that the increased 
uCRP/c in these CKD dogs reflects an inflammatory response leading to increased plasma 
concentrations and subsequent leakage of CRP through the damaged glomerular barrier. In 
humans, inflammation and oxidative stress start early in the process of failing kidney function 
and mild increases in CRP concentration are present even in patients with moderate renal 
impairment.
26,27
 In dogs with CKD, however, increases in serum CRP seem to be variable, as 
is the case in dogs with pyometra.
28
 Because of this variability and the fact that circulating 
levels of CRP are expected to be low in dogs with cortisol excess, we decided to measure 
uIgG instead of uCRP as a HMW glomerular marker in our subsequent studies.
29
 
Regarding the last aim of this study, there was no difference in urinary markers 
between healthy dogs of 1-3 years old and healthy dogs ≥ 7 years old. Although the number 
of dogs was too small to define actual reference ranges for the urinary markers, the study in 
Chapter IV provided essential information on assay validation, urinary marker concentrations 
in healthy dogs and in dogs with kidney disease. Because Cushing’s syndrome occurs in 
middle-aged to old dogs, the absence of an age-related difference in the urinary markers was a 
relevant finding especially for our patient group. 
 
2. Renal function in dogs with Cushing’s syndrome 
In Chapter V we used measurement of routine renal markers, GFR and urinary 
markers to evaluate our literature-based hypothesis that Cushing’s syndrome may affect renal 
function in dogs. 
 
In a first cross-sectional study (Chapter V, § 5.1), screat and USG were lower, while 
UPC, uALB/c, uIgG/c, uRBP/c and uNAG/c were significantly higher in the dogs with 
Cushing’s syndrome than in the healthy controls. Plasma Clendo but not Clexo was also higher 
in the affected dogs. Urea and SBP were not different between groups. One dog with ATH 
and one dog with PDH had concomitant CKD. After exclusion of these two dogs, the overall 
results remained similar. 
Regarding routine renal variables, results were similar to those reported by other 
authors. Screat was decreased by about 30% in the Cushing group, as previously reported.
30  
However, screat concentration is not only affected by renal function, but also by the 
production of creatinine from creatine-phosphate in skeletal muscle, as shown in dogs with 
experimental CKD and hypothyroidism.
23,31,32
 In Cushing patients, both decreased muscle 
mass and increased GFR may contribute to a lower screat. Urea is usually within or in the  
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lower part of the reference range in these patients.
33
  
 In our study, median UPC was somewhat higher than previously reported, with the 
highest UPC found in a dog with combined PDH and CKD (UPC 16.8), although one dog 
with only ATH and two dogs with PDH also had very high UPC’s (10.2, 10.1 and 16.3, 
respectively), in absence of UTI.
4,6,34
 Unique to this study is that it demonstrated proteinuria 
in dogs with Cushing’s syndrome to have a combined glomerular and tubular component, 
illustrated by HMW (uIgG) and LMW (uRBP) protein loss.  Glomerular filtration of plasma 
proteins may result from glomerular hypertension or altered glomerular permselectivity. The 
latter mechanism may certainly play a role, since the glomerular barrier is normally 
impermeable to IgG, which was highly increased in the dogs with Cushing’s syndrome.35 
Tubulo-interstitial injury leads to impairment of megalin-mediated endocytosis by proximal 
tubular cells and an increased urinary RBP.
36
 Similarly, tubular cell dysfunction leads to 
increased leakage of lysosomal enzymes such as uNAG into the urine.
37
  
This study was the first to evaluate GFR in dogs with Cushing’s syndrome. We found 
that plasma Clendo but not Clexo was increased in the affected dogs compared to healthy control 
dogs. Differences in plasma clearance of the two stereo-isomers have previously been 
described and indicate that dispositions of exo- and endo-iohexol may vary in different 
clinical settings and that they need to be viewed as different markers.
38
 Exo-iohexol is the 
major stereo-isomer and is typically considered a marker of GFR in dogs.
39
 Short term 
administration of GCs increases GFR in humans, dogs and other species.
40-42
 In contrast, a 
decreased GFR was observed in human patients with Cushing’s syndrome.43 Therefore, GFR 
may be higher in dogs with short duration of disease and lower in dogs with longstanding 
Cushing’s syndrome, leveling out differences in Clexo between affected and healthy dogs in 
our study.  
This study also showed that glomerular and tubular function is altered in untreated 
dogs with Cushing’s syndrome. The discrepancy between Clexo and Clendo did not allow us to 
draw definitive conclusions regarding GFR. The next step in our research was therefore to 
conduct a longitudinal study to determine the effect of treatment on these changes and to 
better investigate long term variations of GFR in Cushing patients. 
 
The second study in Chapter V (§ 5.2) therefore aimed to longitudinally assess renal 
function in dogs with PDH (Cushing’s disease) before and after treatment with trilostane (Mx 
group) or transsphenoidal hypophysectomy (Hx group).  
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In this study, UPC, uALB/c, uIgG/c and uRBP/c significantly declined following 
treatment of  hypercortisolism in the complete group of dogs, indicating that hypercortisolism 
causes reversible proteinuria in most dogs, similar to results in previous studies.
6,44
 However, 
it is important to note that 1) proteinuria persisted in almost one third of the dogs and 2) post-
treatment decrease of proteinuria seemed to be more pronounced in surgically treated than in 
medically treated dogs. In the Mx group, decline of UPC was slower and at T12 3/7 dogs had 
an increased UPC. In the Hx group, UPC was already significantly decreased at T1 and 
moreover, the only two dogs with a mild proteinuria at T6 and T12 were dogs with recurrence 
of Cushing’s disease. These findings suggest that 1) recurrence of PDH is associated with 
recurrence of proteinuria, and 2) surgically treated dogs may be less prone to post-treatment 
proteinuria than medically treated dogs. However, further research is warranted to confirm the 
latter results because of the lack of randomisation and the small number of dogs in each 
group. 
In the Hx group, uALB/c, uIgG/c and uRBP/c were lower following treatment, 
whereas no significant difference was found in the Mx group. In medically treated dogs with 
PDH, clinical signs of hypercortisolism are controlled without removing the primary cause of 
the disease. Thus, serum cortisol may still exceed physiological levels during a certain period 
of the day. Therefore, it is tempting to hypothesize that this “temporary hypercortisolism” 
might contribute to proteinuria in these patients, as opposed to dogs that underwent 
hypophysectomy and are substituted with physiological doses of cortisone. 
There was no significant change in uNAG/c ratio post-treatment. In humans with 
glomerulonephritis
45
, in geriatric cats with azotemia
46
 and in dogs with CKD
47
, it has been 
demonstrated that uNAG/c is correlated with UPC and/or albuminuria, but not with screat 
concentration (or GFR in humans). Therefore, increased uNAG/c may reflect high lysosomal 
activity rather than active tubular damage. In our study, post-treatment uNAG/c may remain 
high in the dogs with persistent proteinuria or albuminuria because of increased tubular 
protein processing. 
As in § 5.1, results indicate a combined HMW (uIgG) and LMW (uRBP) proteinuria 
in dogs with Cushing’s disease. Exactly how GC excess enhances glomerular filtration of 
protein is currently unknown. Hemodynamic as well as structural alterations of the glomerular 
barrier may play a role.
44
 
 In our follow-up study, GFR was high pre-treatment and declined post-treatment, 
paralleled by a decrease in proteinuria and urinary markers. Therefore, a cortisol-induced 
increase in GFR may increase glomerular pressure and contribute to proteinuria.  
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It would have been very interesting to examine kidney biopsies pre- and post-
treatment for evaluation of structural changes, especially in patients with persistent 
proteinuria. However, this would cause the study protocol to be even more intensive, leading 
to owners declining participation of their pet. Post-mortem kidney histopathology was 
available for two dogs. The first dog had quite prominent glomerular and tubular lesions, 
despite never being proteinuric during the study. The second dog had mild glomerular lesions 
and focal interstitial inflammation and was only proteinuric at baseline. Renal histopathology 
was not standardized, and electron microscopic and immunofluorescent examinations were 
not available. No baseline kidney biopsies were taken, so these lesions may have been pre-
existing and independent of the Cushing’s disease. 
Regarding GFR, Clcreat and Clendo were significantly decreased post-treatment in the 
complete group. None of the dogs developed azotemia during the follow-up period or died of 
renal-related causes, but GFR was < 2 ml/min/kg in four dogs at the end of the study, a value 
previously suggested to be compatible with renal impairment.
32,48,49
 In human patients with 
Cushing’s syndrome, post-treatment GFR was also shown to be decreased, with four of 18 
patients being identified with CKD. The authors concluded that monitoring of GFR seems 
mandatory in these patients and that the low GFR may have consequences for individual drug 
dosage.
43
 However, cardiovascular risk factors and atherosclerosis may play an important role 
in the pathophysiology of renal consequences in humans with Cushing’s syndrome, whereas 
in dogs these factors seem less important.
50,51
 The clinical relevance of GFR changes in dogs 
with Cushing’s disease is currently unclear, as is the case for the observed GFR decrease in 
hypothyroid dogs.
32,48
 Dogs included in the current study were middle-aged to old and part of 
the observed decline in GFR during the 12-month period may have been age-related. 
Glomerular hypofiltration is a well known phenomenon in aging humans, and one study 
suggested a decrease of Clcreat in aging dogs.
52,53
 Effects of Cushing’s disease on GFR might 
have clinical implications in patients with concurrent renal or cardiac dysfunction, which is 
not uncommon in a geriatric population. Both are associated with a low GFR, which might be 
masked by the hypercortisolism-induced increase in GFR.
49
 Whether these patients could be 
at risk for deterioration of renal function after treatment of Cushing’s disease is currently 
unknown. 
 
The studies in chapter V show that glomerular and tubular function is altered in dogs 
with Cushing’s syndrome, causing an increased GFR and a combined HMW and LMW 
proteinuria. There is a post-treatment decline in GFR, which was not associated with 
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development of CKD during the one year follow-up period. Proteinuria is reversed after 
treatment in most dogs, but persisted in 43% of dogs treated with trilostane and in two dogs 
with recurrence of PDH after hypophysectomy, but not in any of the other surgically treated 
dogs. 
 
3. Renal function and morphology in Beagle dogs before and after hydrocortisone 
administration 
Because the study in § 5.2 did not include renal biopsies, it remained unclear whether 
cortisol-excess could also cause structural renal changes. Furthermore, it remained to be 
examined if the observed functional changes in GFR and protein excretion were reproducible 
in an experimental setting. Although effects of exogenous GC on renal function had been 
studied in dogs, this was never done in older dogs, nor using GFR, urinary markers and 
standardized kidney histopathology including both light and electron microscopy.
44,54
 
Therefore, objectives of the following study (Chapter VI) were to evaluate GFR, renal 
histological and ultrastructural changes, and proteinuria in old Beagle dogs before and after 
administration of hydrocortisone (HC). 
 In this study, GFR was increased after 16 weeks of HC administration and decreased 
to baseline values after tapering and cessation of the treatment, which corroborates our 
previous findings in dogs with spontaneous Cushing’s syndrome (Chapter V). A possible 
mechanism for this increase in GFR is GC-interaction with the renin-angiotension-aldosteron 
system (RAAS). In dogs with Cushing’s disease, plasma renin activity and aldosteron 
concentration are low and in dogs treated with dexamethasone, intrarenal angiotensin II and 
angiotensin converting enzyme-activity is decreased, which leads to renal vasodilation.
55,56
 In 
combination with an increased cardiac output and renal blood flow as discussed in Chapter I, 
this causes an increased GFR. Following treatment with trilostane, plasma renin activity is 
increased, which may lead to RAAS-activation and renal vasoconstriction.
56,57
 Renal 
vasoconstriction causes contraction of mesangial cells, which lowers available filtration 
surface in the glomerulus and decreases the ultrafiltration coefficient.
58
 Together with a 
decreased circulating volume and renal blood flow, GFR declines after cessation of HC 
administration or after treatment of Cushing patients with trilostane.  
As in both studies in Chapter V there was a discrepancy between Clexo and Clendo. 
Nevertheless, in these healthy dogs, Clexo and not Clendo was significantly increased, in 
contradiction to our previous studies in patients with Cushing’s syndrome. One hypothesis 
might therefore be that the two stereo-isomers behave differently according to disease status. 
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 Although all dogs included in the study were clinically healthy with no abnormalities 
on CBC, biochemistry profile and abdominal ultrasound, two dogs from the HC group and 
four dogs from the control group had unexpectedly high UPCs at baseline. The dog with the 
highest UPC had severe glomerulosclerosis, obsolescent glomeruli at baseline and the highest 
percentage of obsolescent glomeruli throughout the study. Pre-existing renal lesions and 
proteinuria, independent of HC administration, in these healthy aged Beagle dogs raise 
questions for interpretation of similar findings in dogs with glomerular diseases. Moreover, 
this important observation has to be kept in mind when using Beagle dogs as a model for 
human renal disease or toxicological studies.
59
 
 Renal lesions found at baseline may have been age-related. Glomerulosclerosis has 
been described to be age-related in dogs and in people.
59,60
 Tubular atrophy, interstitial 
inflammation and fibrosis have also been shown to increase with aging in both species.
61,62
 
Throughout the study, brownish cellular pigment was detected in many dogs, which is most 
likely lipofuscin accumulation and again may be an age-related phenomenon, previously 
documented in rats and dogs.
61,63
  
At the end of the HC administration period, most striking light microscopic findings in 
the treatment group, not detected at baseline, were obsolescent glomeruli and tubular atrophy. 
However, there was a higher prevalence of renal lesions at baseline than expected and 
glomerular, tubular and interstitial changes also progressed in the control group. Therefore, it 
is not possible to separate HC effects from progression of pre-existing renal lesions. It is 
possible that HC administration accelerated age-related glomerulosclerotic and tubular 
changes in the HC group, but definitive conclusions cannot be drawn from these data.  
Proteinuria was significantly higher in the control group than in the HC group at all 
time points, except for T16wks. This can be explained by an increase of UPC in the treatment 
group at T16wks, followed by a decrease after tapering and cessation of HC treatment. No 
significant changes between both groups were detected for the urinary markers. However, 
similar to UPC, uALB/c, uIgG and uRBP/c tended to increase during HC treatment and 
declined afterwards within the HC group. These findings again suggest a reversible increase 
in proteinuria, similar to our findings in previous studies (Chapter V). Proteinuria and 
hyperfiltration were rapidly reversible after cessation of treatment in the HC group, 
supporting a link between hemodynamic glomerular changes and proteinuria. 
Interestingly, the longitudinal study in Chapter V (§5.2) and the study in Chapter VI 
both showed different results for uNAG/c in comparison to the other markers. Although 
uNAG/c is increased in untreated dogs with Cushing's syndrome compared to healthy controls 
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(Chapter V, §5.1), its post-treatment decline was not statistically significant, as opposed to the 
other urinary markers (Chapter V, §5.2). Time course of uNAG/c during administration of HC 
(Chapter VI) did not show an increasing trend, followed by a decline after cessation of HC 
treatment, as documented for the other urinary markers (Chapter VI, Figure 2).  
Urinary NAG is a lysosomal enzyme with several isoenzymes, and in case of tubular 
impairment not only total uNAG will increase but also isoenzyme ratios will change.
64
 Our 
assay only measures total uNAG and it would be very interesting to measure the isoenzymes 
to better characterize the changes in  uNAG activity. Furthermore, the NAG assay is based on 
a colorimetric technique, which may be prone to more analytical interaction than the 
antibody-based ELISAs for measurement of uALB, uIgG and uRBP. 
 
4. Future perspectives 
 Our results show that urinary markers are increased in dogs with CKD as well as in 
dogs with Cushing’s syndrome, that do not have azotemia. These data suggest that the urinary 
markers may be sensitive indicators of early renal dysfunction, in contrast to routine renal 
markers. However, we did not investigate their ability to detect mild decreases in GFR. Raila 
and coworkers (2010) reported that uALB and uRBP cannot distinguish dogs with a normal 
GFR from those with a mildly decreased GFR.
21
 Even if this suggestion is confirmed in future 
studies, urinary markers may still be useful to monitor response to therapy or predict a uremic 
crisis in dogs or cats with CKD. Consequently, further research in patients with different 
stages and etiologies of renal disease is necessary.  
We have not tested the specificity of the urinary markers and therefore future studies 
should assess to which extent urinary markers are influenced by concurrent diseases. In our 
studies, concurrent systemic disease was an exclusion criterion. 
The use of urinary markers is limited by the relatively expensive and labour-intensive 
assays needed for their analysis. If future studies prove them to be useful clinical tools, 
simplified analytical methods should be developed to allow use in clinical settings. The same 
is true for measurement of GFR. A sophisticated HPLC-UV method was used to 
simultaneously determine exo- and endo-iohexol, whereas plasma Cr can be measured with 
much simpler techniques. Plasma clearance of exogenous Cr is therefore the most feasible 
method to measure GFR in practice, but an exogenous Cr solution is not commercially 
available and limited sampling strategies need to be further optimalised.
23
 
 Human and canine patients with Cushing’s syndrome are predisposed to thrombo-
embolic disease.
66-68
 We did not test coagulation and it would be very interesting to 
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investigate this in Cushing patients with and without proteinuria, since hypercoagulability has 
been associated with urinary loss of anti-thrombin III, among other mechanisms.
33,65
 
 Regarding proteinuria in general, many questions remain unanswered. Follow-up of a 
large number of Cushing patients with post-treatment proteinuria over a longer time period, 
including kidney biopsies may provide more in-depth information. In human and canine 
patients with CKD, hypertension and proteinuria are associated with progression of disease 
and proteinuria may contribute to tubulo-interstitial damage.
9,68,69
 Therefore, ACE-inhibitors 
(and in humans also angiotensin receptor-blockers) are widely used as anti-hypertensive and 
anti-proteinuric agents to slow progression of renal disease in both species.
70,71
 It remains to 
be investigated whether Cushing patients with longstanding post-treatment proteinuria 
develop tubulo-interstitial injury and whether these drugs would also be indicated.  
 The high prevalence of proteinuria found in old Beagle dogs also warrants further 
investigation. We did not observe increased UPCs in the healthy control dogs included in our 
studies, but there are no large scale studies evaluating proteinuria in aged dogs of breeds other 
than Beagles.
72
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5. General conclusion 
Throughout this thesis we have gained significant knowledge on renal function in dogs 
with Cushing’s syndrome. Furthermore, we have investigated the use of urinary markers in 
canine patients. First, sampling methods and sample storage conditions were evaluated, and 
assay validation was performed to ensure optimal measurement of urinary markers. Then 
uALB, uCRP, uRBP and uNAG were evaluated in healthy young and old dogs, and in dogs 
with CKD. This study showed that the urinary markers were increased in dogs with CKD 
compared to healthy dogs, and that there was no difference between young and aged healthy 
dogs. In the second part of this thesis we evaluated renal function in dogs with Cushing’s 
syndrome in a cross-sectional study pre-treatment and a longitudinal study pre- and post-
treatment with trilostane or transsphenoidal hypophysectomy. Patients with Cushing’s 
syndrome had significantly higher UPC, glomerular (uALB/c and uIgG/c) and tubular urinary 
markers (uRBP/c and uNAG/c), which declined following treatment, indicating reversible 
combined HMW and LMW proteinuria in most dogs. However, almost 40% of dogs remained 
proteinuric at the end of the one year follow-up period. Pre-treatment GFR measured by 
plasma Clcreat and Clendo was significantly higher in untreated dogs with Cushing’s syndrome 
and declined post-treatment. None of the patients developed CKD during the study period, but 
a low Clcreat was detected in about 30% of dogs at the end of the study. We did not detect 
significant differences for Clexo, indicating that dispositions of the two stereo-isomers may 
vary according to the clinical setting. Similar functional changes in GFR and proteinuria were 
detected in older Beagle dogs treated with exogenous HC. Renal lesions and proteinuria were 
present in many dogs before the start of HC administration. At the end of the HC treatment 
period, glomerular and tubulo-interstitial lesions had progressed in both the treatment and 
control group. Therefore, additional studies are needed to elucidate GC effects on renal 
morphology. 
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Summary 
Cushing’s syndrome is a common endocrine disorder in middle aged to older dogs. 
Proteinuria occurs in 44 to 75% of affected dogs and is a sign of kidney dysfunction. 
Moreover, there is evidence that protein overload in the ultrafiltrate may be toxic to the 
tubular cells and triggers pathways that cause tubulo-interstitial injury. Another frequent 
complication in up to 80% of human and canine Cushing patients is hypertension, which can 
also be detrimental to the kidney. Because of its similarity with the syndrome in humans and 
its high estimated incidence compared to the low incidence in people, canine Cushing’s 
syndrome is an interesting animal model for its human counterpart. Surprisingly, very little 
scientific information exists on renal consequences of Cushing’s syndrome in people as well 
as in dogs.  
Routine markers such as serum creatinine (screat) and urea only detect renal disease 
when up to 75% of kidney function is already lost. Hence the need for markers that allow 
early detection of renal dysfunction. Glomerular filtration rate (GFR) is considered the best 
overall index of renal function. In human medicine, certain urinary markers allow early and 
site-specific indication of renal dysfunction. 
 
Aims of this thesis were to evaluate renal function in dogs with Cushing’s syndrome 
using routine renal parameters as well as GFR and urinary markers. 
 
At the start of this research, only few studies had described measurement of urinary 
markers in veterinary medicine. Therefore, information about sampling methods and urine 
sample storage conditions was mandatory. In a first study (Chapter III), we evaluated effects 
of sampling method (voided urine versus cystocentesis) and storage temperature (-20° 
compared to -80°) on urinary concentrations of albumin (ALB), retinol-binding protein (RBP) 
and N-acetyl-β-D-glucosaminidase (NAG). Urinary marker concentrations were not 
influenced by sample type. However, caution may be warranted, because one dog had 
markedly elevated urinary (u) ALB, uRBP and uNAG concentrations in the voided sample. 
Samples for analysis of uALB and uRBP can be stored at –20°C for up to 4 months, whereas 
–80°C is preferred for storage up to 12 months. Urinary NAG enzyme activity is less stable at 
–20°C as well as –80°C, with already substantial losses after 4 months at –20°C and a more 
severe decline after 12 months at –80°C.  
Because of the paucity of knowledge on the use of urinary markers in dogs, solid assay 
validation was required as well as information about normal values and concentrations in dogs 
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with kidney disease. In the second study (Chapter IV), our objectives were to validate a 
canine ALB ELISA and a uNAG colorimetric test and to compare two glomerular markers, 
uALB and uCRP, and two tubular markers, uRBP and uNAG, between healthy and chronic 
kidney disease (CKD) dogs. A third aim was to detect a possible age-related difference in 
these markers between healthy young and older dogs. Assay characteristics of the ALB 
ELISA and NAG colorimetric test were satisfactory for both assays. Urinary glomerular and 
tubular markers were higher in dogs with CKD than in healthy controls and there was no 
difference in urinary marker concentrations between healthy young and older dogs. Although 
the number of dogs was too small to define actual reference ranges for the urinary markers, 
the study in Chapter IV provided essential information on assay validation, and urinary 
marker concentrations in healthy dogs and in dogs with CKD. Because Cushing’s syndrome 
occurs in middle-aged to old dogs, the absence of an age-related difference in the urinary 
markers was an important finding. 
 
In the second part of the thesis, we applied the urinary markers as well as GFR to 
evaluate renal function in dogs with Cushing’s syndrome (Chapter V). We conducted a 
cross-sectional study in untreated dogs (§ 5.1) and a longitudinal follow-up study (§ 5.2) 
before and after treatment of Cushing’s disease with trilostane or transsphenoidal 
hypophysectomy. Patients with Cushing’s syndrome had significantly higher UPC, 
glomerular (uALB/c, uIgG/c) and tubular urinary markers (uRBP/c and uNAG/c), which 
decreased after treatment, indicating reversible combined HMW and LMW proteinuria in 
most dogs. However, proteinuria persisted in 43% of dogs treated with trilostane and in two 
dogs with recurrence of PDH after hypophysectomy, but not in any of the other surgically 
treated dogs. Post-treatment decrease of urinary markers was also less pronounced in the 
medically treated than in the surgically treated dogs, suggesting that the latter may be less 
prone to persistent proteinuria. Pretreatment GFR measured by plasma Clcreat and Clendo was 
significantly higher in untreated dogs with Cushing’s syndrome and declined post-treatment. 
None of the patients developed CKD during the study period, but a low Clcreat was detected in 
four of 13 dogs at the end of the study. Significant changes in Clexo were not detected, 
indicating that the two iohexol stereo-isomers need to be considered as different markers. 
 
Finally, in Chapter VI we investigated changes in GFR and urinary markers in old 
Beagle dogs before and after treatment with hydrocortisone, including renal biopsies. Similar 
to our findings in patients with Cushing’s syndrome, GFR was higher after hydrocortisone 
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treatment in these Beagle dogs and proteinuria tended to increase. Renal lesions and 
proteinuria were present in many dogs before the start of hydrocortisone administration, 
which raises questions for interpretation of similar findings in dogs with glomerular diseases. 
Moreover, this important observation has to be kept in mind when using Beagle dogs as a 
model for human renal disease or toxicological studies. At the end of the hydrocortisone 
treatment period, glomerular and tubulo-interstitial lesions had progressed in both the 
treatment and control group. Therefore, additional studies are needed to elucidate 
glucocorticoid effects on renal morphology. 
 
The main findings of the thesis are the following: 
 Urine samples for measurement of uALB and uRBP can be stored at –20°C for up to 4 
months, whereas –80°C is preferred for storage up to 12 months. For uNAG, storage 
at -80°C and analysis within 4 months is advised. 
 Effects of sampling method on urinary marker concentrations (voided compared to 
cystocentesis) seems to be minimal, after urine sample centrifugation and in absence 
of UTI. 
 Intra- and inter-assay CV, limit of detection and linearity of a canine uALB ELISA 
and a uNAG colorimetric test were determined.  
 uALB/c, uRBP/c and uNAG/c are significantly increased in dogs with CKD (IRIS 
stages II to IV) and their concentrations do not differ between healthy young and aged 
dogs. 
 Pretreatment, urinary glomerular (uALB and uIgG) and tubular markers (uRBP and 
uNAG), UPC and GFR measured with plasma Clcreat and Clendo are significantly 
increased in dogs with Cushing’s syndrome.  
 Post-treatment, there is a decline of GFR, without development of azotemia in any of 
the dogs during a 12 month follow-up. Persistent proteinuria was detected in 43% of 
dogs treated with trilostane and in none of the dogs treated with hypophysectomy and 
without recurrence. 
 Apparently healthy aged Beagle dogs may have significant histopathological renal 
lesions and proteinuria. 
 Chronic administration of hydrocortisone causes an increase in GFR in Beagle dogs. 
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Samenvatting 
Cushing's syndroom is een vaak voorkomende endocriene aandoening bij honden van 
middelbare tot oude leeftijd. Proteïnurie komt voor bij 44 tot 75% van de gevallen en is een 
teken van een verstoorde nierfunctie. Bovendien zijn er studies die suggereren dat een 
overmaat aan proteïnen in het ultrafiltraat toxisch zou zijn voor de tubuluscellen en aanleiding 
kan geven tot een cascade reactie die tubulo-interstitiële schade veroorzaakt. Een andere 
frequente complicatie bij ongeveer 80% van de mensen en honden met het syndroom van 
Cushing is hypertensie, wat ook schadelijk kan zijn voor de nier. Omdat dit syndroom zeer 
gelijkaardig is bij honden en mensen, maar bij de hond een veel hogere geschatte incidentie 
heeft, is Cushing's syndroom bij de hond een interessant diermodel voor de humane 
tegenpool. Verrassend genoeg bestaat er zeer weinig informatie over de gevolgen van 
Cushing's syndroom voor de nier, zowel bij mensen als bij honden.                                  
 Routinemerkers zoals serum creatinine (screat) en ureum detecteren een daling in de 
nierfunctie pas als deze reeds met 75% verminderd is. Er is daarom nood aan merkers die 
vroegtijdige detectie van een gedaalde nierfunctie toelaten. De glomerulaire filtratiesnelheid 
(GFS) wordt beschouwd als de beste manier om de algemene nierfunctie te evalueren. In de 
humane geneeskunde zouden bepaalde urinaire merkers vroege detectie en lokalisatie van een 
verstoorde nierfunctie mogelijk maken.  
 Het doel van deze thesis was om de nierfunctie bij honden met Cushing's syndroom te 
evalueren aan de hand van routineniermerkers evenals GFS en bepaalde urinaire merkers. 
Bij het begin van dit onderzoek waren er in de diergeneeskunde slechts een beperkt 
aantal studies die meting van urinaire merkers beschreven. Informatie ontbrak over het nemen 
van de urinestalen en de optimale condities om deze te bewaren. In een eerste studie 
(Hoofdstuk III) evalueerden we het effect van staalname (urine via mictio in vergelijking met 
cystocenthese) en bewaartemperatuur (-20°C in vergelijking met -80°C) op de urinaire 
concentraties van albumine (ALB), retinol-bindingsproteïne (RBP) en N-acetyl-β-D-
glucosaminidase (NAG). De concentraties van deze urinaire merkers werden niet beïnvloed 
door het type van staalname. Deze bevinding moet echter voorzichtig geïnterpreteerd worden, 
omdat er bij één hond duidelijk gestegen uALB, uRBP en uNAG concentraties werden 
teruggevonden in het mictio staal. Monsters voor analyse van urinair (u) ALB en uRBP 
kunnen tot 4 maanden bewaard worden bij -20°C, terwijl -80°C aangewezen is voor langere 
bewaring tot één jaar. Enzymactiviteit van uNAG is minder stabiel bij -20°C alsook bij  -
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80°C, met al substantiële daling na 4 maanden bij -20°C en een nog sterkere afname na één 
jaar bij -80°C.  
Door de beperkte kennis over het gebruik van urinaire merkers bij honden was een 
solide validatie van de testkits nodig, evenals meer informatie over normaalwaarden bij 
gezonde honden en concentraties bij honden met nierziekte. De doelstelling van een tweede 
studie (Hoofdstuk IV) was om een caniene ALB ELISA en uNAG colorimetrische test te 
valideren voor gebruik met urine. Verder werden twee glomerulaire merkers, uALB en uCRP, 
en twee tubulaire merkers, uRBP en uNAG, vergeleken tussen gezonde honden en honden 
met chronische nierziekte (CNZ). Ten derde werden deze urinaire merkers vergeleken bij 
gezonde jonge en oude honden om na te gaan of er een leeftijdsgerelateerd verschil was. Alle 
analytische karakteristieken van de ALB ELISA en uNAG colorimetrische test voldeden aan 
de vooropgestelde criteria. Urinaire glomerulaire en tubulaire merkers waren hoger bij honden 
met CNZ dan bij gezonde honden en er was geen verschil in urinaire merker concentraties 
tussen gezonde jonge en oude honden. Hoewel het aantal honden te klein was om effectief 
referentie intervallen te definiëren, zorgde de studie in Hoofdstuk IV voor essentiële 
informatie over validatie van de tests en concentraties van de urinaire merkers bij gezonde 
honden en honden met nierziekte. Omdat Cushing's syndroom voorkomt bij honden van 
middelbare tot oude leeftijd was het ontbreken van een leeftijdsgerelateerd verschil bij de 
urinaire merkers een belangrijke bevinding. 
In het tweede gedeelte van de thesis werden de urinaire merkers alsook de GFS 
gebruikt om nierfunctie bij honden met Cushing's syndroom te evalueren (Hoofdstuk V). Er 
werd een studie bij onbehandelde honden uitgevoerd (§ 5.1) en een longitudinale 
opvolgingsstudie (§ 5.2) voor en na behandeling van de ziekte van Cushing met trilostane of 
transsphenoidale hypofysectomie. Patiënten met Cushing's syndroom hadden significant 
hogere eiwit/creatinine ratio's (e/c), glomerulaire (uALB/c en uIgG/c) en tubulaire urinaire 
merkers (uRBP/c en uNAG/c), die afnamen na de behandeling, wat duidt op een reversibele 
proteïnurie bij de meeste honden. De proteïnurie bleef echter aanwezig bij 43% van de 
honden behandeld met trilostane en bij twee honden met een herval van de ziekte van Cushing 
na hypofysectomie. Geen enkel van de chirurgisch behandelde honden had persisterende 
proteïnurie. De urinaire merkers daalden minder sterk na behandeling bij de medisch 
behandelde honden, wat er eventueel op zou kunnen wijzen dat deze laatste vaker 
persisterende proteinurie hebben dan honden na hypofysectomie. Deze hypothese moet echter 
verder onderzocht worden bij een grotere groep honden en met randomisatie. De GFS vóór 
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behandeling, gemeten aan de hand van Clcreat en Clendo was significant hoger bij de 
onbehandelde honden met Cushing's syndroom en daalde na de behandeling. Geen van de 
patiënten ontwikkelde CNZ gedurende de studieperiode, maar een lage Clcreat werd gevonden 
bij vier van de 13 honden op het einde van studie. Significante veranderingen van Clexo 
werden niet teruggevonden, wat er op wijst dat de twee stereo-isomeren van iohexol als twee 
verschillende merkers moeten beschouwd worden. 
Tot slot werden in Hoofdstuk V GFS-veranderingen, urinaire merkers en nierbiopten 
bij oude Beagles onderzocht, voor en na behandeling met hydrocortisone. Gelijkaardig aan de 
resultaten bij patiënten met Cushing's syndroom, was de GFS hoger na behandeling met 
hydrocortisone en was er een stijgende trend in de proteïnurie. Nierletsels en proteïnurie 
waren aanwezig bij veel honden voor de start van de hydrocortisone toediening, wat vragen 
oproept over de interpretatie van dergelijke bevindingen bij honden met glomerulaire ziekten. 
Bovendien moet deze belangrijke observatie in acht genomen worden wanneer Beagles 
gebruikt worden als model voor humane nierziekten of toxicologische studies. Aan het einde 
van de hydrocortisone behandeling was er progressie in de glomerulaire en tubulo-interstitiële 
letsels zowel als bij de controle groep als bij de behandelde honden. Er zijn dus bijkomende 
studies nodig om de effecten van glucocorticoïden op de niermorfologie op te helderen. 
Samenvattend kan men uit deze thesis het volgende besluiten: 
 Urinemonsters voor meting van uALB en uRBP kunnen tot 4 maanden bewaard 
worden bij –20°C, terwijl –80°C aangewezen is voor bewaring tot één jaar. Voor 
uNAG wordt bewaring bij -80°C met analyse binnen de 4 maanden aangeraden. 
 Type van staalname (mictio in vergelijking met cystocentesis) lijkt minimale effecten 
te hebben op urinaire merker concentraties, na centrifugatie van de monsters en in 
afwezigheid van een urineweginfectie. 
 Intra- en inter-assay variatie coëfficiënt, detectielimiet en lineariteit van een canine 
uALB ELISA en uNAG colorimetrische test werden bepaald.  
 uALB/c, uRBP/c en uNAG/c zijn significant gestegen bij honden met CNZ (IRIS 
stages II tot IV) en hun concentraties verschillen niet tussen gezonde jonge en oude 
honden.  
 Voor behandeling zijn urinaire glomerulaire (uALB en uIgG) en tubulaire merkers 
(uRBP en uNAG), e/c en GFS, gemeten met  Clcreat en Clendo, significant gestegen  bij 
honden met Cushing’s syndroom.  
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 Na behandeling is er een daling van de GFS zonder dat één van de patiënten azotemie 
ontwikkelde gedurende de studieperiode van één jaar. Persisterende proteïnurie werd 
teruggevonden bij 43% van de honden behandeld met trilostane, terwijl geen enkele 
van de patiënten behandeld met hypofysectomie, zonder herval, persisterende 
proteïnurie vertoonde.  
 Schijnbaar gezonde oude Beagles kunnen duidelijke histopathologische nierletsels 
hebben en proteïnurie. 
 Chronische toediening van hydrocortisone veroorzaakt een stijging van de GFS bij 
Beagles. 
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Een citaat van de Engelse schrijver Samuel Johnson klinkt als volgt:  
“What is written without effort is, in general, read without pleasure.”  
Dit boekje heeft me vier jaar hard werk gekost en ik hoop dat enkelen onder jullie het met 
plezier gelezen hebben. 
De meeste mensen bladeren echter meteen verder naar het dankwoord. Dit dankwoord heeft 
me veel minder moeite gekost, omdat het voor mij heel vanzelfsprekend is om onderstaande 
mensen te bedanken, maar toch denk ik dat jullie het met plezier zullen lezen! 
 
Allereerst wil ik mijn hoofdpromotor, prof. dr. Sylvie Daminet, bedanken. Sylvie, bedankt 
voor uw vertrouwen in mij reeds als student. Niet iedereen laat zich vrijwillig blinddoeken 
door een laatstejaarsstudent om dan bij prikkelbare hyperthyroïde katten de schildklier te 
palperen! U heeft me gesteund in mijn keuze om na dit scriptie onderzoek een jaar de kliniek 
in te duiken als intern. Toen ik toch weer nieuwsgierig werd naar wat onderzoek en een 
doctoraat inhielden, stelde u een interessant project voor en vier jaar later is dit boekje er. Met 
uw wetenschappelijke en klinische ervaring was u er steeds om dit onderzoek in goede banen 
te leiden, maar toch heb ik veel vrijheid gekregen om zelfstandig te werken. Op congres 
supporterde u steevast bij mondelinge presentaties en dankzij uw connecties hebben we met 
vele experts kunnen samenwerken. Van harte bedankt, ik had me geen betere promotor 
kunnen wensen! 
 
Als promotor was prof. dr. Evelyne Meyer de tweede hoeksteen van dit doctoraat, in het 
bijzonder in de beginfase toen ik amper kon pipetteren, laat staan assays valideren! De 
inbreng van de vakgroep Biochemie, Farmacologie en Toxicologie was zeer belangrijk 
doorheen dit onderzoek om onze ideeën voor klinische studies ook werkelijk te kunnen 
uitvoeren. Evelyne, de vergaderingen met een positieve ingesteldheid en gemoedelijke sfeer 
blijven me zeker bij. Verder heb ik u ook als een positief en heel moedig persoon leren 
kennen. 
 
Aan prof. dr. Siska Croubels, hartelijk bedankt voor de goede samenwerking voor de iohexol 
analyse en het kritisch nalezen van mijn manuscripten. Honderden stalen werden er op de 
dienst Farmacologie en Toxicologie geanalyseerd en telkens werd dit vlot ingepland in jullie 
drukke laboschema. Hartelijk dank aan Siegrid, Maggy en Jelle voor de vele analyses. 
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Aan prof. dr. Luc Duchateau, heel erg bedankt voor uw statistische analyses. Een optimaal 
studie design en een analyse die het maximum uit de resultaten haalt, zijn niet zo eenvoudig. 
Bedankt om me hiermee uit de nood te helpen en  me toch een beetje wegwijs te maken in de 
statistiek! 
 
To prof. dr. Hervé Lefebvre, many thanks for all the pharmacokinetic and statistical analyses 
you have performed, in between your hectic schedule. To me you are the “king of GFR” and 
it was an honour to collaborate with you. I have learned so much during our brainstorm 
sessions with Sylvie. Thank you for all the time you have taken to discuss my research, even 
early in the morning during a breakfast meeting! 
 
Prof. dr. Hans Kooistra, met u hadden we een echte expert in de veterinaire endocrinologie 
aan boord. Het was een waar genoegen om de klinische studies met u te bespreken en te leren 
van uw scherp wetenschappelijk en klinisch inzicht. Ik zal de nieuwe editie van uw boek nog 
vaak raadplegen!  
Bedankt ook aan de andere leden van het endocrinologie team uit Utrecht: dr. Sara Galac en 
dr. Jenny Buijtels voor alle “monsters” (geen stalen) die jullie voor mij genomen hebben. 
Proficiat ook met jullie recente, prachtige proefschriften!  
Prof. dr. Björn Meij, bedankt om mij uw patiënten toe te vertrouwen voor de opvolgingsstudie 
en voor uw inbreng bij het manuscript. 
Manon en het team van dierverplegers, bedankt voor de hulp bij de bloednames en 
bloeddrukmetingen.  
 
Aan prof. dr. Ingeborgh Polis, bedankt voor het rigoureus nalezen van dit boekje en voor het 
uitlenen van uw manschappen om “mijn” Beagletjes onder anesthesie te brengen. Koen, 
Bossie en Tim, bedankt! 
 
Dr. van Hoek, Ingrid, tijdens het eerste jaar van mijn doctoraat was jij mijn “voorbeeld van 
een doctoraatstudent” en ik heb toen heel wat van je geleerd. Heel erg bedankt voor je advies 
(i.v.m. doctoreren, maar ook huwelijksdagtips!). We komen elkaar zeker nog vaak tegen op 
congres. Je bent duidelijk gelukkig daar in Zuid-Frankrijk en ik wens je samen met Lars en 
Else het allerbeste. 
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Van harte bedankt aan de doorverwijzende dierenartsen voor het aan ons toevertrouwen van 
hun patiënten en de goede samenwerking. Dit doctoraat was er niet geweest zonder de vele 
gemotiveerde hondeneigenaars die bereid waren om meermaals met hun hond op controle te 
komen. Van harte bedankt aan ieder van hen! Een speciaal woord van dank aan alle honden, 
die in ruil voor een knuffel en een lekker bordje korrels na de bloednames, hun bijdrage 
geleverd hebben aan de diergeneeskundige wetenschap!  
 
Ik heb de voorbije jaren steeds heel graag op de vakgroep Kleine Huisdieren gewerkt en daar 
zijn heel wat leuke collega’s mede verantwoordelijk voor. Bedankt aan iedereen! Het zijn er 
teveel om op te noemen, maar ik wil er toch enkelen vermelden.  
Allereerst mijn bureaugenootjes: Isabel, Bart, Liesbeth en Evelyne, die alle ups en ook downs  
van dit onderzoek live meegemaakt hebben, bedankt voor jullie steun! Bart en Isabel, jullie 
zijn het levende bewijs dat een chirurg en een internist wel degelijk met elkaar kunnen 
opschieten (meestal)! Het was gezellig! 
Verder mijn collega’s van de interne geneeskunde: Dominique, Miguel, Katrien, Geert, Pieter 
en Alenka, het is een plezier om van jullie te leren, met jullie samen te werken, te lunchen en 
buiten de werkuren eens een stapje in Gent te zetten! 
Hartelijk bedankt ook aan alle ZAP leden van onze vakgroep voor hun steun en vertrouwen 
voor de toekomst. 
Ik wil ook graag onze laboranten Hanne en Jolien bedanken voor hun hulp bij het invriezen of 
analyseren van mijn stalen. Peggy, bedankt voor de vele bloednames en het rekruteren van de  
bloeddonoren die lid waren van mijn controlegroep. Bedankt aan alle interns en studenten die 
geholpen hebben bij de vele clearance testen en bij de studie met de Beagles. Cindy, de 
financiën waren soms niet eenvoudig, bedankt voor je inzet. Filip, bedankt voor je tips bij het 
maken van dit boekje. 
Ik wil ook enkele mensen van de vakgroep Medische Beeldvorming bedanken voor de goede 
samenwerking: prof. dr. Jimmy Saunders, Pascaline, Elke, Anaïs en Iseu, merci! Hendrik, 
bedankt voor de echobegeleide nierbiopten van superkwaliteit. 
 
Mijn tweede vakgroep was “de Biochemie”. Bert, ondanks het feit dat je liever op Safari gaat 
in Afrika, dan naar mijn verdediging te komen, zal ik je toch vermelden in mijn dankwoord. 
Je zorgde steeds voor een vrolijke noot in het labo en we hebben elkaar  kunnen motiveren als 
er eens een onderzoeksdipje was, bedankt! Ook bedankt aan Kristel om me te coachen bij 
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mijn eerste ELISA’s en aan Jella, Donna, Koen en Dieter (voor de babbels en de kopjes 
koffie). 
 
Heel erg bedankt aan al mijn vrienden met wie ik de voorbije jaren veel memorabele 
momenten beleefd heb, voor hun steun en hun enthousiasme.  
Katrienie, we hebben ons studenten-, intern- en doctoraatsleven gedeeld en ons heel goed 
geamuseerd! Het lijkt nog maar gisteren dat ik op je bureau stond net voor jouw verdediging 
en vandaag is het al aan mij… Ik wens je veel succes met je plannen na Aruba en vooral ook 
nog veel goeie windsurfseizoenen. 
Bartjan, Caro, Geert, Jeanette en Marjan, ons fantastisch jaar samen als interns ligt al een 
tijdje achter ons en ondertussen zijn we alleen nog betere vrienden geworden. Moge er nog 
veel weekendjes Ardennen/Frankrijk volgen!  
Ine Peeters, Ine Cornelis, Alejandro, Sabine, Miguel en Barbara, thanks for all the good times! 
Katrien, Charlotte,Veronique en Evelyne, bedankt voor een fantastische studententijd. 
Eline, Eva, Isabelle en Nele, bedankt voor jullie jarenlange vriendschap. 
 
Bedankt aan mijn familie voor hun jarenlange steun. Rosemie, Karolien en Maarten, bedankt 
voor de tweede thuis waar ik me meteen welkom voelde en voor jullie “doctoraatstips”. 
 
Oma, je hebt al je kleinkinderen mee “grootgebracht” en nu ben je er nog steeds voor ons, dit 
boekje is ook voor jou. 
Elyn en Emilie, zussies, bedankt voor alles (en voor een superleuk vrijgezellenfeest)! Ik wens 
jullie samen met Pieter en Filip een fantastische toekomst toe. 
 
Mama en Papa, ik ben een grote geluksvogel met ouders als jullie! Jullie gaven me een 
zorgeloze jeugd, waarin ik de liefde voor de beestjes van kindsbeen af meekreeg. Ik kreeg 
jullie onvoorwaardelijke steun toen ik op kot ging in Gent, tijdens mijn internship en nu nog 
steeds. Het was allemaal vanzelfsprekend voor jullie. Woorden schieten tekort om jullie 
hiervoor te bedanken. 
 
Lieve Pieter, bedankt voor al het moois dat we de voorbije vier jaar gedeeld hebben. Voor je 
onuitputtelijke steun, je geduld, je positivisme en je humor. Ik ga hier niet uitspreken hoeveel 
 je voor me betekent, dat doe ik binnen 10 dagen op onze grote dag!
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Pascale Smets werd geboren op 3 april 1982 te Leuven. 
 
Zij behaalde in 2000 het diploma algemeen secundair onderwijs Latijn-wetenschappen aan het 
Heilig Hartinstituut te Heverlee.  
Nadien startte ze de studie Diergeneeskunde aan de Universiteit van Gent. In 2006 behaalde 
ze met grote onderscheiding het diploma van Dierenarts in de afstudeerrichting 
Gezelschapsdieren. Onmiddellijk daarna volgde zij een roterend Internship bij de vakgroep 
Geneeskunde en Klinische Biologie van de Kleine huisdieren aan de faculteit 
Diergeneeskunde. 
 
Geboeid door de mogelijkheden die het wetenschappelijk onderzoek kan bieden voor de 
kliniek, startte zij een doctoraatsstudie naar nierfunctie bij honden met het syndroom van 
Cushing. Deze studie werd gefinancierd door het Fonds voor Wetenschappelijk Onderzoek 
Vlaanderen en het Bijzonder Onderzoeksfonds van de universiteit Gent. Tevens vervolledigde 
zij in 2011 het trainingsprogramma van de Doctoral School of Life Science and Medicine van 
de Universiteit Gent.  
 
Pascale Smets is auteur of mede-auteur van 20 wetenschappelijke publicaties en abstracts. Zij 
nam actief deel aan meerdere internationale congressen. 
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